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Abstract
 The enzyme aspartate transcarbamoylase (ATCase) is an enzyme in the 
pyrimidine nucleotide biosynthetic pathway. It was once an attractive target for  anti-
proliferation drugs but has since become a teaching model due to kinetic properties 
such  as cooperativity  and allostery  exhibited by  the Escherichia coli form of the 
enzyme. ATCase from E. coli has been extensively  studied over that  last  60 years and 
is the textbook example of allosteric enzymes. Through this past research it  is 
understood that ATCase is allosterically  inhibited by  CTP, the end product  of 
pyrimidine biosynthesis, and allosterically  activated by  ATP, the end product of the 
parallel purine biosynthetic pathway.
 Part of the work discussed in this dissertation involves further understanding 
the catalytic properties of ATCase by  examining an unregulated trimeric form  from 
Bacillus subtilis,  a bacterial ATCase that more closely  resembles the mammalian 
form than E. coli ATCase. Through X-ray  crystallography  and molecular  modeling, 
the complete catalytic cycle of B. subtilis ATCase was visualized,  which provided new 
i
insights into the manifestation of properties such  as cooperativity  and allostery  in 
forms of ATCase that are regulated. 
 Most of the work described in the following chapters involves understanding 
allostery  in E. coli ATCase.  The work here progressively  builds a new model of 
allostery  through new X-ray  structures of ATCase•NTP complexes. Throughout these 
studies it has been determined that the allosteric site is bigger  than previously 
thought  and that metal ions play  a significant role in the kinetic response of the 
enzyme to nucleotide effectors. This work proves that what is known about ATCase 
regulation is inaccurate and that currently  accepted, and taught, models of allostery 
are wrong. This new model of allostery  for E. coli ATCase unifies all old and current 
data for ATCase regulation, and has clarified many previously unexplainable results.
ii
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Chapter 1: Introduction
1.1 ATCase: Structure and Function
 Aspartate transcarbamoylase (E.C. 2.1.3.2, aspartate carbamoyltransferase, 
ATCase) is an enzyme that  has been extensively  studied over the last 50 years.1, 2 
ATCase is a transferase enzyme in the de novo pyrimidine nucleotide biosynthetic 
pathway  and the products, the pyrimidine nucleotides,  are incorporated into DNA 
and RNA. ATCase catalyzes the transfer of the carbamoyl group of carbamoyl 
phosphate (CP) to the amino group of L-aspartate (Asp). The reaction proceeds 
through  the formation of a tetrahedral intermediate which collapses to the products 
N-carbamoyl-L-aspartate (CA) and inorganic phosphate (Pi) (Fig. 1-1).
Figure 1-1 | The reaction  catalyzed by  ATCase.  Nucleophilic attack of the carbamoyl group 
on  CP by  the amino group of Asp leads to the formation  of a  tetrahedral intermediate. 
Collapse of the intermediate gives the products CA  and Pi. N-phosphonacetyl-L-aspartate 
(PALA) is a potent inhibitor of ATCase.
 Pyrimidine nucleotide biosynthesis, like all metabolic pathways, is a highly  
regulated  process. One such regulation mechanism is feedback inhibition, where the 
enzymes responsible for early  reactions in the pathway  are regulated by  downstream 
2
products.3 In many  prokaryotes this enzyme is ATCase, as the formation of CA is the 
committed step in pyrimidine biosynthesis for certain  species. However,  in higher 
organisms such as mammals, the point of regulation is the preceding enzyme in the 
pathway, carbamoyl phosphate synthetase (CPSase).
 ATCases have been studied from  numerous prokaryotic and eukaryotic 
sources. Three classes of prokaryotic ATCases have been identified, defined by 
differences in quaternary  structure and association  with other proteins.4-7 ATCases 
that are classified as Class A contain  a catalytic subunit encoded from  the gene pyrB 
complexed in a 1:1  ratio with  either an active dihydroorotase (DHOase), the enzyme 
encoded by  the gene pyrC that catalyzes the next step in pyrimidine biosynthesis, or 
an inactive DHOase-like protein  (Fig. 1-2A). Class B ATCase holoenzymes consist of 
two types of subunits: the pyrB encoded catalytic subunit and the pyrI  encoded 
regulatory  subunits.  The Class B holoenzyme is a dodecamer consisting of two 
catalytic trimers and three regulatory  dimers (Fig. 1-2B). These subunits are 
dissociable upon chemical or  physical treatment.8 There is a subclass B’ that has 
been identified in  the thermophilic species Thermatoga maritima and Treponema 
denticola.9 Class B’ has catalytic and regulatory  subunits that are covalently  linked 
and therefore can  not be dissociated. Finally, Class C ATCases exist as unregulated 
catalytic trimers (Fig. 1-2C).10 Eukaryotic ATCases are often part of multifunctional 
enzyme complexes. In mammals specifically, the enzyme is part of the CAD complex 
(CPSase, ATCase, DHOase), where the ATCase component resembles the 
prokaryotic Class C trimers.11, 12 Currently  there are no high resolution structures of 
eukaryotic ATCases or the multifunctional enzyme complex.
3
A B C 
Figure 1-2 | Quaternary  structures of different  classes of ATCase.  (A) Class A  are 
complexed with  DHOase or  a DHOase-like inactive protein,  (B)  Class B ATCases are 
dodecomeric  containing  regulatory  subunits (purple) and catalytic  subunits (blue) that  are 
dissociable upon  chemical or  physical treatment, (C) Class C ATCases exist  as unregulated 
trimers.
 Although there are differences in assembly  and quaternary  structure across 
species, all ATCases are composed of a basic subunit and assembled as catalytic 
homotrimers.  The oligimerization of the catalytic polypeptide is critical for  function 
because each active site is located at the interface of two adjacent  chains with 
catalytic residues donated from  both chains.13 The primary  sequence of the catalytic 
chain of ATCase is highly  conserved. Based upon an analysis of 250 species, 20% of 
the residues are conserved, including all of the residues thought to be involved in 
catalysis. (Fig.  1-3).  The most  studied form  of the enzyme is the Class B ATCase from 
Escherichia coli which will be the ATCase discussed in detail.
4
5
Figure 1-3 | Sequence alignment of ATCase from  250  different sequences.  The numbering 
of the residues is based on  pyrB from  E.coli K12.  Relative size of the amino acid codes 
corresponds to conservation  across species.  Note the high  level of conservation in 50s,  80s, 
105, 130s, and 230s regions (Active site residues). This image was created using WebLogo.14
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1.2 Allostery
 E. coli ATCase, being a Class B ATCase, has regulatory  properties that are 
coupled with  catalytic activity  and is part  of a whole class of enzymes known as 
allosteric enzymes.  Allostery  was first discovered by  Bohr in 1904  through  the 
sigmoidal oxygen-binding curve of hemoglobin.15, 16 The observation that 
hemoglobin exhibited an increased affinity  for  O2 as the partial pressure of O2 
increased indicated that oxygen bound cooperatively.  Another allosteric effect 
observed was the influence in O2 affinity  by  the binding of CO2 or  2,3-
bisphosphoglycerate (BPG). The molecular basis for these allosteric effects was 
determined through the crystal structure of hemoglobin solved by  Perutz in 1964.17 It 
was determined that hemoglobin  existed in  two different conformations: a T (tense) 
state that had low affinity  for O2 and a R (relaxed) state that  had a high affinity  for 
O2. The binding  of O2 to the heme of one subunit  induced the transition to the R state 
and thus increasing the affinity  for O2 to the hemes in the other subunits of the same 
molecule. It was also found that CO2 and BPG bind to sites other than the heme that 
stabilize the T state of hemoglobin and thereby lowering oxygen affinity.
 Because ATCase has been investigated extensively, it has become a paradigm 
of allostery  and has been referred to as the “hemoglobin of enzymology.”18 The 
allosteric properties of ATCase allow the enzyme to control the rate of flux 
throughout the pyrimidine nucleotide biosynthetic pathway.19 ATCase exhibits both 
homotropic and heterotropic regulation. Downstream products of pyrimidine 
biosynthesis,  CTP and UTP, are heterotropic effector  molecules and bind to remote 
sites on the enzyme that significantly  change the catalytic rate.19, 20 Like the oxygen-
7
binding curve of hemoglobin, the aspartate saturation curve of ATCase is sigmoidal 
in  shape, meaning that Asp binds cooperatively.3 Asp is a  homotropic effector  of 
ATCase in that as the concentration of aspartate increases, the affinity  of the enzyme 
for Asp also increases. Like hemoglobin, ATCase exists in two states that differ  in 
activity  and substrate affinity.  There are two different theoretical models that have 
been proposed to explain allostery  in proteins,  a sequential model and a concerted 
model. 
 The sequential model was proposed by  Koshland, Nemethy, and Filmer 
(KNF)21 and is outlined in Fig. 1-4. Their model states that any  of the subunits of the 
protein can be in two conformational states, the T and R states. They  proposed that 
the binding of a ligand induces the transition from  the T state to the R state in the 
same subunit. The affinity  for  the ligand in adjacent subunits is affected by  the 
conformational change of this subunit because the interface between them is altered.  
 The concerted model of allostery  was proposed by  Monad, Wyman, and 
Changeux (MWC)22 and is outlined in  Fig.  1-5. The MWC model is referred to as a 
concerted model.  In this model, the protein is in  equilibrium  between two 
conformational states: the T state that has a low affinity  for  ligands and the R state 
that has a high affinity  for ligands. The binding of a ligand to one subunit of the high 
affinity  R state locks the other  active sites of the enzyme into the R state. The binding 
of a ligand shifts the equilibrium (L) of the two unbound states toward the R state, 
thus reestablishing equilibrium. In the case of ATCase, the equilibrium constant L = 
[T]/[R] is about  250 in the absence of any  homotropic or  heterotropic effectors.23 
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This equilibrium  shifts more towards the T state or  the R state in the presence of 
effector molecules (described below).
Figure 1-4 | Simplified scheme of the KNF (sequential) model of allostery.24 (Top) Gold and 
brown  colors of the protein  subunits indicate the T  and R states, respectively.  The blue 
square represents the binding  of a  ligand and the allosteric transition of the same subunit to 
the R state.  In  this model the affinity  neighboring  subunits have for  ligands is altered due to 
changes in  the subunit  interface.  (Bottom) Same model describing the binding of an 
inhibitor to the T state of the protein.
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Figure 1-5 | Simplified scheme of the MWC (concerted) model of allostery.24 Orange and 
pink protein  subunits represent the T  and R states,  respectively. The equilibrium  constant L 
is defined as the ratio [T]/[R].  The binding  of a substrate,  activator, or  inhibitor  shifts the 
equilibrium between bound and unbound states, thus shifting the equilibrium L.
1.3 ATCase Kinetics, Homotropic, and Heterotropic 
Regulation
 As previously  mentioned, ATCase exhibits a sigmoidal Asp saturation curve, 
as shown in Fig. 1-6. This suggests that the allosteric properties associated with 
homotropic regulation follow the MWC model of allostery. A study  by  Macol et al.24 
supported this theory  by  showing that a  hybrid holoenzyme that contained only  one 
functional active site was able to undergo the conformational change to the R state 
upon the binding of one molecule of N-phosphonacetyl-L-aspartate (PALA; see Fig. 
1-1), a bisubstrate analog and nanomolar inhibitor of ATCase.25
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Figure 1-6 | Asp saturation curves for WT ATCase in  the presence and absence (circles, 
blue) of nucleotide effectors.  ATP (squares,  green) shifts the saturation curve to the left 
enhancing  ATCase activity  at  all concentrations of Asp. CTP (triangles, red) shifts the 
saturation curve to the right  inhibiting ATCase activity  at  all concentrations of Asp.  Data 
shown was presented by  Kantrowitz.1 Concentration  of ATP and CTP were 4  mM and 2  mM 
respectively.
 ATCase is allosterically  regulated by  the heterotropic effectors CTP, UTP, and 
ATP. The end product of the pyrimidine nucleotide biosynthetic pathway, CTP, binds 
and allosterically  inhibits enzyme activity.19 In the presence of CTP, the Asp 
saturation curve is shifted to the right and the equilibrium constant  L is increased to 
1250.  23 The binding of CTP to the allosteric site lowers the affinity  the enzyme has 
for Asp (see Fig. 1-6). The pyrimidine nucleotide, UTP, binds to the enzyme but  only 
elicits a kinetic response if CTP is present.20 The synergistic inhibition of CTP and 
UTP is greater than that of CTP alone.  Conversely,  the end product of the parallel 
purine nucleotide biosynthetic pathway, ATP, binds and allosterically  activates the 
enzyme.19 The allosteric activation of ATCase by  ATP is enhanced by  the presence of 
Mg2+.26 Thus balanced purine and pyrimidine pools are maintained. In the presence 
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of ATP, the Asp saturation curve is shifted to the left, indicating an increase in the 
enzyme affinity for Asp, and the equilibrium constant L is reduced to 75.23 
 The heterotropic regulation of ATCase however, can not accurately  be 
described using the MWC model. Binding studies of CTP to ATCase have identified 
two classes of binding sites, a high affinity  site and a  low affinity  site.27 This could be 
explained by  negative cooperativity, where upon binding of a CTP molecule to the 
allosteric site, the binding of the next  CTP molecule becomes more difficult. The 
MWC model of allostery  can not explain negative cooperativity  as the conformational 
change of all the subunits is concerted. However,  the KNF model of allostery  does 
account for negative cooperativity,  as the conformational changes of one subunit 
affect neighboring subunits in  a sequential transition. This observation could also be 
explained by  asymmetry  between allosteric sites of a regulatory  dimer. Zhang et al.28 
proposed that the low affinity  CTP sites were actually  UTP binding sites for 
synergistic inhibition. Mendes et. al.29 showed that CTP and UTP could bind non-
competitively  to ATCase and that the binding constants for  each nucleotide were the 
same regardless if CTP was present first or UTP was present first, strengthening the 
theory that the two binding sites of the dimer were asymmetric. 
1.4 Quaternary Structure and Conformational Changes
! The quaternary  structure of E. coli ATCase is a dodecamer consisting of 
catalytic chains and regulatory  chains. The catalytic chains are organized into two 
trimers and the regulatory  chains are organized into three dimers.30 The spacial 
arrangement of these subunits is shown in Fig. 1-7. The upper  catalytic trimer 
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consists of catalytic chains c1, c2,  and c3 and the lower catalytic trimer consists of the 
catalytic chains c4, c5, and c6. The catalytic subunits lie on a single three-fold axis of 
symmetry. The three regulatory  dimers are composed of chains r1/r6,  r2/r4, and r3/
r5. Each regulatory  chain is adjacent  to the corresponding numbered catalytic chain. 
One of the three molecular  two-fold axes passes between the two regulatory  chains of 
the dimer.
 The T and R states of ATCase have been observed by  small-angle X-ray  
scattering (SAXS)31, 32,  sedimentation centrifugation33, and gel chromatography.34 
Each conformational state has also been characterized by  X-ray  crystallography  (Fig. 
1-8). The T state structure was determined in the absence of active site ligands.35 The 
T-state structure has also been determined with  the first substrate to bind, CP,36 and 
an analog of CP, phosphonacetamide (PAM).37 All of these structures are in the T 
state, however, there were several localized changes in  the active site with CP or  PAM 
binding. The binding of these ligands helps to create the high affinity  Asp binding 
site.  The R state ATCase structure was obtained by  crystallization in the presence of 
PALA.38, 39 The bisubstrate analog PALA induces the allosteric transition to the R 
state. The overall  conformational change between the T and R states results in an 
expansion of 11  Å and a rotation of 10° along the three-fold axis of symmetry.  Each 
regulatory dimer also rotates 15° along its respective two-fold symmetry axis.38 
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Figure 1-7 | Simplified model  of the quaternary  structure of ATCase.  The holoenzyme 
consists of two catalytic  trimers (yellow,  c1-c6) and three regulatory  dimers (red, r1-r6). The 
dimer  consisting  of r3/r5  is located in  the back  of the diagram  and is not visible.  The three-
fold axis of symmetry  (Blue arrow) is in  the  plane of the drawing. Three two-fold axes of 
symmetry (Teal lines) are perpendicular to the drawing.
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Figure 1-8 | Differences in  the T state and R state  quaternary  structures. The T state is 
elongated along  the three fold axis of symmetry  by  11  Å. A  rotation  of 10° around the three-
fold axis of symmetry  and 15° along  each  two-fold axis also occurs (not easily  visible from 
this perspective).38
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 Analysis of the T and R state structures determined sets of inter-domain 
interactions that  stabilized each state. A  cartoon schematic of all  T-state stabilizing 
interactions is shown in Fig. 1-9. A notable example of these stabilizing interactions 
is the inter-domain electrostatic interaction between Asp236 (c1) and Lys143 (r4).40, 
41 A mutation to either  of these residues results in a  destabilized T state structure, the 
consequence of which is a shift in the T to R equilibrium, causing the binding of only 
CP to stabilize the R state.The allosteric transition to the R state breaks the T state 
stabilizing interactions and new inter-domain interactions are formed that stabilize 
the R state. These interactions are shown in Fig. 1-10. 
Figure 1-9 | Proposed inter-domain interactions that stabilize the T state of ATCase.1
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Figure 1-10 | Proposed inter-domain interactions that stabilize the R state of ATCase.1
1.5 Catalytic Subunit
 The catalytic chains of E. coli ATCase are 310 residues long and have a 
molecular weight  of 34 kDa. The holoenzyme consists of six catalytic chains which 
creates a total of six active sites located between adjacent chains. Each catalytic chain 
consists of two domains: a CP-binding domain (residues 1-135 and 292-310) and an 
Asp-binding domain (residues 136-291).  The active site of ATCase is highly  positive 
to promote binding of the negatively  charged substrates, CP and Asp. Active site 
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residues include Ser52, Thr53,  Arg54, Thr55, Ser80, Lys84, Arg105, His134, Arg167, 
Gln231, Arg229, and Leu267. Shown in Fig.  1-11  are the interactions of these 
residues with PALA in the R state active site.
Figure. 1-11 | The active site of ATCase with  PALA  bound. Hydrogen bonding  interactions 
are shown as teal dotted lines. All active site residues are labeled.  A  (*)  denotes the residue is 
donated from the adjacent chain. Image was created in PYMOL42 using PDB 1D09.39
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 The binding of the substrates to the active site is ordered, with  CP binding 
before Asp.43 As previously  mentioned, the binding of CP to the active site induces 
localized conformational changes but does not  cause the allosteric transition to the R 
state. 36, 37 More specifically, these localized changes occur primarily  in the 50s loop, 
where these residues have moved more closely  to their R state positions.  The binding 
of Asp to the ATCase●CP complex induces the allosteric transition and causes the 
two domains to move closer  together. This creates the high affinity, high activity 
active site that facilitates catalysis.  After  the reaction occurs, the release of the 
products is also ordered with CA leaving before Pi.43
1.6 Regulatory Subunit
 The regulatory  chains of ATCase are 153 residues in length and have a 
molecular weight of 17  kDa. Each regulatory  chain is composed of two domains, the 
allosteric (AL) domain (residues 1-100) and the zinc (ZN) domain (residues 101-153). 
The ZN domain is responsible for tetrahedrally  binding a Zn2+ ion solely  for 
structural purposes.44 The allosteric domain contains the binding site for  the 
heterotropic effector molecules. These allosteric sites are located almost  60 Å away 
from the nearest  active site. The allosteric binding site has been characterized by 
crystal structures of ATCase in  complex with the nucleotides CTP36, 45, 46 and ATP.46 
Shown in Fig. 1-12,  CTP and ATP bind to the same site,  however  kinetic studies show 
opposite effects on the activity of the enzyme.
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Figure 1-12 | Overlaid structures of the allosteric binding  site in  the presence of CTP 
(green) and ATP (purple).  Allosteric site residues are labeled. Structures show  CTP and ATP 
compete for the same binding site .1
 Crystal structures of these ATCase●nucleotide complexes in  both the T and R 
states have been used as a structural basis to explain the shift  in equilibrium between 
the two states upon binding  of the heterotropic effector molecules. The structure of 
ATCase in the T state with  ATP bound showed that the separation of the catalytic 
trimers was expanded by  0.5 Å towards the R state.47 The structure of ATCase in  the 
R state with CTP bound showed the opposite effect, the separation of the catalytic 
trimers was reduced by 0.5 Å towards the T state.46
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1.7 Research Goals
 This work focuses on understanding catalysis in ATCase as well as 
investigating the esoteric aspects of regulation in E. coli ATCase. Chapters 2-4 
outline the work done exploring catalysis in ATCase and Chapters 5-7  describe new 
insights into regulation. Together, this work has allowed a  more complete 
understanding of the properties of ATCase such as cooperativity and allostery.
 Chapter 2  investigates the catalytic process of ATCase using X-ray  
crystallography  and molecular modeling. In  this work three crystal structures were 
solved mapping the first half of the catalytic cycle in the Class C ATCase from 
Bacillus subtilis. Crystal structures of B. subtilis ATCase were solved in the absence 
of ligands, with  CP bound, and with PALA  bound. Molecular modeling was used to 
visualize steps in the catalytic process that were unattainable by  crystallography, 
such  as models of the two reactants bound and tetrahedral intermediate bound in 
the active site. Studying  ATCase from  B. subtilis allowed the analysis of catalytic 
properties separate from  those coupled with regulation. This is the first Class C 
ATCase to be crystallized in the presence of substrates or substrate analogs.
 Chapters 3  and 4 shift  the focus from  catalysis to regulation, more specifically  
the role of UTP in the feedback inhibition mechanism. In  Chapter 3, X-ray 
crystallography  was used to show the binding of UTP to the allosteric site. How UTP 
bound to the enzyme was previously  unknown. Chapter 4 expands on the role of UTP 
in  the allosteric regulation of ATCase. A series of high resolution  X-ray  crystal 
structures was solved to elucidate how  UTP binds to the allosteric site in the 
presence of CTP. This work also led to the discovery  that metals play  a critical role in 
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the allosteric regulation of ATCase.  A new model of allostery  was proposed for E. coli 
ATCase that factored in this work as well as clarified published results that were 
previously unclear.
 Chapter  5 expands further on the influence metal ions have on ATCase 
regulation. In this work a complete allosteric model was proposed incorporating 
previous experimental results with new kinetic experiments in  the presence of 
different combinations of nucleotides with and without  Mg2+. New crystallographic 
evidence of metal ion involvement with  the structure of ATCase complexed with ATP 
Mg2+ was also presented.
 The final chapter  outlines the process for  creating ViewMotions Rainbow 
diagrams and describes a web server  developed to easily  and automatically  create 
them. These diagrams are an excellent resource for visualizing macromolecular 
motions in a two-dimensional image. These diagrams can be created from crystal 
structures of the two extreme conformational states. These figures have been created 
and used in several publications on ATCase,  however  this chapter  shows the utility  of 
ViewMotions Rainbow  diagrams in describing macromolecular motions in  any 
protein. 
 Two supplementary  chapters are included which outline work completed but 
have yet to be published. Supplementary  Chapter 1  is a structural analysis that deals 
with  the binding of PALA to the active site of ATCase. In this study  various analogs of 
PALA were co-crystallized with E. coli ATCase and the X-ray  structures were solved 
by  molecular replacement. These analogs were designed to reduce the overall charge 
of PALA by  substituting the negatively  charged functional groups with neutral 
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functional groups. Each crystal structure discussed provides insights into the role of 
each charged functional group on PALA by  analysis of the structural consequences 
associated with the substitution.
 S u p p l e m e n t a r y  C h a p t e r 2 d e s c r i b e s t h e s y n t h e s i s o f 7 -
[Bis(carboxymethyl)amino]-4-yl-methyl aspartate. This compound is known as a 
caged compound in that the substrate aspartate can be rapidly  and efficiently 
released by  photolysis and does not elicit  a  biological response before its release. 
This compound could potentially  be used to monitor the conformational changes of 
E. coli ATCase from the T state to the R state as a function of time. With the 
unprotected aspartate this transition occurs too quickly  to be measured due to 
instrument dead-time limitations. The T to R transition can be measured by  small 
angle X-ray  scattering (SAXS) techniques, coupled with a stopped flow apparatus. 
With a premixed solution of the caged substrate, a  homogeneous solution could be 
achieved without the transition occurring and therefore overcoming the dead-time 
limitations.
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Chapter 2: Crystallographic Snapshots of the 
Complete Catalytic Cycle of the Unregulated 
Aspartate Transcarbamoylase from Bacillus 
subtilis
This work was published in the Journal of Molecular Biology.
Harris, K. M., Cockrell, G. M., Puleo, D. E., and Kantrowitz, E. R. Crystallographic 
Snapshots of the Complete Catalytic Cycle of the Unregulated Aspartate Transcarbamoylase 
from Bacillus subtilis. Journal of Molecular Biology. 2011, 411, 190–200.
Contribution to work: Solved the structure of the B. subtilis ATCase•CP complex, involved 
in data analysis, and assisted in preparation of the manuscript.
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2.1 Summary
! Here we report high-resolution X-ray  structures of Bacillus  subtilis  aspartate 
transcarbamoylase (ATCase),  an enzyme that  catalyzes one of the first reactions in 
pyrimidine nucleotide biosynthesis. Structures of the enzyme have been determined 
in  the absence of ligands, in  the presence of the substrate, carbamoyl phosphate,  and 
in  the presence of the bisubstrate/transition state analog N-phosphonacetyl-L-
aspartate. Combining the structural data  with in silico  docking and electrostatic 
calculations, we have been able to visualize each step in the catalytic cycle of ATCase, 
from the ordered binding of the substrates, to the formation  and decomposition of 
the tetrahedral intermediate, to the ordered release of the products from  the active 
site.  Analysis of the conformational changes associated with these steps provides a 
rationale for the lack of cooperativity  in trimeric ATCases that do not possess 
regulatory subunits. 
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2.2 Introduction
 As outlined in Chapter 1.1,  the quaternary  structure of ATCases varies across 
different species. However, there is one repeating theme; the core catalytic unit  is 
composed of three chains (the catalytic chains) grouped together as a trimer (c3), 
exhibiting 3-fold rotational symmetry. The trimeric arrangement is required for 
catalysis, since the three active sites each occur at the interface between two adjacent 
chains with catalytic residues donated from both chains.1, 2 As is the case for many 
other transferases, each chain of ATCase is composed of two domains, specifically  CP 
and Asp domains, each binding their  respective substrate.  A  closure of the domains 
provides assistance in lowering the activation energy via catalysis by approximation.3
 The structurally  simplest ATCases are composed of one homotrimer of 
catalytic chains (Class C) and exhibit no cooperativity, as observed in  B. subtilis. 
Other organisms have more complex ATCases, as is the case in E. coli (see Chapter 
1.4).  The E. coli enzyme demonstrates both homotropic cooperativity  and allosteric 
regulation, mechanisms that modulate the rate of pyrimidine nucleotide 
biosynthesis.4 Unregulated ATCases often exist as multi-enzyme complexes with 
other pyrimidine biosynthetic enzymes. For example, several genera  of the fungi 
kingdom  such as Saccharomyces  and Neurospora display  ATCase as a complex with 
carbamoyl phosphate synthase (CPSase).5 However, in some eukaryotes, the first 
three enzymes in pyrimidine nucleotide biosynthesis, CPSase,  ATCase and 
dihydroorotase (DHOase), are fused together  on a  single polypeptide chain (CAD).6 
These enzymes oligomerize to create a complex with at least one ATCase catalytic 
trimer. Structural data  from a variety  of species have been determined but no 
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unregulated, trimeric ATCase has had its structure determined in more that one 
functional form.
 Numerous X-ray  structures of ATCase have been reported from a variety  of 
organisms in the presence and absence of substrates and substrate analogs,7 
although most of the structures are of the E. coli enzyme either as the dodecamer or 
the isolated catalytic trimer.  The E. coli catalytic trimer  has the same quaternary 
structure as the B. subtilis ATCase for  which structures are available in the absence 
of ligands8 and in the presence of PALA.9 These structures have been used to assess 
the allosteric mechanism  based upon a comparison of the structures of the isolated 
catalytic trimer with the corresponding component of the holoenzyme. From these 
studies the details of the catalytic cycle could not be deduced since the only 
information available is for the enzyme in the absence of ligands or  that with a 
bisubstrate analog bound. Although a structure of the holoenzyme in the presence 
and absence of CP is available,10 the conformational changes associated with ligand 
binding and those involved in allostery  are not  easy  to deconvolute. By  using the 
unregulated B. subtilis ATCase as our  model system, the conformational changes 
involved in allostery  are disconnected from those involved in substrate binding and 
catalysis. 
 Here we report a  description of the entire catalytic cycle of the unregulated 
ATCase from  B. subtilis. Using X-ray  structures in  the absence and presence of CP or 
a substrate analog (Table 2-1), in silico docking, and electrostatic calculations, we 
provide a molecular level glimpse into catalysis by  the unregulated ATCase that  helps 
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to explain  the manifestation of homotropic cooperativity  in those ATCases that 
exhibit this property. 
2.3 Results and Discussion
2.3.1 Overall Structure of B. subtilis ATCase
 The overall topology  of the B. subtilis ATCase structure is similar  to that 
observed for c3 units of other ATCases,  such as that from  E. coli,8, 11 and is congruous 
with  a previously  published 3Å α-carbon trace.12 All active site residues shown to be 
important  in other ATCases13 are conserved in the B. subtilis  enzyme, including 
Ser74 and Lys77, which are donated into the active site from an adjacent chain.
2.3.2 The binding of the first substrate, CP, in the ordered-binding 
mechanism
 In the ordered-binding mechanism,14 CP must bind before Asp. A comparison 
of the structures of the unliganded (open form) and ATCase•CP complexes reveals 
extensive conformational changes induced by  CP binding. Fig 2-1A illustrates these 
movements with  the unliganded structure highlighted in blue and the CP-bound 
structure highlighted in  red. These conformational changes are localized around the 
active site with the 40s (44-49), 70s (69-78), 100s (101-105),  120s (122-126), 160s 
(160-165), 180s (184-191) and 220s (212-225) loops all moving substantially  toward 
the CP binding site in the ATCase•CP structure (CP-bound form).
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Table 2-1. Data collection and refinement statistics
Unliganded CP-Bound PALA-Bound
Data collection
Space Group C2 C2 C2
Cell Dimensions:
     a, b, c (Å) 253.5, 153.0, 51.1 251.9, 153.0, 51.2 189.7, 141.4, 114.8
     α, β, γ (°) 90.0, 96.9, 90.0 90.0, 96.1, 90.0 90.0, 110.0, 90.0
Resolution (Å)a 50-2.20 (2.28-2.20) 50.0-2.10 (2.18-2.10) 50-2.60 (2.69-2.60)
Rsym(%)a 0.088 (0.52) 0.085 (0.61) 0.126 (0.61)
Average (I/σ) a 20.02 (3.21) 22.55 (3.31) 17.38 (2.98)
Completeness (%)a 99.9 (99.8) 100.0 (100.0) 100.0 (100.0)
Redundancy a 7.2 (6.8) 7.5 (7.5) 7.2 (6.8)
Refinement
Resolution (Å) 49.17-2.20 34.12-2.10 47.28-2.58
Reflections 98,205 111,454 88,161
Rwork / Rfree 0.17 / 0.20 0.17 / 0.20 0.18 / 0.22
Number of atoms
     Protein 6,974 6,922 13,752
     Waters 583 624 720
R.m.s. deviations
    Bond lengths (Å) 0.007 0.008 0.007
     Angles (°) 1.01 1.06 0.74
Mean B value (Å2) 45.4 47.8 36.6
a Values in parentheses are for the highest resolution shell
37
Figure 2-1 | Structural  changes of the α-carbon  backbone associated with  the binding of CP 
and PALA.  (A,B) Structure of one catalytic chain  of B. subtilis  ATCase along  with  the 70s 
loop from  the adjacent  chain  (70s loop*), and (C,D)  one catalytic chain  of E. coli ATCase 
along  with  the 80s loop from  the adjacent  chain (80s loop*) (A,C). The structure of the 
unliganded enzyme is shown  with  blue highlights,  while  the structure of the ATCase•CP 
complex is shown with  red highlights, CP represented as spheres,  and active site residues as 
sticks. (B,D)  The structure of the ATCase•CP complex  is shown  with  blue highlights,  while 
the structure of the ATCase•PALA  complex  is shown  with  red highlights, PALA represented 
as spheres, and active site residues as sticks. The color  spectral change from  blue to red 
corresponds to 30  structures calculated linearly  between the two determined X-ray 
structures. PDB entries 1ZA1,11 1ZA2,11 and 1D0925 were used for (C) and (D).
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 The movement of the 40s loop, specifically  Arg49, dramatically  reconfigures 
the active site pocket  in the CP-bound form of the enzyme. Using Castp,15 the volume 
of the active site cavity  was calculated and is visualized in Fig.  2-2A-D. The binding 
of CP reduces the volume of the active site cavity  by  one-half, from 1848 Å3 (Fig. 
2-2A) to 918 Å3 (Fig. 2-2B). In  order to help understand how the substrates bind to 
the enzyme and induce the conformational changes (Fig. 2-1A,B), DELPHI16 was 
used to calculate the electrostatic potentials of each of the structures and the 
potentials were mapped onto the corresponding surface (Fig. 2-3A-D). In addition 
GLIDE,17, 18 in extra precision (XP) mode,19 was used to dock substrates to the 
unliganded and ATCase•CP structures as a tool to identify  potential binding sites. 
Shown in Fig. 2-3A is a sliced image of the surface of the unliganded enzyme. An 
area of significant positive electrostatic potential is observed where CP docks. The 
position of CP in Fig. 2-3A corresponds to the CP pose with highest affinity  to the 
unliganded enzyme. The docked position of CP is not the site observed in the 
ATCase•CP structure (compare the positions of CP in Fig. 2-3A and C). 
 Analysis of the structural data,  electrostatics, and docking results suggests 
that the initial binding of CP, particularly  the phosphate portion,  induces 
conformational changes of the 40s, 70s, 100s and 120s loops. The conformational 
changes of the 40s loop,  in particular  Arg49, reorient CP into a higher-affinity  CP 
binding site in the ATCase•CP structure (Fig. 2-2B). The GLIDE XP docking scores 
for CP binding to the unliganded structure and the ATCase•CP structure with CP 
removed are -6.8 and -9.6 kcal/mole, respectively. These in silico  docking 
calculations reveal that CP interacts mainly  with residues Arg49, Thr50,  Gln130 and 
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Arg281  of the unliganded enzyme. All of these interactions are maintained after the 
conformational changes induced by  CP binding except  for Arg281. In addition, new 
interactions are observed between CP and Ser47, Thr48, Arg99, His127  and Ser74 
from the adjacent chain. All of the interactions to CP in the ATCase•CP structure 
(Fig. 2-4A) explain the enhanced CP affinity  to the active site conformation of the 
ATCase•CP structure compared to the unliganded active site as predicted by  the 
GLIDE XP calculations.
Figure 2-2 | X-ray  structures of the B. subtilis  ATCase showing  the active site cavity  as 
calculated by  Castp15 (A-D).  (A) The active site  of the enzyme in  the absence of ligands. (B) 
The active site of the ATCase•CP complex  with  CP shown  as sticks.  (C) The active site of the 
ATCase•PALA  complex.  (D) A  cut  away  view  into the active site cavity  of the ATCase•PALA 
complex showing the interactions (dotted lines) between  the active site residues and PALA 
(sticks).
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Figure 2-3 | X-ray  structures of the B. subtilis  ATCase showing the active site electrostatic 
potential mapped onto the surface as calculated by  DELPHI16 (A-D). Also shown, 
represented as sticks,  are (A) CP,  (B)  Asp, (C) Asp, and (D) CA  docked into the structures. 
(A,B)  Solvent  accessible surface representation  of the structure of the B. subtilis  ATCase in 
the absence of ligands, (C)  in  the presence of CP,  and (D)  in the presence of PALA. The 
surface was sliced to reveal details of the active site.  The electrostatic  potential  of the 
structure was mapped onto the surface (-10 kT/e (red) to +10  kT/e (blue)).  The CP in  (C)  is 
that  determined in  the ATCase•CP complex,  and in (D) the Pi corresponds to the position  of 
the phosphonate of PALA.
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Figure 2-4 | Substrates, products and analogs  bound to ATCase. The active site orientation is the 
same as in Fig. 2-3. An asterisk indicates that the residue was donated into the active site from  the 
adjacent chain. (A) Structure of the ATCase•CP  complex with  Asp bound, as determined by  docking. A 
red arrow with  the head at the carbonyl carbon  of CP from the α-amino nitrogen  of  Asp demonstrates 
the first  chemical event in  the reaction  to form  TET. (B) Structure of  the ATCase•PALA  complex  with 
the tetrahedral intermediate (TET) docked in  place of  PALA. (C) Structure of the ATCase•PALA 
complex with  CA  docked into the active site in place of PALA. In  addition, a Pi was substituted for the 
phosphonate of  PALA. (D) Electron density maps of the ATCase•PALA  structure overlaid on the final 
refined coordinates. A  Fo – Fc electron  density map with PALA  omitted from the calculation is shown 
in  green contoured at 5σ, and a  2Fo – Fc electron density  map shown  in blue contoured at  2σ. (E) The 
active site of  the ATCase•PALA complex with a Pi at the position  occupied by  the phosphonate of 
PALA  (Pi1). Pi2 corresponds to one of  three binding sites for Pi determined in  the GLIDE docking 
calculations. (F) A  possible path  of  Pi release from the active site. For clarity  docked substrates are 
shown with pink carbon atoms, while substrates or  analogs determined by  crystallography  are shown 
with cyan carbons.
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2.3.3 The binding of the second substrate, Asp, in the ordered-binding 
mechanism
 A feature of the kinetics of many  ATCases including the B. subtilis enzyme is 
very  strong substrate inhibition by  Asp.20 A possible explanation for  the observed 
substrate inhibition  is that aspartate binds in a nonproductive mode with  its two 
carboxylates reversed. However, GLIDE XP docking  calculations on the unliganded 
structure provide another explanation. When Asp is docked to the unliganded 
enzyme, it docks to approximately  the same positively  charged pocket as does CP 
with  a GLIDE XP score of -6.5 kcal/mole (compare Fig. 2-3A and B). The ability  of 
Asp to bind to the same site as CP in the unliganded enzyme explains the strong 
substrate inhibition exhibited by Asp.
 The conformational changes induced by  the binding of CP dramatically  alter 
the active site pocket (compare Fig. 2-2A and B) and electrostatics of the active site 
(compare Fig.  2-3A and C).  In  the unliganded structure, the portion of the active site 
where Asp would be expected to bind in order  to react with CP is, essentially, neutral 
in  charge. However,  in the ATCase•CP structure, there exists a positively  charged 
pocket adjacent to CP. In order  to visualize how Asp might bind to the ATCase•CP 
structure, Asp was docked to the ATCase•CP structure using the XP mode of GLIDE. 
Shown in  Fig. 2-4A is the highest affinity  Asp docking pose with  a  GLIDE XP score of 
-8.4  kcal/mole. PROPKA21, 22 was used to calculate the pKa of the amino group of Asp 
in  the active site of the ATCase•CP complex: the calculation gave a pKa value less 
than 2, such  that at physiological pH Asp would bind to the ATCase•CP complex  with 
a neutral amino group, poised for nucleophilic attack.
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2.3.4 The reaction between CP and Asp to form the tetrahedral 
intermediate
 Stopped-flow small-angle X-ray  scattering (SAXS) has been used to establish 
that when Asp is mixed with the E. coli ATCase•CP complex, there is an alteration in 
the structure of the enzyme on the millisecond time scale.23 Although these 
experiments were performed on  a type of ATCase with both catalytic and regulatory 
chains, the structure of the E. coli ATCase•PALA complex after the Asp-induced 
conformational change has the same overall structure as the B. subtilis 
ATCase•PALA complex. Therefore, it would be expected that the structure of the B. 
subtilis ATCase•PALA complex corresponds to the overall structure of the enzyme 
immediately  upon the addition of Asp to the ATCase•CP complex. For the B. subtilis 
enzyme, these conformational changes are shown in Fig. 2-1B, with the blue 
highlighting the ATCase•CP structure and the red highlighting  the ATCase•PALA 
structure (closed form). The conformational changes associated with  Asp binding 
involve substantial motions of the 180s and 220s loops, which undergo smaller 
motions upon CP binding to the unliganded enzyme. However, the portions of the 
structure involved in the creation of the CP binding site are less altered upon the 
conversion to the closed form of the active site (compare Fig. 2-1A and B). 
 As indicated above, the conformational changes associated with the binding of 
CP not only  create a  physical binding pocket for Asp but  substantially  change the 
electrostatic environment of the active site (Fig.  2-3C). Shown in  Fig. 2-4A is the 
highest  affinity  pose of Asp docked into the ATCase•CP structure.  The Asp amino 
group nitrogen is 3.4Å from the carbonyl of CP and perpendicular to its plane, at an 
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optimal distance and orientation for the nucleophilic attack. Furthermore, the 
interactions to the carbamoyl group of CP observed in the ATCase•CP structure 
would further promote nucleophilic attack by  stabilizing the negative charge on the 
carbonyl oxygen of the transition state. 
 Asp docks to the ATCase•CP complex (Fig. 2-4A) such that its α-carboxylate 
interacts with Lys77  of the adjacent chain. Conformational changes that occur  as Asp 
binds to the ATCase•CP complex include the closure of the 220s loop towards the 
active site, allowing interactions to form between the β-carboxylate of Asp and 
Arg211  and Gln213. The structural data suggest that  Lys77  first positions Asp for 
nucleophilic attack, then acts as a bridge between the two substrate molecules, 
holding them together as the transition state forms (compare Fig. 2-4A and B). The 
binding of Asp causes the closing of the two domains of the catalytic chain creating 
the environment necessary  for  the formation of the tetrahedral intermediate (TET). 
The structural similarity  between PALA and TET suggests that PALA can be used to 
model the structure of the ATCase•TET complex (see Fig. 1-1).
 Shown in Fig. 2-4D is a closeup of the PALA binding site in the ATCase•PALA 
complex.  A total of 26 interactions position PALA in the active site, of which three 
are hydrophobic in  nature, and are not  shown in Fig. 2-4D. The plethora of 
interactions to PALA explains the nanomolar affinity of this bisubstrate analog.24 
 In order to validate the in silico dockings, PALA was docked into the 
ATCase•PALA complex with PALA removed. PALA docked within the cavity  shown 
in  Fig. 2-2C. All of the highest affinity  poses determined from  the docking 
calculations have the phosphonate in exactly  the same position as observed in  the X-
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ray  structure. Albeit, there were variations in the position of the β-carboxylate within 
this set  of poses. The GLIDE XP docking score of the highest affinity  pose was -11.7 
kcal/mole. For  comparison, the structure of the proposed tetrahedral intermediate 
(TET) was also docked to the ATCase•PALA complex with PALA removed using 
exactly  the same protocol. As seen in Fig. 2-4B,  the tetrahedral intermediate 
interacts with ATCase in essentially  the same manner  as does PALA. However,  the 
number of interactions increases from 26 to 28, two of which are hydrophobic in 
nature. Arg49, Lys77  and Gln130 form  additional interactions to TET that are not 
observed in the ATCase•PALA complex. Three of these interactions are to atoms that 
are not  available in the PALA structure. Two interactions are formed to the amino 
group on the tetrahedral carbon: one from  the side-chain of Gln130 and the other 
from the backbone carbonyl of Pro249. The side chains of Arg49 and Lys77  also 
interact with the bridging  phosphate oxygen. The GLIDE XP docking  score of the 
highest  affinity  pose of TET was -13.6 kcal/mole, almost 2  kcal/mole more negative 
than that calculated for PALA.
 The closure of the domains upon Asp binding further reduces the volume of 
the active site by  an additional one-half,  from 918 Å3 in the ATCase•CP complex (Fig. 
2-2B) to 411  Å3 in the ATCase•PALA complex  (Fig. 2-2C), essentially  forcing Asp 
toward CP. The closure of the domains also dramatically  alters the electrostatic 
environment of the active site (Fig.  2-3D).  Castp calculations indicate that the active 
site cavity  in the ATCase•PALA complex has no exit. This closed, positively  charged 
cavity  provides the perfect environment to promote the formation of the transition 
state and to stabilize its negative charge.
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 The ATCase•PALA complex  and the docked TET to the ATCase•PALA 
structure with PALA removed each show an interaction between the backbone 
carbonyl of Ala250 and the Asp amino group (Fig. 2-4B,D). Ala250 acts as a 
hydrogen-bond acceptor as Asp is brought into proximity  of the CP-binding domain, 
increasing the nucleophilicity  of the Asp amine. Ala250 is not conserved in all 
ATCases, however, since the interaction with  Asp involves the backbone carbonyl of 
Ala250, the nature of the side chain is unimportant. Interestingly, this particular 
alanine is flanked by  two proline residues, which are conserved. Moreover, this 
primary-sequence feature results in Ala250 having phi/psi angles in  a forbidden 
region of the Ramachandran plot. The unusual phi/psi angles at this position are 
observed in other ATCase structures even when alternate residues are present.10, 25
2.3.5 The breakdown of the tetrahedral intermediate to form CA and Pi
 The breakdown of the tetrahedral intermediate involves the collapse of the 
oxyanion and the release of Pi (see Fig. 1-1). For the E. coli enzyme, Gouaux and 
Lipscomb26 proposed that  the conformation of the transition state for the breakdown 
of TET involves an intramolecular proton transfer  where a  phosphate oxygen acts as 
a general base, accepting a  proton from  the ionized secondary  amine. The interaction 
between the phosphate oxygen and the amine proton completes a six-membered ring 
in  a chair  conformation, supporting their  modeling and mechanism for  the 
decomposition of the transition state.
 Analysis of the structure of TET docked into the B. subtilis enzyme (Fig. 2-4B) 
indicates the conformation of the transition state would, most likely, be in a 
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distorted chair  conformation. The structural data of the ATCase•PALA complex and 
the conformation of TET docked into that structure with PALA removed suggest an 
alternate mechanism, which  utilizes an enzyme-mediated proton transfer with Arg99 
acting as a  general acid. Using PROPKA, the pKa values of all ionizable amino acid 
side chains in the structure were calculated. The pKa of Arg99 was calculated to be 
6.2  as compared to the average pKa of 12.0 for all the other Arg residues in the 
structure. This decrease in the pKa can be explained by  the highly  electropositive 
pocket in which Arg99 lies (Fig. 2-3D). This extremely  low pKa value allows Arg99 to 
act as an acid at  physiological pH. The phosphate oxygen acceptor was 2.1Å from the 
labile Arg99 proton. Protonation of the phosphate group makes it  a better  leaving 
group and promotes product formation. 
2.3.6 The conformational changes needed for the release of the first 
product, CA
 There is sufficient room  in  the closed form of the active site pocket  (Fig. 
2-2C,D) to not only  accommodate PALA or TET but also the products CA and Pi. 
However,  the combination of CA and Pi takes up sufficiently  more space than PALA 
or TET, due to the required separation between the two products as opposed to the 
unimolecular  nature of PALA or TET. We propose that the closed form  of the 
enzyme, as exemplified by  the ATCase•PALA complex (Fig. 2-2C) is transient in 
nature. As the transition state decomposes, the products separate and destabilize the 
closed form. Based upon modeling, the 220s loop that closed in toward the active 
site during Asp binding now opens at least  partially. We estimate that the 
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conformation of the catalytic chain must relax back between 30-40% towards the 
CP-bound conformation before an  exit  route forms that is large enough for CA to 
leave the active site and be released into solution.
2.3.7 The exit of the second product, Pi, from the active site
 Once CA leaves the active site, the remaining product Pi can leave the active 
site via the same opening.  In silico docking calculations were performed on the 
ATCase•PALA complex with PALA removed and Pi positioned in place of the PALA 
phosphonate. Three different Pi locations were identified with GLIDE XP docking 
scores of -7.2, -7.1  and -6.3 kcal/mole (Fig. 2-4E,F). As the XP docking scores 
become more positive, the relative position of the Pi becomes farther  from the 
position occupied by  the phosphonate portion of PALA and closer  to the exit  from 
the active site.  These three positions suggest an exit route of Pi from  the active site 
(Fig. 2-4E,F).
2.3.8 Lack of cooperativity in the B. subtilis unregulated ATCase
 One of the properties of the B. subtilis ATCase that distinguishes it  from some 
other ATCases is its lack of homotropic cooperativity. The structure of the B. subtilis 
ATCase•CP complex, reported here, helps clarify  the lack of cooperativity  in c3 
ATCases. Although the wild-type B. subtilis ATCase is not cooperative, amino acid 
substitutions can result in the manifestation of cooperativity  in the B. subtilis 
ATCase. Specifically, the R99A mutation results in a cooperative enzyme with  a Hill 
coefficient of 1.5.27 As seen in Fig. 2-4A, Arg99 is critically  involved in the binding of 
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CP. Although  the R99A mutation allows the B. subtilis ATCase to manifest 
cooperativity, it has a  detrimental influence on both  the binding of CP and Asp. In 
order for  the R99A B. subtilis  ATCase to exhibit cooperativity, the enzyme shifts 
between two states that  differ  in activity  and/or  affinity  for substrate28, 29 The altered 
binding of the substrates to the R99A enzyme essentially  creates a two-state system 
that did not previously  exist,  providing an explanation for  the observed cooperativity 
of this mutant.27 
 How is it then that the E. coli ATCase holoenzyme (c6r6) exhibits cooperativity  
while the E. coli c3 ATCase and the wild-type B. subtilis ATCase do not? A 
comparison of the structural changes induced by  the binding of CP to the B. subtilis 
ATCase and the E. coli ATCase holoenzyme provides an explanation. As seen in Fig. 
2-1A, CP binding induces dramatic alterations to the B. subtilis enzyme structure, 
with  major  conformational changes involving the 40s, 70s, 100s, 120s, 160s, 180s 
and 220s loops. The binding of CP to the E. coli holoenzyme induces much less 
dramatic conformational changes, with only  the equivalent of the 40s and 70s loops 
undergoing major structural alterations26 (Fig. 2-1C). The reduced magnitude of the 
conformational changes is partially  due to stabilizing interactions between the 
catalytic and regulatory  chains that  restrict some of the loop motions observed in the 
B. subtilis enzyme. 
 The conformational changes induced by  the saturation of the unliganded B. 
subtilis ATCase with CP results in  the creation of active sites that  has high activity 
and high affinity  for Asp. Thus, Asp binding does not induce cooperativity.  In 
contrast, the R99A B. subtilis ATCase does not bind CP in the correct position  to 
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induce the necessary  conformational changes. Asp binding to one of the active sites 
in  the R99A ATCase•CP complex can transmit conformational changes to the other 
active sites, enhancing  their affinity  for Asp. In the case of the E. coli holoenzyme, 
the binding of CP alone does not  shift the active site conformation sufficiently  to 
create the high-affinity  binding site; rather, it is only  the binding of Asp to the E. coli 
ATCase•CP complex that causes the necessary  loop movements inducing 
cooperativity. This explanation is supported by  SAXS measurements that showed CP 
has little or  no influence on the quaternary  structure of the E. coli holoenzyme,30 
while the binding of Asp to the E. coli ATCase•CP complex induces the allosteric 
structural transition which manifests itself in the observed kinetic cooperativity.23 
Furthermore,  CP binding induces much larger  quaternary  conformational changes in 
versions of E. coli ATCase that have weakened interactions either between the 
regulatory  and catalytic chains31 or  between the two catalytic trimers in the 
holoenzyme.32
 The unique set  of three X-ray  crystallographic structures of B. subtilis ATCase 
reported here, in the absence and presence of a  substrate and a bisubstrate analog in 
combination with electrostatic calculations and ligand docking has provided 
sufficient data to visualize each step in the catalytic cycle of ATCase. The steps being 
the ordered binding of the substrates, the formation of the tetrahedral intermediate 
followed by  its decomposition  to the products, the conformational changes 
associated with these steps, and the ordered release of the products from  the active 
site.  In addition, this work has helped us understand the manifestation of 
homotropic cooperativity in some ATCases.
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3.1 Summary
 E. coli aspartate transcarbamoylase is feedback inhibited by  CTP and by  UTP 
in  the presence of CTP. Here, we show by  X-ray  crystallography  that UTP binds to a 
unique site on each regulatory  chain of the enzyme that is near to but  not 
overlapping with the known CTP site. These results bring into question all of the 
previously  proposed mechanisms of allosteric regulation in aspartate 
transcarbamoylase.
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3.2 Results and Discussion
 The preceding chapters have focused on work related to the catalytic activity  
of ATCase. The next several chapters shift the focus from catalysis to the properties 
of allosteric regulation observed for ATCase. To reiterate the regulatory  properties of 
ATCase outlined in Chapter 1.3, the enzyme exhibits regulation homotropically  by  L-
aspartate and heterotropically  by  nucleotide effectors. ATP, the end product of the 
purine biosynthetic pathway, is an activator  of ATCase, while CTP, as one of the end 
products of the pyrimidine pathway, is an inhibitor. The pyrimidine nucleotide UTP 
does not inhibit the enzyme alone, but  it  synergistically  inhibits the enzyme in the 
presence of CTP.1 The substrates and allosteric effector influence the equilibrium 
between the T-state and the R-state structures (see Chapter 1.4).2
 Structural and kinetic analyses have shown that ATP and CTP, which exhibit 
opposing effects on ATCase activity,  compete for  and bind to the same sites on the 
regulatory  chains,3 with one binding site per chain. Similarly, other studies have 
indicated that UTP and ATP bind competitively.4 Binding experiments have shown 
that for  both CTP and ATP there are three high-affinity  sites and three low-affinity 
sites per holoenzyme,5 suggesting that each regulatory  dimer  contains one high-
affinity  site and one low-affinity  site. Binding experiments using the isolated 
regulatory  dimer confirm the two classes of sites with high and low affinities.5 To 
explain the synergistic inhibition by  UTP in the presence of CTP, it has been 
proposed that CTP binds to the high-affinity  sites while UTP binds to the low affinity 
sites, since addition of UTP to ATCase with CTP bound results in a decrease in the 
number of CTP binding sites from six to three.6
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 The binding of nucleotides to the regulatory  sites was further investigated 
using an unnatural fluorescent amino acid (L-(7-hydroxycoumarin-4-yl)ethylglycine) 
in  place of Glu52, located near the nucleotide binding site.7 Fluorescence 
measurements showed that CTP and UTP did not bind competitively, consistent with 
the notion of a functional asymmetry  between the two allosteric sites of the 
regulatory  dimer. This study  also indicated that ATP, CTP, GTP, and UTP bind with 
similar affinities, and have two classes of binding sites, one with  high affinity  and 
one with low affinity.  However,  other studies have shown that UTP has a  much  lower 
binding affinity than CTP.8-10
 While CTP and UTP are structurally  very  similar, they  have very  different 
effects on ATCase activity. To further elucidate the mechanism  of UTP action, 
specifically  the synergistic inhibition in the presence of CTP and the lack of 
inhibition by  UTP alone, X-ray  crystallography  was used here to determine the 
structure of ATCase in the presence of UTP. R-state crystals of ATCase were obtained 
by  microdialysis in 50 µL wells using previously  reported conditions.11 The crystals 
were then dialyzed overnight in crystallization buffer plus 10 mM UTP. Before being 
flash  frozen in liquid nitrogen, the crystals were dipped into UTP crystallization 
buffer with 20% (v/v) 2-methyl-2,4-pentandiol. These crystals diffracted to a 
maximal resolution of 2.3 Å in space group P321  (Table 3-1). The 2.1  Å R-state 
structure of ATCase (PDB ID 1D09)12 was used as the initial model.  After  a number 
of rounds of refinement,  model building  and water placement, the final Rfactor/Rfree 
was 0.173/0.207. As an indication of the quality  of the refinement, Fig. 3-1  shows a 
portion of the electron density  map corresponding to a portion of the regulatory 
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chain. Residues 1-10 of the regulatory  chains were omitted from  the final model, due 
to weak electron density. Complete experimental details including data collection 
and refinement, are provided in the Supporting Information. Coordinates and 
structure factors for the structure have been deposited in the Protein Data Bank 
under accession code 4F04.
Table 3-1.  X-ray Data collection and refinement statistics
 RPALA•UTP
Data Collection Statistics
PDB entry 4F04
Space group  P321
Cell Dimensions
 a, b, c (Å) 121.3, 121.3, 155.1
 α, β, γ (°) 90, 90, 120
Resolution (Å) 50-2.30 (2.38-2.30)
Rsym 0.101 (0.698)
Average (I/σ) 33.5 (4.9)
Completeness (%) 100.0 (99.8)
Redundancy 23.2 (20.4)
Refinement Statistics
Resolution (Å) 49.7-2.3
Reflections 59217
Rwork/Rfree 0.173 / 0.207
Number of atoms
 Protein 7067
 Waters 291
R.m.s. deviations
 Bond lengths (Å) 0.009
 Angles (°) 1.10
Mean B value (Å2) 64.6
Values in parentheses are for the highest resolution shell
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Figure 3-1 | Electron  density  profile for  a portion  of the regulatory  chain of ATCase in  the 
presence of UTP.  The omit  electron density  is shown at  3.0 σ,  with  the refined coordinates 
overlaid.
 The main-chain root mean square deviation (RMSD) between the 1D09 and 
the UTP bound structures was 0.42 Å, indicating that the binding of UTP had little 
overall influence on the structure of the enzyme. For the regulatory  chain and its 
allosteric domain,  the main-chain  RMSDs between the structure with and without 
UTP were 0.43  Å and 0.47  Å, respectively, suggesting that UTP binding may  result in 
localized conformational changes near its binding site. Fig.  3-2  shows a 
representation of the conformational changes that occur  in the r6  regulatory  chain 
due to the binding of UTP. Besides motions near the N- and C-termini, the major 
conformational change is restricted to the 50’s loop (residues 48-58), with smaller 
motions in the 70’s helix (residues 68-77) and the 130’s loop (residues 129-134).
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Figure 3-2 | Structural  changes upon the binding of UTP to a  regulatory  chain of ATCase. 
The structure of ATCase in  the absence and presence of UTP (PDB ID 1D09)  are shown  with 
blue and red highlights, respectively. Thirty  structures are shown,  calculated linearly 
between  the two determined X-ray  structures.  The portions of the structures with  main 
chain RMSD greater than 1.5 Å are spectrally colored. 
 The binding site of UTP is located adjacent to,  but not overlapping with, the 
site canonically  occupied by  CTP and ATP.3 In the P321  space group the asymmetric 
unit  is composed of c1-r1-r6-c6 chains, or  one-third of the holoenzyme. The electron 
density  for  UTP is not as strong as the density  for  the protein overall. In addition, the 
electron density  for  UTP is weaker in the r1  than in the r6  chain.  Still, the data clearly 
show that UTP binds in this unique location on the regulatory chain.
 The relatively  weak electron density  observed for  UTP is reflected in the high 
B-factors of the UTP atoms,  173 and 140 Å2 for  UTP in the r1  and r6  chains 
respectively. These values are considerably  higher than the B-factors for the atoms of 
the r1  (76 Å2) and r6  chains (94  Å2). The weaker  electron density  of UTP in the r1 
versus r6  regulatory  chains suggests that these two sites have different affinities for 
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UTP. This supposition is supported by  the data, which show that the UTP in the r6 
chain makes more interactions with the protein  than the UTP in the r1  chain.   Fig. 
3-3 shows the interactions between UTP and the r6  chain, and stereo views of UTP 
bound in the r1  and r6  chains are shown in Fig. 3-4. Of particular  note is the stretch 
of residues Leu48-Pro49-Ser50-Gly51-Glu52 and Lys56, Leu58 and Lys60, which all 
interact with UTP in the r6  chain. These residues comprise the 50’s loop that 
undergoes the largest structural alteration upon UTP binding (see Fig. 3-2). In 
addition to these residues, Glu10, His20 and Arg41  also interact with UTP. The 
interaction between UTP and Arg41  is between UTP bound to the r6 chain and Arg41 
of the r1  chain. A complete list of the interactions with UTP in the r1  and r6  chains is 
provided in Table 3-2. The smaller  number  of interactions between residues in the r1 
chain and UTP reinforces the asymmetric nature of the r1  and r6  chains and provides 
support for  the previously  proposed hypothesis that there are two classes of UTP 
binding sites having different affinities for the nucleotide.7
Figure 3-3 | UTP bound to the r6  regulatory  chain  of ATCase.  Residues making  polar 
interactions (dashed lines) are shown  with  gray  carbons while those making  hydrophobic 
interactions are shown  with  light carbons.  The asterisk after  Arg41  is to indicate that  it  is 
donated from the r1 chain.
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Figure 3-4 | Stereo views of UTP bound to ATCase.   UTP is shown  in  the r1  (top) and r6 
(bottom) regulatory  chains in  the same orientation. Polar  interactions are shown  with  black 
broken  lines. Residues making interactions with  either  regulatory  chain, whether  or  not they 
interact  with  the UTP in  the particular  chain,  are shown  to emphasize the asymmetry  of the 
regulatory  dimer. The asterisk after  Arg41  is to indicate that it  is donated from  the adjacent 
regulatory  chain.  Residues drawn  with  light carbons have hydrophobic interactions with 
UTP while those with dark carbons have polar interactions.
 To show the spatial relationship between the new nucleotide-binding site and 
the canonical site, the surface of the regulatory  chain with  CTP (PDB ID 8AT1)13 and 
UTP bound are shown in Fig. 3-5A and B, respectively. To distinguish  between the 
two nucleotide binding sites in each regulatory  chain, the canonical site where ATP 
and CTP bind will be called the A site,  while the newly-discovered, UTP-binding site 
will be referred to as the B site. Thus,  each of the six  regulatory  chains of ATCase has 
two, the A and B, nucleotide sites.
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Table 3-2. Interactions between  the r1  and r6  regulatory  chains and UTP
Ligand Atom* Protein Atom Distance, Å, r1 Distance, Å, r6
O1G His20 NE2 3.2 3.2
O3G His20 NE2 2.8 3.1
O2’ Arg41a NH2 - 2.7
C1’ Leu48 CD1 4.1 3.9
C6 Leu48 CD1 4.6 4.8
C1’ Leu48 CB 5.1 4.6
C4’ Leu48 CB 4.8 4.6
C2’ Pro49 CG - 4.9
C3’ Pro49 CG - 4.1
C4’ Pro49 CG - 3.9
C5’ Pro49 CG - 4.6
O1G Ser50 OG - 2.5
O2G Ser50 OG 2.2 -
O2B Ser50 O 2.7 -
O3B Gly51 N - 2.6
O2G Glu52 N 3.6 2.8
O1G Lys56 NZ 2.6 3.3
O3A Lys56 NZ - 3.6
C4 Leu58 CD2 4.5 3.6
C2 Leu58 CD2 3.9 -
C5 Leu58 CD2 5.0 3.8
C6 Leu58 CD2 4.9 4.1
O4 Lys60 NZ 3.6 2.8
* The naming of atoms in UTP is based on the atom names in the crystal structure and are 
provided below for reference.
a This residue is donated from the r1 chain
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Figure 3-5 | Comparison  of the A  and B nucleotide-binding sites using  PDB ID 8AT1  to 
show  the CTP binding  location. The identical orientation  is shown  for  (A) CTP (white 
carbons) bound in the A site and for (B) UTP (gray carbons) bound in the B site. 
 Some of the residues that make direct  interactions with  UTP have been 
previously  studied by  site-specific mutagenesis. The mutation either  H20A14 or 
K56A15 resulted in complete loss of synergic inhibition by  UTP. These two residues 
make direct  contacts with UTP in  the B site, as shown in Fig. 3-3, explaining the loss 
of synergic inhibition. In  the case of the K56A mutant, previous studies could not 
explain the loss of synergic inhibition as Lys56 did not show any  interactions with 
CTP. 
 The X-ray  structure reported here shows that UTP binds to the B site, a site 
different from  the one normally  occupied by  CTP or ATP (A site). The lack of any 
evidence for  UTP binding in the A site suggests that UTP has a  significantly  higher 
affinity  for  the B site than the A site. The difference in UTP affinity  between the A 
and B sites can be explained by  electrostatic interactions between the UTP and 
Lys60. The 4-keto group of UTP has a more favorable electrostatic interaction  with 
69
the ε-amino group of Lys60 than with the main-chain oxygen atoms of Ile12 and 
Tyr89 in the A site. The oxygen atoms of Ile12  and Tyr89, as well as the 4-keto group 
of UTP bear partial negative charge due to resonance, leading to charge repulsion 
between the protein and UTP in the A site. This also explains why  previous 
crystallographic studies have not observed CTP in  the B site because positive charge-
charge repulsion would occur  between the ε-amino group of Lys60 and the 4-amino 
group of CTP. 
 With the discovery  that UTP binds to a unique site on the regulatory  chain, we 
propose a revised mechanism  of UTP action that is consistent with the structural 
data. The X-ray  structure of ATCase in the presence of UTP reported here provides 
an explanation for the lack of inhibition of the enzyme by  UTP alone, and the ability 
of UTP to synergistically  inhibit ATCase in the presence of CTP. As seen in Fig. 3-5A, 
B, the binding sites of CTP and UTP on one regulatory  chain of ATCase are close in 
proximity  but do not overlap. When UTP alone is present,  binding occurs exclusively 
at the B site, due to the above-mentioned stabilizing interactions between Lys60 and 
the 4-keto group of uracil. This same interaction prevents or reduces CTP binding at 
the B site. This is supported by  the fact that even at  relatively  high concentrations of 
CTP, no CTP is observed in the B site by  X-ray  crystallography.13 However, when 
UTP binds to the B site no allosteric inhibition is observed. 
 When CTP is present in the A site (see Fig. 3-5A), there is sufficient space for 
UTP to bind to the B site.  Previous studies have indicated that the affinity  of CTP is 
enhanced in the presence of UTP, and the binding of UTP is enhanced upon the 
binding of CTP.8 These data suggest that the two nucleotides act together in the 
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combined AB allosteric site to synergistically  enhance the binding of the other and 
induce conformational changes that  shift the T to R equilibrium  further  towards the 
T state than CTP alone can induce.  Thus, the binding of UTP to the B site functions 
to amplify  the effect of the nucleotide bound in the A site. The molecular basis of the 
synergistic inhibition could be via  interactions with  the 50’s loop,  the N-terminal 
and/or the r1:r6 interface, all of which are close to the B site.
 The structure of ATCase in the presence of UTP reported here shows that the 
previously  hypothesized CTP-UTP binding pattern is incorrect. It agrees with the 
notion that there is a  functional asymmetry  between the nucleotide sites of a 
regulatory  dimer, and indicates that  there are four  distinct nucleotide binding sites 
per  dimer. With the discovery  of this new allosteric site in  E. coli ATCase, the 
previously  proposed mechanisms for allosteric regulation based on two asymmetric 
nucleotide binding  sites per  regulatory  dimer must be revised. More crystallographic 
studies are needed to determine conclusively  the mechanism of the synergistic effect, 
although this study provides insights into the likely binding pattern.
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4.1 Summary
 E. coli aspartate transcarbamoylase (ATCase) allosterically  regulates 
pyrimidine nucleotide biosynthesis. The enzyme is inhibited by  CTP and can be 
further  inhibited by  UTP, although  UTP alone has little or no influence on activity; 
however, the mechanism  for  the synergistic inhibition is still unknown. In order to 
determine how  UTP is able to synergistically  inhibit ATCase in the presence of CTP, 
we determined a series of X-ray  structures of ATCase•nucleotide complexes. Analysis 
of the X-ray  structures revealed that (1) CTP and dCTP bind in a very  similar  fashion, 
(2) UTP, in the presence of dCTP or CTP, binds at a site that does not overlap the 
CTP/dCTP site, (3) the triphosphates of the two nucleotides are parallel to each other 
with  a metal ion, in this case Mg2+, coordinated between the β and γ phosphates of 
the two nucleotides.  Kinetic experiments showed that the presence of a metal ion 
such  as Mg2+ is required for synergistic inhibition. Together  these results explain 
how the binding of UTP can enhance the binding of CTP and why  UTP binds more 
tightly  in the presence of CTP. A mechanism for the synergistic inhibition of ATCase 
is proposed in which the presence of UTP stabilizes the T state even more than CTP 
alone. These results also call into question many  of the past kinetic and binding 
experiments of ATCase with nucleotides as the presence of metal contamination  was 
not considered important.
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4.2 Introduction
 Allosteric regulation is critical in  the overall control of many  metabolic 
pathways as the specific needs of the cell are fulfilled by  modulating the flux through 
the pathway. E. coli ATCase has been extensively  studied and has become a  classic 
model of allosteric regulation.1 As described in Chapter  1.3, kinetic studies have 
shown that the enzyme is inhibited by  CTP, activated by  ATP,2 and synergistically 
inhibited by  UTP in the presence of CTP.3 The kinetic response of the enzyme to 
these effectors helps to maintain  a balanced pool of pyrimidine and purine 
nucleotides in the cell.  Structural and kinetic data have shown that ATP and CTP 
compete for and bind to the same site in the allosteric domain, but exhibit opposite 
effects on ATCase activity.4 Binding experiments with the holoenzyme have shown 
that both  ATP and CTP exhibit  three high-affinity  and three low-affinity  sites,5 and 
binding experiments with the isolated regulatory  dimer have shown one high-affinity 
and one low-affinity  site per dimer.5 UTP alone binds but does not inhibit the 
enzyme unless CTP is present.6 Upon the addition of UTP, the number of CTP 
binding sites decreases from  six  to three suggesting that  CTP is binding  to the high-
affinity sites and UTP is binding to the low-affinity sites.7
 The binding study  of nucleotides to the allosteric sites by  fluorescence 
measurements (see Chapter 3.2) indicated that  CTP binds to the enzyme with the 
same affinity  regardless of the presence of UTP and vice versa,  suggesting that CTP 
and UTP do not compete for the same binding site.8 They  concluded by  speculating 
that the two identical allosteric sites on a regulatory  dimer were functionally 
asymmetric.
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 Understanding the allosteric mechanism of ATCase has proven difficult with 
many  conflicting results, notably  the observed asymmetry, and the synergistic 
inhibition by  UTP in  the presence of CTP. The R-state structure of the ATCase•UTP 
complex  discussed in Chapter 3 provided an important clue to understand the 
allosteric regulation of ATCase.9 UTP was shown to bind to the regulatory  chain of 
ATCase in a position different than previously  observed for either ATP or  CTP (see 
Fig. 3-5).  Peterson et al.9 proposed that each regulatory  chain consists of two 
adjacent but  not overlapping binding sites, the A and B sites, with ATP and CTP 
binding in the A site and UTP binding in the B site. In order  to determine how UTP 
is able to synergistically  inhibit ATCase in the presence of CTP, we determined a 
series of X-ray  structures of ATCase•nucleotide complexes including the structures 
of T•dCTP, T•CTP, T•dCTP•UTP, T•dCTP•Mg2+•UTP and T•CTP•Mg2+•UTP. By 
showing that dCTP and CTP bind in  essentially  the same manner to ATCase,  and that 
UTP can synergistically  inhibit ATCase in the presence of dCTP in kinetic 
experiments, we were able to use dCTP as a  surrogate for CTP in the structural 
studies.  The use of dCTP as a functional and structural analogue of CTP allowed us to 
distinguish the nucleotide bound in the A and B sites of the enzyme. These structures 
provide the critical information necessary  for the formulation of a  new  mechanism of 
allostery for ATCase.
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4.3 Results and Discussion
 Structural data of ATCase with only  CTP bound10 or only  UTP bound9 does 
not  clarify  how the two nucleotides synergistically  inhibit ATCase. A  single structure 
of the enzyme with both  nucleotides bound is needed to definitively  determine the 
mode of UTP binding to the enzyme in the presence of CTP and would help to 
elucidate the mechanism  of the synergistic inhibition. However, at a  resolution of ~2 
Å the electron density  profiles for CTP and UTP are virtually  indistinguishable. 
Therefore, we sought  a  functional analogue of CTP with an altered electron density 
profile that still retained UTP synergic inhibition. Previous studies have shown that 
dCTP inhibits ATCase to approximately  the same extent as CTP,11 suggesting  that the 
2’-hydroxyl group is not important  for allosteric inhibition of ATCase. UTP does 
function as a  synergistic inhibitor in the presence of dCTP. As seen in  Fig. 4-1, at 2 
mM dCTP inhibits the enzyme 67% as compared to 43% for CTP. The combination of 
2  mM dCTP and 2 mM UTP inhibits the enzyme 93% as compared to 86% for 2 mM 
CTP and 2  mM UTP. The ability  of UTP to synergistically  inhibit ATCase in 
combination with either dCTP or CTP allowed us to use dCTP as a surrogate of CTP 
in the structure determination.
4.3.1 Comparison of the T•dCTP and T•CTP structures
 To further validate the use of dCTP as a substitute for CTP, the structures of 
the T•dCTP and T•CTP complexes were determined. Identical conditions were used 
to co-crystallize the enzyme with either  dCTP or CTP. Both complexes crystallized in 
the P321  space group with almost identical unit cell dimensions (Table 4-1), and in 
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both cases data were collected to a  resolution  limit  of 2.1  Å. The structure of the 
ATCase•CTP complex determined here is at a higher  resolution than previously 
reported.4, 10, 12 
Figure 4-1 | Influence of nucleotides on  the activity  of ATCase. Relative activity  was 
measured at increasing  concentrations of nucleotide (NTP). When  UTP and CTP or dCTP 
were present  simultaneously,  the abscissa  corresponds to the total  nucleotide concentration. 
(A)  Influence on activity  of dCTP alone (○)  and of dCTP plus UTP•Mg2+ (●).  When  the 
concentration  of dCTP reached 2  mM,  UTP•Mg2+ was added. The UTP•Mg2+ concentration 
was increased from  0 to 2  mM while the concentration  of dCTP remained constant  (2  mM). 
(B) Identical experiment as depicted in (A) using CTP in place of dCTP.
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Table 4-1. Data collection and refinement statisticsa
T•dCTP T•CTP T•dCTP•UTP•Mg2+ T•CTP•UTP•Mg2+
Data collection statistics
PDB entry 4FYV 4FYW 4FYX 4FYY
Space group P321 P321 P321 P321
Wavelength 1.075 1.542 1.075 1.075
Cell Dimensions
a, b, c (Å) 120.7,120.7,142.5 121.3, 121.3, 142.3 121.2, 121.2, 141.8 121.1, 121.1, 141.4
α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (Å) 50 - 2.1 (2.2 -2.1) 43.2 - 2.1 (2.2 - 2.1) 50 - 2.1 (2.2 - 2.1) 50 - 1.9 (2.0 - 1.9)
Rsym 0.107 (0.562) 0.063 (0.450) 0.145 (0.684) 0.137 (0.608)
Average (I/σ) 15.0 (4.3) 11.8 (2.9) 13.2 (4.1) 11.9 (4.0)
Completeness (%) 99.8 (98.4) 99.7 (100.0) 100.0 (99.6) 100.0 (99.9)
Redundancy 23.1 (21.1) 5.4 (5.3) 22.3 (20.3) 22.0 (19.5)
Refinement statistics
Resolution (Å) 49.1 - 2.1 43.2 - 2.1 49.2 - 2.1 49.2 - 1.9
Reflections 70,567 70,733 71,745 89,120
Rwork/Rfree 0.176/0.216 0.184 / 0.229 0.165 / 0.213 0.193 / 0.237
Number of atoms
Protein 7082 7,083 7,149 7,140
Waters 496 571 634 574
R.m.s. deviations
Bond lengths (Å) 0.009 0.008 0.009 0.007
Angles (°) 1.18 1.13 1.07 1.14
Mean B value (Å2) 54.8 30.0 39.3 41.2
Ligand B value (Å2)b
CTP (r1/r6) 103.5/84.0 44.8/55.5 46.2/40.7 46.3/45.7
UTP (r1/r6) - - 46.6/42.0 43.9/47.2
Mg2+ (r1/r6) - - 47.1/43.4 45.5/44.4
aValues in parentheses are for the highest resolution shell.
bOccupancies of all ligands were 1.0.
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 Overall,  the T•CTP and T•dCTP structures are very  similar with a  main-chain 
RMSD of 0.187  Å. For comparison, the main-chain RMSD between the T•CTP 
complex  previously  determined (PDB ID 1ZA1) and the structure of the same 
complex  reported here is 0.221  Å. Both CTP and dCTP bind in the A site of the 
regulatory  chain, as defined by  Peterson et al.9 and bind with identical interactions 
with  the exception of the one involving the 2’-hydroxyl of CTP (Fig. 4-2). The binding 
site includes two Lys residues; Lys94 interacts with the phosphates of the nucleotide, 
and Lys60 interacts with the 2-keto group on the cytosine ring. Backbone atoms of 
Tyr89 and Ile12 also make polar interactions with the cytosine ring and His20 and 
Asp19 interact with the γ-phosphate and the 3’-hydroxyl group, respectively.  There 
are also several residues that contribute to the binding via hydrophobic interactions 
including Ile12, Val17, Leu58, Ile86 and Val91. 
 The binding of dCTP in the r1  and r6  chains is asymmetric. The all-atom 
RMSD between dCTP in the two chains is 2.28 Å. The position of the cytosine rings 
in  the r1  and r6  chains are nearly  identical,  however, the ribose triphosphate portion 
is displaced in  the r1  as compared to the r6 chain.  This displacement may  be due to 
the loss of an interaction between Lys94  and a γ  phosphate oxygen that is observed 
in  the r6 but not  in the r1  chain.  In fact, there are no interactions between the 
triphosphate portion of dCTP with the protein in the r1  chain. In the T•CTP complex, 
the CTP bound in the r1  and r6  chains exhibit very  similar interactions, and the all-
atom  RMSD between CTP in the r1  and r6 chains is 0.269 Å. The all-atom  RMSD 
between dCTP and CTP in the two structures bound in the r1  and r6 chains are 2.39 
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Å and 0.88 Å, respectively. The higher  RSMD in the r1  chain reflects the asymmetry 
observed between the r1 and r6 chains in the T•dCTP structure mentioned above. 
Figure 4-2 | Stereoview  of the r6  regulatory  site of ATCase shown with  (A) dCTP and (B) 
CTP bound. Polar  interactions are indicated with  dashed lines.  Simple Fo – Fc omit electron 
density  maps are shown at  3.0 σ.  For  these maps the nucleotides were omitted from  the 
calculations.
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4.3.2 The structure of the T•dCTP•UTP complex
 Crystals of the T•dCTP complex were dialyzed against a 5 mM solution of UTP 
in crystallization buffer for 12  hours before the crystals were dipped in 
cryoprotectant and frozen for  data collection. The previously  determined structure of 
the ATCase•CTP complex (PDB ID 1ZA1)10 was used as the initial model for  structure 
refinement.  This preliminary  structure of the T•dCTP•UTP complex suggested that 
dCTP bound in the A site and UTP bound in the B site on each regulatory  chain 
simultaneously,  with their  β and γ  phosphates essentially  parallel to each other. The 
data also showed excess electron  density  between the β and γ phosphates up to the 
11.0 σ  level.  This density  and its position could be explained by  the presence of a 
metal ion serving  to neutralize the repulsion of the negatively  charged phosphate 
oxygens of the dCTP and UTP. The metal ion would thereby  assist/stabilize the 
binding of the two nucleotides to the A and B sites by  diminishing the repulsion  of 
the phosphate oxygens and create an additional interaction site for  each  nucleotide. 
The buffers used for growth of these crystals contained no added metals so 
presumably  the electron density  observed was the result  of metal ion contamination 
in the buffer components or the nucleotide solutions. 
4.3.3 The synergistic inhibition of ATCase by CTP and UTP is metal 
dependent
 The preliminary  structure of the T•dCTP•UTP complex, discussed above, 
suggested that a  metal ion was coordinated between the β and γ  phosphates of the 
two nucleotides. Previous studies reported the allosteric effectors ATP and CTP are 
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influenced by  the presence of Mg2+, presumably  due to the formation of the 
ATP•Mg2+ and CTP•Mg2+ complexes.13-15 Honzatko et al.15 tested a  variety  of metal 
ions including Al3+,  Mg2+, Mn2+ and Ca2+ and found that Mg2+ and Mn2+ altered the 
response of the nucleotides the most. However, the influence of metal ions on the 
synergistic inhibition of ATCase by  UTP in the presence of CTP has not been 
reported. Since the concentration of Mg2+ in E. coli cells is approximately  2.5 mM,16, 
17 and the formation of Mg2+ nucleotide complexes is well established, the influence 
of Mg2+ on the ability  of UTP to synergistically  inhibit  ATCase in the presence of CTP 
was measured. For these experiments all nucleotide solutions were de-metaled 
before use (see Chapter 7.2.6 for method).
 As seen in Fig.  4-3, de-metaled UTP did not synergistically  inhibit  ATCase in 
the presence of dCTP or  CTP, although, de-metaled CTP or dCTP was able to inhibit 
the enzyme (see Fig. 4-1). The inhibition profile was different with  UTP•Mg2+ (1:1 
ratio).  UTP•Mg2+ was able to inhibit the enzyme in the presence of CTP or dCTP (Fig. 
4-3A,B).  Therefore,  the metal not  only  assists in the binding of UTP to the B site 
when CTP is present,  as suggested by  the structural data,  but also Mg2+ is critical in 
the synergic inhibition of the enzyme. Furthermore, the reported enhanced affinity 
of UTP in  the presence of CTP and vice versa6 can also be explained by  the Mg2+, as 
it would add additional binding loci for each nucleotide when present. 
 As a control, the influence of Mg2+ on the activity  of ATCase was determined 
in  the presence of 2 mM dCTP or  CTP (Fig. 4-3). In  both cases, the addition of Mg2+ 
increased the activity; however, the extent of the increase was not as large as the 
decrease induced by  the 2 mM dCTP or CTP. One explanation for this increase in 
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activity  is the ability  of Mg2+ to complex with CTP to form CTP•Mg2+. Depending 
upon the relative affinities of Mg2+ and ATCase for  CTP, the addition of Mg2+ may 
result in some dissociation of CTP from  the enzyme thereby  increasing enzyme 
activity.  This explanation is supported by  the results of the experiments in which 
UTP•Mg2+ was added. As seen in  Fig. 4-3, at low concentrations of UTP•Mg2+ there 
is also a small increase in relative activity  before the synergistic UTP inhibition is 
observed. Any free Mg2+ may be complexing with enzyme bound CTP.
Figure 4-3 | Influence of Mg2+, UTP and UTP•Mg2+ on  ATCase activity.  Each data  point 
was determined in  duplicate,  and the data  points shown  are the average.  Relative activity 
was measured in  the presence of either  2  mM (A)  dCTP or  (B) CTP with  increasing 
concentrations of Mg2+ (☐), UTP (○) and UTP•Mg2+ (●).
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4.3.4 The structure of the T•dCTP•Mg2+•UTP complex
 Since the preliminary  structure of the T•dCTP•UTP complex  suggested the 
presence of a  metal ion helping to neutralize the charges on the phosphate oxygens, 
and the fact that  the synergistic inhibition is not  readily  observed in the absence of a 
divalent metal (e.g.  Mg2+), the structure of the T•dCTP•Mg2+•UTP complex was 
determined. In this study,  T•dCTP crystals were dialyzed against crystallization 
buffer supplemented with 5 mM UTP and 5 mM Mg2+. The structure of the 
T•dCTP•Mg2+•UTP complex was essentially  identical to the preliminary 
T•dCTP•UTP structure, with the Mg2+ clearly visible between the dCTP and UTP. 
 Fig. 4-4A shows the 2Fo – Fc electron density  map of the nucleotides bound to 
the allosteric site. To verify  the assignment of dCTP to the A site and UTP to the B 
site,  electron density  maps were generated with UTP modeled in  the A site and dCTP 
modeled in the B site. In the case of UTP, the resulting Fo – Fc electron density  map 
showed significant negative density  around the oxygen at the 2’-hydroxyl in the A 
site (Fig 4-4B), indicating  that the molecule in  the A site was dCTP and not UTP. 
Furthermore,  the Fo – Fc electron density  map for dCTP bound in  the B site (Fig. 
4-4B) exhibited positive density  at  the 2’ ribose position indicating that the molecule 
in the B site was UTP and not dCTP. 
 The interactions observed between the protein and dCTP in  the A site (Fig. 
4-5A) of this structure are consistent with previously  published crystal structures of 
the T•CTP complex,10 as well as the structures of the T•dCTP and T•CTP complexes 
reported here.  As shown in Fig. 4-5A, UTP binds in the B site and exhibits 
interactions with N-terminal residues Gln8 and Val9, 50’s loop residues Ser50, 
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Gly51,  Glu52, and Lys56  and residues His20 and Lys60. The backbone atoms of the 
N-terminal residues Gln8 and Val9  make hydrogen bonding interactions with uracil 
and the ribose ring, while the 50’s loop residues hydrogen-bond with the 
triphosphate portion of UTP. Residues His20 and Lys60 are positioned at the 
interface of the A and B sites and each make contact with both nucleotides. His20 
interacts with the γ  phosphate on each molecule while Lys60 interacts with the 2-
keto group of dCTP and the 4-keto group of UTP (Fig. 4-5A).  In  addition to the polar 
contacts described, there are several hydrophobic interactions that  contribute to the 
binding of UTP in the B site involving Leu7, Leu48, Pro49, and Leu58.  
Figure 4-4 | The allosteric site of ATCase showing  the A  and B sub-sites.  (A)  Mg2+ (green 
sphere)  is coordinated to β and γ  phosphates of both  dCTP (green  carbons) and UTP (yellow 
carbons) and two water  molecules. (B) Modeling  of UTP in  the A  site and dCTP in  the B site. 
Shown  in both  (A) and (B) are the 2Fo – Fc (blue, 1.5  σ) and Fo – Fc  (green, 5.0 σ, and red, 
-3.5 σ) electron density maps.
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Figure 4-5 | Stereo view  of the nucleotide binding  sites in  the (A) T•dCTP•Mg2+•UTP and 
(B) T•CTP•Mg2+•UTP complexes. Polar  interactions are shown as magenta  dashed lines, the 
Mg2+ as a  green  sphere,  and ordered water  as red spheres. The asterisk after  Arg41  indicates 
that this residue is donated from the adjacent regulatory chain in the dimer.
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 The previously  reported structure of the RPALA•UTP complex was crystallized 
in  the presence of N-phosphonoacetyl-L-aspartate (PALA), which stabilizes the 
enzyme in the R state.9 The structures reported here are in the absence of PALA and 
in  the T state, based upon the vertical separation between the catalytic subunits. The 
interactions between the enzyme and UTP in the RPALA•UTP complex in the r6  chain 
are identical to those observed in the T•dCTP•Mg2+•UTP complex with  the exception 
of Arg41  from  the adjacent regulatory  chain.  In the structure reported here, Arg41 
makes a  water mediated interaction with the 3’-ribose oxygen of UTP (Fig. 4-5A). 
The most likely  reason this interaction is not a direct interaction, as seen in the 
RPALA•UTP complex, is the conformational difference of the regulatory  dimer 
between the T and R state structures. 
4.3.5 The structure of the T•CTP•Mg2+•UTP complex
 Based on the fact  that in the T•CTP complex no CTP was observed in the B 
site,  crystals of the T•CTP complex were dialyzed into crystallization buffer 
containing 5 mM UTP and 5 mM Mg2+ for 12 hours in an identical fashion as 
indicated above for the crystallization of the T•dCTP•Mg2+•UTP complex. Crystals 
were then cryoprotected and flash frozen before data collection. Although the density 
of the nucleotides in the A and B sites are nearly  identical, CTP was modeled into the 
A site and UTP was modeled into the B site (Fig.  4-5B), because of the selective 
binding observed for  dCTP/CTP in the A site and UTP in  the B site. All the 
interactions mentioned above between the enzyme and dCTP and UTP are present in 
the T•CTP•Mg2+•UTP structure. However, there is an additional polar  interaction 
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between the 2’-hydroxyl of CTP and the 4-keto group of UTP. Interestingly, the 
interaction between Lys60 and the 2’-hydroxyl group observed in the T•CTP complex 
(Fig. 4-2) was not present  in the T•CTP•Mg2+•UTP complex.  As seen in Fig. 4-6, the 
Mg2+ in the T•CTP•Mg2+•UTP complex exhibits square bipyramidal geometry  with all 
oxygen ligands. The oxygens in the four equatorial positions are donated by  β and γ 
phosphate oxygens of both CTP and UTP, while the axial positions are both donated 
from oxygens of water  molecules.  Hydrogen bonding  interactions that the Mg2+ 
creates, between the side chains of Asp19, His20 and the phosphate oxygens add to 
the interactions between the two nucleotides.
 These structural and kinetic results call into question many  of the previously  
reported binding and kinetic studies involving  the function of the allosteric effectors 
on ATCase, as these studies did not take into account metal ion contamination. Steps 
to control metal ion contamination prior to binding and kinetic experiments with 
ATCase should be taken to ensure that  the allosteric response of the enzyme 
corresponds to what are most likely the conditions in the cell.
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Figure 4-6 | The metal binding  site in  the allosteric  regulatory  site of ATCase.  For  clarity 
only the triphosphate portion of the nucleotides are shown.
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4.3.6 Nucleotide binding site specificity
 X-ray  structures of ATCase•CTP and the RPALA•UTP9 complexes showed that 
CTP and UTP bind at close but not overlapping sites in the allosteric domain.  Fig.  4-7 
shows the electrostatic potential of the protein, calculated using  Delphi,18 mapped 
onto the surface. The entire nucleotide binding site exhibits an overall positive 
electrostatic potential, which would enhance the binding of the triphosphate portion 
of the nucleotides in the A and B sites. 
Figure 4-7 | X-ray  structure of the T•CTP•Mg2+•UTP complex  showing the r6  regulatory 
chain  electrostatic potential  mapped onto the solvent  accessible surface in  the absence of 
ligands, as calculated by  Delphi.18  Also shown  are the regulatory  site ligands, CTP, UTP, 
Mg2+ and the two water  molecules that complete the coordination  sphere of the Mg2+.  The 
electrostatic potential of the structure was mapped onto the surface (-10  kT/e (red) to +10 
kT/e (blue)).
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 The specificity  of CTP for the A site is related to the electrostatic and hydrogen 
bonding interactions with the cytosine ring. The most positive portion of the binding 
site,  corresponding to Lys60, interacts with the 4-keto group of UTP, and the 2-keto 
of CTP, which have negative partial atomic charges. In the A site, the 4-amino group 
of CTP with a  partial atomic charge of +0.4, as calculated using Jaguar (Schrödinger, 
Inc.), interacts with the backbone oxygen atoms of Tyr89 and Ile12, which have 
partial atomic charges of -0.6 and -0.5 respectively. If UTP were to bind in the A site, 
there would be no hydrogen bonding donors to form  interactions with  Ile12  and 
Tyr89 suggesting that UTP would have diminished affinity  for  the A site as compared 
to the B site.
 The specificity  of UTP for  the B site is related to the electrostatic and 
hydrogen bonding interactions with the uracil ring. In the B site,  the 2-keto group 
and the hydrogen on the 3  nitrogen of UTP, interact with the backbone nitrogen and 
oxygen atoms of Val9. In addition, the 4-keto group interacts with the ε-amino group 
of Lys60 and the 2’-hydroxyl of CTP. If CTP were to bind in the B site the 
interactions with Val9 would still be possible, however, the +0.4 partial atomic 
charge on the 4-amino group would result in a repulsive interaction with Lys60,  thus 
significantly reducing the affinity for CTP to the B site.
4.3.7 Conformational changes due to nucleotide binding
 A comparison of the T•CTP•Mg2+•UTP structure to a T-state structure in the 
absence of nucleotides (PDB ID 1NBE)19 indicates that the largest conformational 
changes are observed at  the N-terminus and the 50s loop in  the allosteric domain 
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and the 120’s and 130’s loops in the zinc domain. The conformational differences in 
the N-termini are most likely  due to the mobility  of these regions,  which is reflected 
in  weak electron density. For  this reason, between 5 and 9 residues were not 
included in the deposited coordinates. As Peterson et al.9 previously  observed in  the 
RPALA•UTP structure, the 50s loop is perturbed upon UTP binding as this loop has a 
number of interactions with the nucleotide.  The 120s loop, a  loop remote from the 
nucleotide binding site but in close proximity  to the regulatory-catalytic chain 
interface, undergoes structural alterations upon nucleotide binding. This 
displacement of the 120s loop may  propagate to the CP domain of the catalytic chain 
via the regulatory-catalytic chain interface.
4.3.8 The structures of the T•dCTP•Mg2+•UTP and T•dCTP•Mg2+•UTP 
complexes explain results of previous mutagenesis studies.
 The discovery  that  UTP binds to the B site of each regulatory  chain explains 
previous kinetic results observed for many  single amino acid substitution mutants of 
ATCase that  result in the loss of the ability  of UTP to inhibit catalysis in the presence 
of CTP. Until now the reasons why  regulatory  mutants K56A,20 K60A,21 H20A,22 
D19A,23 K6A,24 and L7A24 did not exhibit UTP synergistic inhibition were not known. 
From  this work, the side chains of Asp19, His20 and Lys60 interact  with both  CTP 
and UTP. The lack of synergistic inhibition previously  reported but not wholly 
understood at the time is most likely  due to reduced affinity  of both CTP and UTP. In 
the case of the D19A mutation, the binding of UTP in the presence of CTP could not 
be detected.23 Both Lys6 and Leu7  were shown by  crystallography  to be involved in 
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the binding of UTP in the B site, and the loss of these stabilizing interactions can 
explain why  the mutant enzymes do not exhibit  synergistic inhibition. The salt link 
between Lys56  and UTP explains the loss of synergistic inhibition,  when Lys56  is 
replaced by alanine. 
 While it  is clear  that these mutant enzymes would show  diminished 
synergistic effects because of the reasons mentioned above, the kinetic studies on all 
of the mutant enzymes involved in CTP and UTP binding can be questioned, because 
of the metal ion  site between the nucleotides. Kinetic experiments in  this study 
showed that  removal of trace metals in the nucleotide solutions resulted in no 
synergistic effect. In previous studies showing synergistic inhibition of UTP in the 
presence of CTP, it is most likely  that there were sufficient  amounts of metal ion 
contamination to induce the effect.  Since the intracellular concentrations of metals 
such  as Mg2+ are significant, metal ion involvement in the allosteric regulation of 
ATCase is certain. 
4.3.9 Mechanism of the synergistic inhibition of ATCase by UTP in the 
presence of CTP.
 Based upon the results reported here and previous studies we know: (1) CTP 
alone binds to the enzyme and causes inhibition, (2) Mg2+ has only  a  small influence 
on the inhibition of the enzyme by  CTP, (3) UTP alone binds to the enzyme but does 
not  cause inhibition,3, 9 (4) Mg2+ is required for the synergistic inhibition of the 
enzyme by  UTP in the presence of CTP, and (5) CTP and UTP bind at distinct sites 
on the regulatory  chain  that are not  overlapping. The crystal structures of the 
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T•dCTP•Mg2+•UTP and T•CTP•Mg2+•UTP complexes, along with these experimental 
results,  allow  us to propose a mechanism for the synergistic inhibition of ATCase by 
UTP in the presence of CTP. 
 The binding of CTP to the allosteric “A site”9 induces conformational changes 
within the enzyme resulting in a stabilization of the T state. In the absence of CTP 
the [T]/[R] ratio is about 250 which increases to about 1250 in the presence of CTP.
25 This shift in the [T]/[R] ratio explains the observed shift to the right in the 
aspartate saturating curve in the presence of CTP, and the decrease in enzyme 
activity  at a fixed concentration of aspartate. The fact that UTP can bind to the 
allosteric “B site”  in the absence of metals,9 but does not influence the activity  of the 
enzyme3, indicates that the binding of UTP alone does not stabilize the T or R states 
of the enzyme. However, under physiological conditions it is unlikely  that UTP would 
not be complexed with Mg2+.  The structures of T•dCTP•Mg2+•UTP and 
T•CTP•Mg2+•UTP both support a  model in which  the two nucleotides act together in 
a combined AB allosteric site. However, a combined allosteric response is only 
elicited if CTP is bound to the A site and UTP•Mg2+ is bound to the B site. The role of 
the Mg2+ is essentially  to allow both nucleotides to bind simultaneously, as the 
repulsion of their  negatively  charged phosphates would preclude their 
simultaneously  binding. Since the binding of UTP alone to the enzyme in the B site 
elicits no inhibitory  response,  we propose that the AB allosteric site, where the two 
nucleotides are linked by  a metal ion allows UTP to amplify  the kinetic response of 
the CTP bound in the A site. Thus, the T•CTP•Mg2+•UTP complex stabilizes the T 
state more than CTP alone, shifts the aspartate saturating curve to the right  more 
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than CTP alone,3 and the activity  of the enzyme is even more reduced than CTP 
alone, at a fixed concentration of aspartate.3
 Previous studies suggested that  the role of the B site to amplify  or  modify  the 
functional effect of the nucleotide in  the A site is not restricted to just  the synergistic 
inhibition of UTP in the presence of CTP. For  example,  Kleppe and Spaeren13 first 
observed that Mg2+ altered the response of the enzyme for ATP. Detailed kinetic and 
small-angle X-ray  scattering experiments26 showed that ATP•Mg2+ could stimulate 
the activity  of ATCase almost twice as much as ATP in the absence of Mg2+.  The 
enhanced stimulation of the enzyme by  ATP•Mg2+ may  be explained by  the 
simultaneous binding of two ATP molecules to the AB allosteric site bridged by  a 
Mg2+. Again in this case the B site nucleotide, here ATP, would amplify  the response 
of the ATP in the A site. ATP alone shifts the [T]/[R] ratio from  250 to about 70. The 
combined binding of ATP•Mg2+•ATP in  the allosteric site could stabilize the R state 
even more than ATP alone and reduce the [T]/[R] ratio even more. This change in 
the [T]/[R] ratio would shift  the aspartate saturating curve to the left such that at a 
fixed concentration of aspartate, the binding of ATP•Mg2+•ATP at the allosteric site 
would stimulate the enzyme more than ATP alone. In addition, Honzatko et al.15 
reported that GTP•Mg2+ had a  larger influence on ATCase activity  than GTP alone. It 
is clear  that the role of a metal cation in the allosteric regulation of ATCase has been 
underestimated. Furthermore, the data from  many  previous studies are now 
essentially  impossible to interpret correctly  as the extent of metal ion contamination 
is unknown. A reevaluation of nucleotide effects on ATCase is now required with 
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emphasis on nucleotide combinations in the presence of physiological levels of metal 
cations.
4.3.10  Rational for the synergistic inhibition of ATCase by UTP in the 
presence of CTP.
 As pointed out by  Wild et al.3,  high concentrations of CTP not only  feedback 
inhibit ATCase, but also inhibit CTP synthetase by  competitive inhibition of its own 
synthesis.27 A possible result of the inhibition of CTP synthetase would be to elevate 
levels of UTP. The synergistic feedback inhibition of ATCase by  UTP in the presence 
of CTP would therefore act to modulate the biosynthesis of UTP as well as CTP. 
However,  if cellular levels of UTP were low, the synergistic feedback inhibition of 
ATCase by  UTP would not occur allowing for  higher levels of pyrimidine nucleotide 
biosynthesis resulting in elevated levels of UTP. 
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4.4 Conclusions
 Although there have been many  binding and kinetic studies measuring the 
affinity  and functional consequences of nucleotide binding at  the allosteric sites of 
ATCase, discrepancies between these studies have hindered the development of a 
consistent mechanism  for allosteric regulation in ATCase. The findings in this work 
provide two new  facts that need to be reconciled with  all of the previous 
experimental data. First, the allosteric site on each regulatory  chain of ATCase can 
bind two nucleotide triphosphates simultaneously,  in adjacent but not overlapping 
sites. Second, a metal ion, Mg2+ in these studies, is required for the nucleotide in the 
B site to function and perhaps for binding as well. In the case of the synergistic 
inhibition of ATCase by  UTP in  the presence of CTP, it  is the UTP•Mg2+ bound in the 
B site that enhances the inhibition of CTP. UTP alone does not  inhibit the enzyme, 
since the A site has a preference for cytosine rather  than a  uracil base.  Furthermore, 
UTP does not enhance the CTP inhibition  without  Mg2+.  Since Mg2+ is known to 
enhance the allosteric activation of the enzyme by  ATP it  is more than likely  that  the 
AB allosteric site of ATCase can accommodate ATP•Mg2+•ATP in a similar fashion as 
has been shown here for CTP•Mg2+•UTP. New  structural and functional studies of 
ATCase are required to probe the allosteric response of the enzyme in the presence of 
nucleotides and metal ions,  conditions that would be more physiologically  relevant 
than those used in previous studies. 
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Chapter 5: A Unified Model for the Allosteric 
Regulation in E. coli Aspartate 
Transcarbamoylase
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Contribution to work: Solved the RPALA•CTP, and RPALA•CTP•Mg2+•UTP structures and did 
final refinements on all structures. Involved in data analysis and preparation of manuscript.
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5.1 Summary
 For  nearly  60 years the catalytic activity  of Escherichia coli aspartate 
transcarbamoylase (ATCase) has been reported to be allosterically  activated and 
inhibited by  ATP and CTP, respectively. We show  that  in the absence of metal ions 
neither CTP, UTP nor GTP alone have a significant influence on catalytic activity. 
However,  the combination of CTP, UTP and Mg2+ is able to allosterically  inhibit the 
enzyme by  88%, while the combinations ATP and Mg2+ or  ATP plus GTP and Mg2+, 
is able to activate the enzyme by  approximately  150%. To provide a  structural 
explanation for  the role of metal ions in the regulation of ATCase, 5 high-resolution 
X-ray  structures were solved. In the presence of Mg2+, two nucleotides bind to each 
allosteric site with the Mg2+ acting as a bridge to help neutralize the charges on each 
triphosphate. These results suggest that under  physiological conditions, the true 
allosteric inhibitor  and activator of ATCase are CTP•Mg2+•UTP and ATP•Mg2+•ATP/
GTP, respectively. Thus,  both end products of pyrimidine and purine nucleotide 
biosynthesis act simultaneously  to allosterically  regulate nucleotide metabolism. The 
X-ray  structures also reveal that the N-terminal region of the regulatory  chains exist 
in  different conformations in the allosterically  activated and inhibited forms of the 
enzyme suggesting a mechanism  for  specific T- and R-state stabilization. These 
results taken together allow us to propose a unified model for  allosteric regulation 
for ATCase.
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5.2 Introduction
 Although numerous models for allosteric regulation of E. coli ATCase have 
been proposed over  the last fifty  years, none are consistent with all of the currently 
available data on the response of the enzyme to the allosteric effectors. The following 
introduction  is a comprehensive summary  from  years of research on the allosteric 
regulation of ATCase (Chapter 1.2 and 1.3) as well as the recent  developments 
outlined in Chapters 3  and 4. All of this work, and the work presented here in this 
chapter, allow us to propose a complete model of allostery for E. coli ATCase.
 London and Schmidt first proposed a  model for  the allosteric regulation of 
ATCase in 1972.1 At that  time it was known that the E. coli ATCase holoenzyme was a 
dodecamer composed of six catalytic and six regulatory  chains,2, 3 regulation was lost 
upon dissociation of the holoenzyme to form catalytic trimers and regulatory 
dimers4,  the allosteric nucleotides bound to the regulatory  chains with a 
stoichiometry  of approximately  one nucleotide per regulatory  chain,5 and the 
allosteric inhibitor  CTP and the allosteric activator ATP were shown to exhibit 
competitive binding.6 The London and Schmidt Model1 rationalized how the enzyme 
was able to use a single binding site on each regulatory  chain to be activated by  ATP, 
inhibited by  CTP, ITP, and GTP, and was insensitive to UTP. They  proposed that  the 
ribose triphosphate portion of both nucleotides bound with similar  interactions. 
However,  the N3  of CTP and the N1  of ATP both acted as hydrogen-bond acceptors 
from a common hydrogen-bond donor on the enzyme. In addition, the amino group 
of each acted as a  hydrogen-bond donor to a common hydrogen-bond acceptor on 
the enzyme.  This arrangement would require a different conformation of the binding 
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site depending upon whether the smaller (cytosine) or  larger  (adenine) nitrogenous 
base was bound.
 In 1989 Wild et al.7 discovered that the allosteric regulation  of ATCase was 
more complex as UTP could inhibit the enzyme,  but only  in the presence of CTP, a 
phenomenon that was more pronounced at neutral pH than at higher  pH values.  The 
synergistic inhibition of ATCase by  the combination of CTP and UTP reduced the 
enzyme activity  by  approximately  95%, suggesting  that  both products of pyrimidine 
nucleotide biosynthesis needed to be present to fully shut down the pathway.
 Structural and functional studies of ATCase suggested a molecular basis for 
the synergistic inhibition of UTP in the presence of CTP. Crystal structures of the 
enzyme in a space group which contained two regulatory  chains in  the asymmetric 
unit  indicated that there was structural asymmetry  between the two regulatory 
chains that composed a regulatory  dimer.8 Furthermore, numerous binding studies 
showed that both  CTP and ATP bound to the holoenzyme and the regulatory  dimer 
with  two different affinities, suggesting that  within one regulatory  dimer  the binding 
of the nucleotides was asymmetric.5, 9, 10 
 Mendes et al.11 were able to obtain more detailed information about 
nucleotide binding to ATCase by  incorporation of the unnatural amino acid L-(7-
hydroxycoumarin-4-yl)ethylglycine very  close to the allosteric site of the enzyme. 
Analysis of fluorescence emission changes of an ATCase containing this amino acid 
in  the presence and absence of nucleotides, indicated that UTP and GTP bind with 
similar affinities as ATP and CTP, suggesting a dissociation between nucleotide 
binding and control of enzyme activity. Furthermore, the binding of CTP and UTP 
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were shown to be independent  suggesting that CTP and UTP do not compete for  the 
same binding site.
 Kleppe and Spaeren12 determined that the ATP•Mg2+ and CTP•Mg2+ 
complexes have modified regulatory  effects on the enzyme relative to the 
corresponding sodium nucleotides. Additional studies of the influence of metal ions 
on the regulation of ATCase carried out by  Christopherson et al.13 and Honzatko et 
al.14 showed enhanced activity  by  the complexes ATP, CTP or GTP with several metal 
ions (e.g.  Mg2+,  Mn2+, Ca2+,  Al3+ and Gd3+) relative to those produced by  the 
nucleotides in the absence of the metal ion. Fetler  et al.15 also determined by  small-
angle X-ray  scattering in  solution (SAXS) that the R state of the enzyme underwent 
significant structural alterations upon the binding of ATP and ATP•Mg2+. 
 Details of the allosteric regulation of ATCase became more clear when the 
structure of ATCase was determined in the presence of UTP (see Chapter 3).16 
Peterson et al.16 found that each  regulatory  chain bound UTP, however, the site at 
which UTP bound was near but not overlapping  the site at which  ATP and CTP 
bound. Cockrell and Kantrowitz17 then used dCTP as a  surrogate for CTP to 
determine the structure of the enzyme in the presence of both dCTP and UTP. This 
structure revealed that the allosteric site of each regulatory  chain could bind two 
nucleotides simultaneously.  This structure showed dCTP bound in essentially  the 
same manner as CTP to the A subsite and UTP bound to the B subsite consistent 
with  data from the ATCase•UTP structure.16 In the ATCase•dCTP•Mg2+•UTP 
structure the triphosphates of the two nucleotides are parallel to each  other with a 
Mg2+ coordinated between the β and γ  phosphates helping  to neutralize the negative 
111
charges. This work also showed that in absence of metal ions UTP was unable to 
synergistically inhibit ATCase in the presence of CTP (see Chapter 4).
 Two new  factors must now be incorporated into any  model for  allosteric 
regulation of ATCase. First,  each regulatory  chain has not one, but two sites capable 
of binding nucleotides, and second, a divalent metal ion  such as Mg2+ influences 
enzyme activity  by  allowing high-affinity  binding of nucleotides in the A and B 
subsites.  Many  of the past  studies examining the kinetic, stoichiometric, and 
thermodynamic consequences of the addition of nucleotides to ATCase were 
performed under conditions in which the divalent metal ion concentration was 
unknown and/or not controlled.  The omission of controlled metal ion concentrations 
in  previous experiments not only  helps to explain the wide discrepancy  in  the 
results5, 9, 10, 18-21 but also helps to explain the inability  of previous investigations to 
detect the binding of nucleotides to the B subsite and correctly  determine the 
stoichiometry  of nucleotide binding.  Here, we use kinetic studies to investigate the 
role of divalent  metal ions on the allosteric regulation of ATCase with ATP, GTP, CTP 
and UTP. In addition, we use X-ray  crystallography  to determine 5 structures of the 
R-state of ATCase with: ATP (RPALA•ATP) or CTP (RPALA•CTP) in the absence of 
metals, ATP (RPALA•ATP•Mg2+•ATP) or  UTP (RPALA•UTP•Mg2+•UTP) in the presence 
of Mg2+, and  CTP and UTP in  the presence of Mg2+ (RPALA•CTP•Mg2+•UTP).  These 
studies in conjunction with  previous work allow us to propose a  new  unified model 
for the allosteric regulation of ATCase.
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5.3 Results
5.3.1 Comparison of the effect of nucleotides on the activity of ATCase 
in the absence and presence of Mg2+ 
 To ensure that  the nucleotides did not have metal ion contamination, all 
nucleotide solutions were pretreated with Chelex 100 resin before use.  Table 5-1 
compares our  results, under identical pH and buffer conditions, with those of Wild et 
al.7 where the nucleotides were not pretreated to remove metal ion contamination. 
The results of Wild et al.7 with CTP alone or  in  combination with ATP or  GTP agree 
more closely  with our  results in  the absence of Mg2+, while the remainder of their 
data agrees more closely  with  our data in the presence of 1-2  mM Mg2+.  This trend is 
most evident for the data corresponding to the combination of CTP and UTP. Wild et 
al.7 reported a relative activity  of 0.06, while our result is 0.47  in the absence of Mg2+ 
and 0.12  in  the presence of Mg2+. In all likelihood the UTP used by  Wild et al.7 had 
more metal ion contamination than the other nucleotides used.  
 Fig. 5-1  and Table 5-1  show the influence of 2 mM Mg2+ on the activity  of the 
enzyme in the presence of various NTPs and NTP combinations. The data  in Table 
5-1  and Fig. 5-1  shows a number of interesting trends. First, the activation of the 
enzyme by  ATP is enhanced by  the presence of Mg2+,  increasing from  a relative 
activity  of 1.29 in the absence of Mg2+ to a relative activity  of 1.52 at  2 mM Mg2+. 
Second, the ability  of CTP to inhibit  the enzyme is reduced as the Mg2+ concentration 
increases. Third, the purine nucleotide GTP in the absence of Mg2+ is not inhibitory, 
however at 1  mM Mg2+ GTP inhibits the enzyme to a relative activity  of 0.61.  Fourth, 
in  the presence of Mg2+ the combination of the two purine nucleotides, ATP and 
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GTP, activates the enzyme about the same as ATP alone. Fifth, the ability  of CTP to 
reverse the activation by  ATP, as previously  reported,7 is possible only  in the absence 
of Mg2+. In the presence of Mg2+, CTP plus ATP results in a  relative activity  of 1.25, 
approximately  the same relative activity  as observed for  ATP alone (1.29). Sixth, in 
the absence of Mg2+, GTP or UTP alone have little influence on the activity  of the 
enzyme.
Table 5-1. Influence of Allosteric Effectors on the Relative Activitya of ATCase in  the 
Absence and Presence of Mg2+.
Mg2+ (mM)d
NTPb Reported Valuec 0 1.0 2 .0
none 1.0 1.0 1.0 1.0
ATP 1.35 1.29 ± 0.071 1.33 ± 0.067 1.52 ± 0.13
CTP 0.43 0.49 ± 0.011 0.80 ± 0.051 0.97 ± 0.050
UTP 0.95 0.99 ± 0.0068 0.97 ± 0.014 0.89 ± 0.036
GTP 0.71 0.95 ± 0.051 0.61 ± 0.060 0.84 ± 0.042
ATP + CTP 0.85 0.87 ± 0.023 1.25 ± 0.034
ATP + UTP 1.52 1.40 ± 0.055 1.43 ± 0.056
ATP + GTP 1.58 1.38 ± 0.041 1.57 ± 0.054
CTP + UTP 0.06 0.47 ± 0.098 0.12 ± 0.041
CTP + GTP 0.58 0.61 ± 0.080 0.81 ± 0.15
UTP + GTP 0.84 0.68 ± 0.011 0.75 ± 0.02
a Relative activity  was determined by  dividing the value of  specific  activity  of  ATCase in  the presence of 
nucleotide(s) by that in the absence of nucleotide(s).
b All nucleotide concentrations were 2 mM.
c The relative activities reported by Wild et al.7
d All  experiments were performed at  28 °C in  20 mM Bis-Tris, 20 mM Tris, and 20 mM CAPS buffer, pH 7.0 at 
saturating carbamoyl  phosphate (2 mM) and 5 mM aspartate. The values reported are the average of  four 
determinations.
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Figure 5-1 | Influence of allosteric effectors on  the activity  of ATCase in  the absence and 
presence of Mg2+ at  pH 7. Relative activity  was determined at  2  mM NTPs in the absence or 
presence of 2 mM Mg2+. Data used for this figure are provided in Table 5-1.
5.3.2 Kinetics of ATCase under maximal activation and inhibition
 As seen in Fig  5-1,  ATP•Mg2+ is able to enhance the activity  of ATCase more 
than ATP in the absence of Mg2+, an effect  that has been previously  shown 12-14. 
Furthermore in the presence of Mg2+, the only  significant  inhibition of the enzyme is 
induced by  the combination of CTP, UTP and Mg2+. Considering the physiological 
conditions of an E.  coli cell,  metal ions such as Mg2+ are in relatively  high 
concentrations.22 Therefore, under physiological conditions the regulatory  sites on 
each regulatory  chain should be filled by  two nucleotides bridged by  a metal ion. The 
highest  level of allosteric activation  of ATCase is with either ATP and Mg2+ or  a 
combination of ATP, GTP and Mg2+ (see Fig. 5-1). The highest  level of allosteric 
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inhibition of ATCase occurred with the combination of CTP, UTP and Mg2+ (see Fig. 
5-1).
 Aspartate saturation curves for  ATCase under maximal inhibition 
(CTP•Mg2+•UTP) and maximal activation (ATP•Mg2+•GTP) conditions are shown at 
pH 7.0 (Fig. 5-2A) and 8.3  (Fig.  5-3A).  These pH values were selected as almost all 
previous such curves for ATCase have either been performed at neutral pH (pH 7) or 
the pH at which the enzyme exhibits maximal activity  (pH 8.3). For  a direct 
comparison,  aspartate saturation curves in the absence of Mg2+ with  no nucleotides, 
and either ATP or CTP are shown in Fig.5-2B and Fig. 5-3B.
 At pH 7.0, the [Asp]0.5, the aspartate concentration at half the maximal 
observed velocity, is altered by  10-fold from  2.2 mM in  the presence of 
ATP•Mg2+•GTP to 22  mM in the presence of CTP•Mg2+•UTP (Fig. 5-2A). The enzyme 
does not exhibit cooperativity  in absence of nucleotides or in the presence of 
ATP•Mg2+•GTP,  however, the Hill coefficient increases to 2.0 in  the presence 
CTP•Mg2+•UTP. These curves emphasize the ability  of CTP•Mg2+•UTP to essentially 
shut down pyrimidine nucleotide biosynthesis under  physiological Asp 
concentrations of approximately 10 mM.
 The ability  of ATP•Mg2+•GTP to allosterically  activate ATCase and for 
CTP•Mg2+•UTP to allosterically  inhibit ATCase is even more evident at pH 8.3  (Fig. 
5-3A). At pH 8.3,  the [Asp]0.5 is altered by  more than 30-fold from  1.1  mM in the 
presence of ATP•Mg2+•GTP to 34.5 mM in the presence of CTP•Mg2+•UTP. In the 
presence of ATP•Mg2+•GTP the enzyme exhibits no cooperativity  however, in the 
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absence of nucleotides or with CTP•Mg2+•UTP the Hill coefficient increases to 
approximately 2.5.
Figure 5-2 | Asp saturation  curves in  the presence of NTPs and Mg2+ at pH 7.0.  (A) Data 
are shown  in the absence of NTPs and in  the absence (circle,  black)  or  presence of 2  mM 
Mg2+ (circle, gray),  in  the presence 2  mM CTP,  2  mM UTP and 2  mM Mg2+ (square,  black), 
in  the presence of 2  mM ATP,  2  mM GTP and 2  mM Mg2+ (triangle, black)  and in  the 
presence of 4  mM ATP and 2  mM Mg2+ (triangle,  gray). (B)  Asp saturation  curves in  the 
absence and presence of ATP and CTP in the absence of Mg2+.  Specific  activity, mM 
carbamoyl aspartate•min-1•mg-1, at  28ºC was determined colorimetrically  at  a  saturating 
concentration  of carbamoyl phosphate  (2  mM) and 2  mM MgCl2 in  20  mM Bis-Tris, 20 mM 
Tris, and 20 mM CAPS buffer.
 Fetler et al. 15 showed that higher concentrations of ATP and Mg2+, higher 
than used in our study,  resulted in an even greater increase in enzyme activity. They 
showed that 10 mM ATP•Mg2+ enhanced the activity  by  2-fold as compared to 10 
mM ATP in the absence of Mg2+ at  pH 8.3.  Fetler et al.15 also used SAXS to show that 
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there was a change in the R-state quaternary  structure of the enzyme in the presence 
of ATP and ATP•Mg2+ as compared to the R-state structure of the enzyme in the 
absence of ATP. In order to understand the molecular basis of Mg2+ involvement in 
the allosteric response of ATCase and the structural alterations induced by 
ATP•Mg2+, we determined the structure of ATCase in the presence of ATP alone and 
in the presence of ATP•Mg2+.
Figure 5-3 | Asp saturation  curves in  the presence of NTPs and Mg2+ at  pH 8.3. (A) Data 
are shown  in the absence of NTPs and in  the absence (circle,  black)  or  presence of 2  mM 
Mg2+ (circle, gray),  in  the presence 2  mM CTP,  2  mM UTP and 2  mM Mg2+ (square,  black), 
in  the presence of 2  mM ATP,  2  mM GTP and 2  mM Mg2+ (triangle, black)  and in  the 
presence of 4  mM ATP and 2  mM Mg2+ (triangle,  gray). (B)  Asp saturation  curves in  the 
absence and presence of ATP and CTP in the absence of Mg2+.  Specific  activity, mM 
carbamoyl aspartate•min-1•mg-1,  at  28º C was determined colorimetrically  at  a  saturating 
concentration  of carbamoyl phosphate  (2  mM) and 2  mM MgCl2 in  20  mM Bis-Tris, 20 mM 
Tris, and 20 mM CAPS buffer.
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5.3.3 Structure of the R-state of ATCase•ATP in the absence of metal 
ions
 There are two structures of ATCase with ATP bound deposited in the Protein 
Data Bank.23 The 2.6 Å T-state structure of ATCase in the presence of ATP (T•ATP, 
PDB ID 4AT1)24 shows one ATP bound to each regulatory  chain. The 2.8 Å R-state 
structure of ATCase in the presence of ATP (RPAM,MAL •ATP, PDB ID 7AT1)25 shows 
one ATP bound per regulatory  dimer, with the R state being induced by  the 
combination of phosphonoacetamide (PAM) and malonate (MAL). The publications 
corresponding to these structures make no mention of any  special treatment of the 
ATP to remove metal ion contamination. In addition,  the structure factors for 
neither structure have been deposited rendering it impossible from  the PDB data  to 
determine if any  electron density  was observed at the metal binding sites. Therefore, 
we determined the structure of ATCase in the presence of de-metaled ATP. 
 The crystal structure of ATCase in the presence of ATP was obtained by  
soaking P321  crystals of the RPALA complex  in 5 mM de-metaled ATP and allowing 
the crystals to equilibrate for 12  hrs before flash freezing. Data were collected to a 
resolution of 2.1  Å (Table 5-2), the same resolution as previously  reported for the 
RPALA structure in the absence of ATP (PDB ID 1D09).26 
 An overall comparison of the RPALA and the RPALA•ATP structures are very  
similar. For the two catalytic and regulatory  chains in the asymmetric unit, the RMS 
deviations between the backbone atoms of the two structures are 0.252 and 0.514  Å, 
respectively, indicating that the binding of ATP has a larger  influence on the 
regulatory  than the catalytic chains. A comparison of the vertical separation  between 
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the centers of mass of the catalytic subunits is 55.63  Å and 55.54  Å for the RPALA and 
the RPALA•ATP structures respectively,  suggesting that ATP binding does not  alter the 
separation of the catalytic subunits. Analysis of the RPALA•UTP structure 16 revealed 
that UTP binds to the allosteric site of the regulatory  chain; however,  UTP binds 
adjacent to but not overlapping the site to which ATP and CTP bind. Thus, the 
allosteric site of ATCase is actually  composed of two subsites: the A subsite which 
binds ATP or CTP and the B subsite which binds UTP.16 In the crystal structure of 
the RPALA•ATP complex in the absence of Mg2+ reported here,  ATP was found only 
bound in the A subsite (Fig. 5-4). Furthermore,  ATP was bound, and observed at an 
occupancy  of 1.0, in each of the regulatory  chains in the asymmetric unit, a result  in 
contrast to the RPAM,MAL•ATP structure at 2.8 Å resolution.25 
 As seen in Fig. 5-4 and Fig.  5-5A, the interactions of ATP in the A subsite 
include Lys94 and His20 that have polar interactions with the triphosphate portion 
of ATP. Backbone atoms from  Ile12  and Tyr89  interact with the 6-amino group of 
adenine. Asp19 interacts with the 3’-hydroxyl of the ribose. Finally, Lys60 has polar 
interactions with the 2’-hydroxyl of the ribose and the N3 of adenine. The ATP in the 
A subsite also exhibits hydrophobic interactions with  Ala11, Val17, Leu58, Ile86, and 
Val91.
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Figure 5-4 | The allosteric  site with  ATP bound with  electron  density.  Stereoview  of r6 
regulatory  site of ATCase with  ATP bound in  the absence of Mg2+. Shown is the electron 
density  (blue) at  1.0 σ  with  the final  coordinates of the atoms overlaid. Shown  in  green is the 
electron  density  map at  4.0  σ calculated by  omitting the atoms of the ATP from  the 
calculations. Hydrogen bonding interactions are shown as dash lines (magenta).
5.3.4 Structure of the R-State of ATCase•CTP in the absence of metal 
ions
 For  a  direct comparison of the allosteric site environment caused by  the 
binding of de-metaled ATP versus de-metaled CTP in the R state, P321  crystals of the 
RPALA complex were soaked in crystallization buffer  containing 5 mM de-metaled 
CTP. After equilibration for  12  hrs the crystals were flash frozen and data were 
collected to a resolution of 2.2  Å (Table 5-2). A previous structure, RPAM,MAL•CTP is 
available (PDB ID 8AT1) at a resolution of 2.8 Å, which has one CTP bound to each 
regulatory  chain in the asymmetric unit. For  comparison a T-state structure,  T•CTP, 
at 2.1 Å resolution is also available (PDB ID 4FYW).
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Figure 5-5 | Comparison  of ATP,  CTP and UTP bound in  the A  subsite. (A) ATP,  (B)  CTP 
and (C) UTP are shown  in A  subsite of the r6  regulatory  domain of ATCase.  In  the case of (C) 
UTP,  the A  subsite  is only  occupied in  the presence of Mg2+ (not  shown). Hydrogen-bonding 
interactions are shown as dash  lines (black).  The first  10 residues of each  regulatory  chain 
are not shown. This figure was generated using CHIMERA.27
 CTP binds to the regulatory  A subsite as does ATP. As seen in Fig.  5-5B, the 
interactions involved in  the binding of ATP and CTP are very  similar, in  fact, the 
ribose triphosphate portion of ATP or  CTP interact  identically  with the enzyme. In 
addition,  the amino groups of the purine and pyrimidine rings also have identical 
interactions with the backbone of Tyr89  and Ile12. The backbone interaction 
between Ile12  and the N1  of the adenine ring of ATP is replaced by  the equivalent 
interaction with the N3 of the cytosine ring of CTP. In addition, the side chain 
interaction between Lys60 and the N3 of the adenine ring of ATP is replaced by  an 
interaction between Lys60 and the 2-keto group of CTP. The only  major difference 
observed in the binding of ATP versus CTP is that the larger adenine ring displaces 
the backbone around Ala11  and Ile12. This displacement may  have a ripple effect on 
the entire N-terminal region, however the weak electron density  of the N-terminus 
prevents the determination of its position accurately in these two structures.
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Table 5-2. Data  collection and refinement statistics for  the structures in  the absence of 
Mg2+.
RPALA•ATP RPALA•CTP
Data collection statistics
PDB entry 4KGV 4KGX
Space Group P321 P321
Wavelength 1.542 1.075
Cell Dimensions
a, b, c (Å) 121.1, 121.1, 155.5 121.2, 121.2, 154.7
α, β, γ (°) 90, 90, 120 90, 90, 120
Resolution (Å) 38.4 - 2.1 (2.2 - 2.1) 50 - 2.2 (2.3 - 2.2)
Rsymb 0.05 (0.38) 0.08 (0.65)
Average (I/σ) 12.8 (3.3) 19.9 (3.9)
Completeness (%) 100.0 (100.0) 100.0 (99.9)
Redundancy 5.3 (5.3) 22.4 (18.9)
Refinement statistics
Resolution (Å) 38.4 - 2.1 49.7 - 2.2
Reflections 77,282 67,081
Rwork/Rfree 0.168 / 0.208 0.156 / 0.192
Number of atoms
Protein 7,098 7,082
Waters 688 683
R.m.s deviation
Bond lengths (Å) 0.007 0.007
Angles (°) 1.07 1.07
Mean B value (Å2) 48.3 39.3
a Values in parentheses are for the highest resolution shell.
b Rsym = ∑|(I - <I>)|/∑(I), where I is the observed intensity.
123
5.3.5 Structure of the R-state of ATCase with UTP and Mg2+ 
 Mendes et al.11 showed that  UTP was able to bind to the enzyme in the 
absence of other  nucleotides even though it  caused no kinetic response.  However, in 
light of the role of metal ions in the allosteric regulation of ATCase, we determined 
the structure of ATCase with  UTP and Mg2+. As seen in  Table 5-1, UTP slightly 
inhibits the enzyme in the presence of Mg2+.  Crystals of the RPALA complex were 
soaked in 5 mM UTP and 5 mM MgCl2 and the crystals were allowed to equilibrate 
for 12  hrs before being flash frozen. Data for  the RPALA•UTP•Mg2+•UTP structure 
were collected to a  resolution of 2.4  Å in the P321  space group (Table 5-3). The 
electron density  showed UTP bound in both the A and B subsites with one Mg2+ ion 
coordinated between them in each regulatory  chain. The previous structure of the 
RPALA•UTP complex only  had UTP bound in the B subsite.16 In the presence of Mg2+, 
UTP is able to occupy both the A and B regulatory subsites.
 Shown in Fig. 5-5C is UTP bound only  in the A subsite, for a direct 
comparison to the interactions between ATP (Fig. 5-5A) or CTP (Fig.  5-5B) and the 
enzyme in the A subsite.  The phosphate portion of UTP in  the A  subsite makes the 
same interactions with His20 and Lys94  as does ATP and CTP. Comparing the 
interactions between the pyrimidine rings of CTP and UTP, UTP has only  half the 
number of interactions that CTP has in the A subsite. There is a polar interaction 
between Lys60 and the 2-keto oxygen of both CTP or UTP, but the 4-keto group of 
UTP is unable to hydrogen bond with the backbone carbonyls of Tyr89 and Ile12. 
Since the pyrimidine ring of UTP is not held as strongly, it  is somewhat displaced 
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compared to CTP. This displacement prevents an interaction between the uridine N3 
and the backbone of Ile12.
 Shown in Fig. 5-6C is UTP bound in both the A and B subsites. The uridine of 
the UTP in the B subsite is held by  two interactions, each  to the ε-amino group of 
Lys60. The majority  of the binding affinity  comes from interactions of the 
triphosphate with the Mg2+ and the side chains of His20, Ser50, Lys56 and the 
backbone of Glu52. The side chain of Asp19  also has a water mediated interaction 
that further adds to the triphosphate interactions. The Mg2+ is octahedrally 
coordinated to six oxygen atoms; two from water molecules, and one from  a β-
phosphate oxygen and a γ-phosphate oxygen from  each of the two UTP molecules in 
the A and B subsites. The water molecules coordinated to the Mg2+ have additional 
stabilizing interactions with a β and γ phosphate oxygen. The interactions of UTP 
bound in the B subsite are the same as those described by  Peterson  et al.16 However, 
the pyrimidine ring is flipped such that the 4-keto group and N3  both interact  with 
Lys60. This orientation was also observed in one B subsite of the RPALA•UTP 
structure (PDB ID 4F04).16
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Table 5-3. Data  collection and refinement  statistics for  the structures in  the presence of 
Mg2+.
RPALA•UTP•Mg2+•UTP RPALA•ATP•Mg2+•ATP RPALA•CTP•Mg2+•UTP
Data collection statistics
PDB entry 4KGZ 4KH0 4KH1
Space Group P321 P321 P321
Wavelength 1.075 1.075 1.542
Cell Dimensions
a, b, c (Å) 121.4, 121.4, 155.1 121.1, 121.1, 155.1 120.9, 120.9, 154.7
α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (Å) 50 - 2.4 (2.5 - 2.4) 50 - 2.25 (2.33 - 2.25) 31.8 - 2.2 (2.3 - 2.2)
Rsymb 0.11 (0.68) 0.09 (0.74) 0.04 (0.37)
Average (I/σ) 14.6 (3.7) 21.8 (3.7) 17.8 (3.8)
Completeness (%) 100.0 (100.0) 100.0 (100.0) 99.4 (100.0)
Redundancy 24.1 (21.2) 24.1 (22.0) 5.7 (5.6)
Refinement statistics
Resolution (Å) 49.8 - 2.4 49.7 - 2.25 31.8 - 2.2
Reflections 52,387 62,983 66,367
Rwork/Rfree 0.165 / 0.203 0.168 / 0.208 0.163 / 0.196
Number of atoms
Protein 7,074 7,202 7,132
Waters 339 467 458
R.m.s deviation
Bond lengths (Å) 0.009 0.007 0.008
Angles (°) 1.09 1.13 1.08
Mean B value (Å2) 56.9 48.2 60.2
a Values in parentheses are for the highest resolution shell.
b Rsym = ∑|(I - <I>)|/∑(I), where I is the observed intensity.
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Figure 5-6 | Structural comparison  of the allosteric site with  Mg2+ and NTPs. The r6 
regulatory  chain  of ATCase with  (A) ATP•Mg2+•ATP,  (B) CTP•Mg2+•UTP,  and (C) 
UTP•Mg2+•UTP bound in  the A  and B subsites.  For  clarity,  residues Asp19  and Ser50  are 
shown but  not labeled.  The Mg2+ is shown  as a  gray  sphere and coordindated ligand 
interactions are shown  with magenta  lines. Hydrogen-bonding  interactions are shown as 
dash  lines (black).  Water ligands to Mg2+ are shown  as red spheres. The first  10 residues of 
each regulatory chain are not shown.
5.3.6 The R-state structure of ATCase with ATP and Mg2+
 Fetler and Vachette15 determined that Mg2+•ATP induced a  change in the 
structure of ATCase in both the T and R states by  SAXS. Although the alterations to 
the scattering curve in the T state could be reconciled as being additional scattering 
from the bound ATP•Mg2+ itself,  the alteration in the scattering curve in the R state 
could not. Using modeling  techniques, they  concluded that the R structure of the 
enzyme was significantly  altered by  the binding  of either ATP or ATP•Mg2+. 
Therefore, we also determined the R-state structure of the enzyme in the presence of 
ATP•Mg2+. Since neither  ATP nor ATP•Mg2+ promote the quaternary  transition from 
the T state to the R state, we used PALA to convert the enzyme into the R structure. 
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The structure of ATCase with ATP•Mg2+ was obtained by  soaking crystals of the 
RPALA complex in 5 mM ATP and 5 mM MgCl2 and allowing the crystals to equilibrate 
for 12  hrs before being flash  frozen.  Data for the RPALA•ATP•Mg2+•ATP structure 
were collected to a  resolution of 2.2  Å in the P321  space group (Table 5-3). The 
electron density  in the allosteric site clearly  shows nucleotides bound in both the A 
and B subsites with  a Mg2+ ion coordinated between the β and γ phosphates of each 
(Fig. 5-7). As seen in  Fig. 5-6A, the interactions between the enzyme and ATP in  the 
A subsite are very  similar  to those between the enzyme and ATP in the structure 
without Mg2+ (see Fig. 5-5A). The phosphates of the ATP bound in  the B subsite 
interact with the backbone nitrogen of Glu52 as well as the side chains of Asp19, 
His20,  Ser50 and Lys56, all of which are involved in the binding of UTP in the B 
subsite.16, 17 The ε-amino of Lys60 has a water mediated interaction and a polar 
interaction with  the N7  and 6-amino group of the adenine ring, respectively  (Fig. 
5-6A). However, in the B subsite of the adjacent  chain there is a direct interaction 
between Lys60 and N7. The Mg2+ binding  site is identical to the T-state structure of 
the T•CTP• Mg2+•UTP complex (PDB ID: 4FYY)17 as wel l as the 
RPALA•UTP•Mg2+•UTP structure just described. 
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Figure 5-7  | The allosteric  site with  ATP•Mg2+ bound with  electron  density. Stereoview  of 
r6  regulatory  site of ATCase with  ATP bound in the presence of Mg2+. Shown  is the electron 
density  (blue) at  1.0 σ  with  the final  coordinates of the atoms overlaid. Shown  in  green is the 
electron  density  map at 4.0 σ calculated by  omitting  the atoms of ATP and Mg2+ from  the 
calculations. Hydrogen bonding interactions are shown as dash lines (magenta).
5.3.7 The R-state structure of ATCase with CTP, UTP and Mg2+
 For  a  direct comparison of the ATCase structure with the nucleotides bound 
that cause the highest level of activation (ATP•Mg2+) versus the highest  level of 
inhibition (CTP•UTP•Mg2+; see Fig. 5-1) the structure of the R state of ATCase with 
CTP, UTP and Mg2+ bound was solved. Crystals of the RPALA complex were soaked in 
5 mM CTP, 5 mM UTP, and 5 mM MgCl2 and allowed to equilibrate for 12 hrs before 
being flash-frozen. Data for  the RPALA•CTP•Mg2+•UTP structure were collected to a 
resolution of 2.2  Å in the P321  space group (Table 5-3). The electron density  shows 
nucleotides bound in the A and B subsites with Mg2+ coordinated between the β and 
γ phosphates. CTP was modeled into the A subsite and UTP was modeled into the B 
subsite based upon the subsite specificity  previously  determined using dCTP and 
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UTP.17 In particular, the 4-amino group of the cytosine acts as a hydrogen bond 
donor to the backbone carbonyls of Ile12  and Tyr89. Furthermore,  all the 
interactions to CTP observed in the RPALA•CTP structure in  the absence of Mg2+ are 
also observed in the RPALA•CTP•Mg2+•UTP structure (compare Fig.  5-5B and Fig. 
5-6B). The best fit  to the observed electron density  required occupancy  refinement of 
CTP and UTP. The CTP molecules were observed at an occupancy  of 0.82 and 0.83 
in  each A subsite of the r1  and r6  chains, respectively, and the UTP molecules were 
observed at an occupancy  of 0.68 and 0.78 in each B subsite of the r1  and r6 chains, 
respectively.
5.3.8 The N-terminal region of the regulatory chains
 The position of the N-terminal region of the regulatory  chains of ATCase has 
not  been well established. In many  structures up to ten  residues have been omitted 
due to weak electron density  that is often attributed to the high  mobility  of this 
region. One T-state structure (PDB ID 1R0C), with no regulatory  nucleotides bound, 
includes the complete N-terminal region of the regulatory  chains. In this structure 
the first  ten residues of each of the two regulatory  chains in the asymmetric unit curl 
away  from the regulatory  site. However, in a T-state structure with  CTP bound in the 
A subsite (PDB ID 1ZA1) residues 2-10 of the two regulatory  chains in the 
asymmetric unit curl towards the B subsite. After alignment of the 1R0C and 1ZA1 
structures,  the α-carbon of Thr2 moves by  12 Å and 20 Å for the r1  and r6 chains of 
the asymmetric unit, respectively. Considering the R state of the enzyme without 
regulatory  effectors bound, two RPALA structures have been reported (PDB ID 1D09 
and 1Q95); one structure in the P321  space group with the other in the P212121 space 
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group. The structures include the entire N-termini of the regulatory  chains. In  the 
P321  and P212121 space groups there are two and six regulatory  chains in the 
asymmetric unit, respectively. In each  of the eight  independent regulatory  chains 
between the two structures, the N-terminus curls back towards the B subsite with 
RMS deviations of the backbone greater than 10 Å. Alanine scanning  mutagenesis of 
the N-terminal region showed that Asp4, Lys6 and Leu7  are important for the 
allosteric response of the enzyme, however  how  they  exert  their  effect is not obvious 
from analysis of the available structures.28
 With nucleotides bound in both the A and B subsites the functional role of the 
N-terminus of the regulatory  chain  is more obvious as this part of the structure 
interacts with the nucleotide in the B subsite. Shown in Fig. 5-8A is the allosteric 
domains of the regulatory  subunit of the RPALA•CTP•Mg2+•UTP structure.  This 
structure has the first 6  residues omitted on each chain. The N-termini of the r1  and 
r6 chains are parallel to one another  at  the dimer  interface. Shown in Fig. 5-8B is the 
allosteric domains of the regulatory  subunit of the RPALA•ATP•Mg2+•ATP structure. 
As previously  mentioned the larger purine ring on ATP displaces the N-terminus. 
The N-terminus of the r1  chain is displaced into the allosteric site of the r6  chain and 
interacts with  the nucleotide bound in the B subsite of the r6 chain and vice versa. 
The penetration of the N-terminal region into the opposite regulatory  chain  positions 
Lys6 to help neutralize the negative charges on the two triphosphates. In addition, 
additional stabilization of the nucleotide in the B subsite is provided by  hydrophobic 
interactions with  Leu7  and Val9. These two crystal structures are the first to show a 
remarkable difference in the regulatory  subunit structure when nucleotides are 
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bound that  cause inhibition  versus those that  cause activation. The position of the 
regulatory  N-terminal region in the RPALA•ATP•Mg2+•ATP structure enhances the 
stability of the r1-r6 interface when ATP•Mg2+ is present, but not in its absence.
Figure 5-8 | Alternate conformations of the N-terminal region.  The (A)  RPALA• 
CTP•Mg2+•UTP and (B) RPALA• ATP•Mg2+•ATP structures showing  the allosteric  domains of 
the regulatory  subunit.  In  (A) the N-termini curl  around and interact  with  the B subsite 
within  their  own  chain, while in  (B) the N-termini  of one regulatory  chain  penetrates into B 
subsite of the other  regulatory  chain. In  the RPALA• CTP•Mg2+•UTP and RPALA• 
ATP•Mg2+•ATP structures,  6  and 3  residues were omitted from  the N-termini due to weak 
electron  density. Fig. 5-9  shows the relationship of the portion  of the regulatory  subunit 
shown in this figure to the holoenzyme.
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Figure 5-9 | The regulatory  subunit of ATCase in  the context  of the holoenzyme. The 
structure the RPALA•ATP•Mg2+•ATP holoenzyme composed of two catalytic  trimers and three 
regulatory  dimers is shown  on  the left. The catalytic trimers (light  brown) comprise the 
upper  and lower  parts of the molecule.  Surrounding the catalytic  trimers are the three 
regulatory  dimers,  with  the two chains shown  in green and yellow.  The front most regulatory 
dimer  is shown  enlarged on the right.  The two ATP molecules and the Mg2+ in each 
regulatory  chain  are visible. The N-terminal of each  regulatory  chain penetrates into the 
allosteric site of the adjacent chain thereby  strengthening  the interface between the two 
chains of the regulatory dimer.
5.4 Discussion
5.4.1 Nucleotide site specificity
 The ATCase structures reported here confirm that the allosteric site on each 
regulatory  chain of ATCase is composed of two subsites. Furthermore, the nucleotide 
that occupies each of the subsites must be considered in any  model of allosteric 
regulation of ATCase. The A subsite can bind CTP, ATP, and UTP, while the B subsite 
can bind ATP and UTP. Although GTP has been shown to bind to the allosteric site,11 
its specificity, or lack thereof, for the A or B subsite has not been established. 
133
However,  preliminary  data suggest that in the absence of Mg2+ a single GTP binds in 
a conformation involving side chains from both the A and B sites (data not shown). 
The simultaneous binding of two nucleotides to the A and B subsites,  in any 
combination, is dependent upon the presence of a  metal ion. In the absence of metal 
ions, CTP and ATP bind with high affinity  only  to the A subsite. The only  nucleotide 
that is able to bind to the B subsite with  reasonable affinity  in  the absence of Mg2+ is 
UTP.16  
 The preferential binding of CTP to the A subsite and UTP to the B subsite is 
due to the interactions involving the functional group difference at the 4 position of 
the pyrimidine ring. The 4-keto group of uracil  cannot interact with  the A subsite 
because there are no appropriately  positioned hydrogen-bond donors (see Fig. 5-5). 
However,  the backbone carbonyls of Ile12  and Tyr89 serve as hydrogen bond 
acceptors for  the 4-amino group of the cytosine ring of CTP. The 6-amino group of 
adenine interacts with  the same two groups on the enzyme providing the specificity 
with respect to ATP.
 In the presence of Mg2+,  ATP can occupy  both the A  and B subsites,  and when 
the two subsites are populated in this fashion the enzyme is activated more than 
when ATP is bound just  to the A subsite (see Fig. 5-1). The combination of CTP 
binding at the A subsite and UTP binding to the B subsite results in the highest level 
of inhibition of the enzyme. In fact,  in the presence of Mg2+, neither  CTP nor UTP 
alone inhibit the enzyme significantly  (see Table 5-1). Cockrell and Kantrowitz17 have 
described selective binding of the nucleotides CTP and UTP to the A and B subsites, 
respectively. Part of the subsite selectivity  is due to electrostatic interactions between 
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the pyrimidine ring and Lys60, a residue that lies at the interface between the A and 
B subsites, and has interactions with the nucleotides bound in each subsite. 
Therefore, an unfavorable electrostatic interaction between Lys60 and the 4-amino 
group of CTP precludes the binding of CTP to the B subsite. The structure 
determined of RPALA crystals soaked with CTP•Mg2+ showed no evidence of CTP 
binding to the B subsite (data not shown). It is likely  that the CTP•Mg2+ complex  has 
a low binding affinity  to the allosteric site, and explains why  the 2  mM CTP•Mg2+ 
does not  inhibit the enzyme (see Table 5-1). The structural basis for the ability  of 
ATP to bind to both  the A  and B subsites can also be ascribed to electrostatic 
interactions between the ATP and Lys60. The adenine N3 of ATP in the A subsite 
interacts with  Lys60, and in the B subsite Lys60 interacts with N7  and the 6-amino 
group, all of which bear a partial negative charge.29
 
5.4.2 The importance of metal ions for the allosteric regulation of 
ATCase
 It  has been known for many  years that metal ions influence the allosteric 
regulation of ATCase,12-15 however  the mechanism of metal ion involvement in 
allosteric regulation was not understood. The kinetic studies reported here shed new 
insight on the importance of metal ions for  the allosteric regulation of ATCase. Kung 
et al.22 have estimated that the intercellular  concentration  of Mg2+ is greater than 20 
mM, and does not change appreciably  during the cell  cycle.  Since metal ions, 
particularly  Mg2+,  are known to form complexes with the triphosphate portion of the 
nucleotides, it  is more reasonable to consider  how ATCase responds to the 
nucleotide triphosphates in  the presence rather  than  the absence of Mg2+. Table 5-1 
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and Fig. 5-1  summarize the results reported here on the allosteric response of 
ATCase in the presence of 2 mM Mg2+.
 As has been reported,  CTP can inhibit ATCase in  the absence of metal ions, 
however, CTP has essentially  no influence on the activity  of the ATCase in the 
presence of 2 mM Mg2+. Only  ATP has a  significant influence on the activity  of the 
enzyme in the presence of 2  mM Mg2+. In  the presence of Mg2+, only  the 
combination of the two end products of pyrimidine nucleotide biosynthesis, CTP and 
UTP, inhibit  the enzyme. In  fact, CTP, UTP and Mg2+ inhibit the enzyme almost 
completely. The molecular  basis of the ability  of CTP•Mg2+•UTP to inhibit the 
enzyme was revealed by  crystallographic studies of the enzyme,17 which  showed that 
CTP, UTP and Mg2+ bind simultaneously  to each regulatory  binding site. This 
binding arrangement was shown by  using dCTP as a surrogate for  CTP (see Fig. 
4-5A). In this T•dCTP•Mg2+•UTP structure (PDB ID 4FYX) one Mg2+ ion coordinates 
to two phosphate oxygen atoms from  CTP, two phosphate oxygen atoms from  UTP 
and oxygen atoms from  two water molecules.  Without the presence of the Mg2+, the 
negative charges on the phosphates would repel each other preventing the 
simultaneous binding of the two nucleotides. Thus, the natural allosteric inhibitor of 
ATCase is the combination of the two end products of pyrimidine nucleotide 
biosynthesis in complex with Mg2+. 
 The data in Fig. 5-1  indicates that CTP•Mg2+ induces no regulatory  influence 
on the enzyme. It  is known that CTP competitively  inhibits its own production by 
binding to CTP synthetase, which  would elevate the levels of UTP.7 The combination 
of CTP, UTP and Mg2+ as the natural allosteric inhibitor  of ATCase would thus 
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maintain an  overall balance in relative pyrimidine and purine nucleotide pools 
without disrupting the balance between the CTP and UTP pools. 
 ATP is able to bind to the enzyme in the absence of Mg2+ and activate the 
enzyme (Table 5-1).  Previous structural data of ATCase•ATP complexes24, 25 have 
shown this, as well as the structure of the RPALA•ATP complex reported here. 
However,  in the presence of 2  mM Mg2+ ATP is able to activate the enzyme to a 
greater  extent  than in its absence. The RPALA•ATP•Mg2+•ATP structure reported here, 
see Fig. 5-6A,  shows that the allosteric site of ATCase can accommodate two ATP 
molecules in an orientation similar to that observed in the T•CTP•Mg2+•UTP 
structure,17 with a Mg2+ between the two ATP molecules.  However, the allosteric 
activation of ATCase may  be more complex.  In the presence of 5 mM Asp and 2 mM 
Mg2+, ATP plus GTP activates the enzyme slightly  more than ATP. However  at  higher 
concentrations of Asp, the combination of ATP,  GTP and Mg2+ activates substantially 
more than ATP, Mg2+ (see Fig.  5-2A).  Thus, both  end products of purine nucleotide 
biosynthesis are involved in the allosteric regulation of ATCase.
5.4.3 The Structure of ATCase in the presence of Mg2+•ATP in solution
 Using SAXS, Fetler  and Vachette15 showed that  the R-state solution structure 
was altered in the presence of ATP, and to an even larger  extent,  in the presence of 
ATP•Mg2+. Based upon the SAXS profiles, they  modeled R-state solution structures 
of ATCase in the presence of ATP (RSOL•ATP) and ATP•Mg2+ (RSOL•ATP•Mg2+). The 
RSOL•ATP and the RSOL• ATP•Mg2+ structures were elongated along the 3-fold axis 
2.8 Å and 4.4  Å more than the RPALA crystal structure. Furthermore, the catalytic 
subunits of the RSOL•ATP and the RSOL• ATP•Mg2+ structures rotated 8° and 13° 
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more around the 3-fold axis and the regulatory  subunits rotated 9° and 15° more 
around their respective 2-fold axes, respectively, than the RPALA structure.
 A comparison of the RPALA structure in the absence of nucleotides (PDB entry  
1D09), with the RPALA•ATP and the RPALA•ATP•Mg2+•ATP structures, reported here, 
is not consistent with the structural changes proposed by  Fetler and Vachette.15 For 
either the RPALA•ATP or RPALA•ATP• Mg2+•ATP structures, neither the expansion 
along the 3-fold axis or the rotations of the subunits about the 3-fold and 2-fold axes 
differ significantly  from  that  observed for the RPALA structure without allosteric 
effectors.  In order to help resolve this discrepancy, we calculated SAXS profiles 
based on the atomic positions as determined by  X-ray  crystallography. As seen in 
Fig. 5-10, the calculated SAXS profile for  RPALA without regulatory  effectors is 
different from that  calculated for the RPALA•ATP• Mg2+•ATP structure. The largest 
differences between these curves is in the region  of the first subsidiary  minimum and 
maximum, exactly  as was observed experimentally  by  Fetler and and Vachette.15 
However,  if all the atoms constituting ATP and Mg2+ are removed from the 
RPALA•ATP• Mg2+•ATP coordinates and the SAXS pattern is recalculated, the pattern 
obtained is essentially  identical to the pattern calculated for  the RPALA structure in 
the absence of allosteric effectors. These calculations indicate that  the structural 
model of ATCase in the presence of ATP•Mg2+ reported by  Fetler and and Vachette15 
is incorrect and that the observed difference in the scattering between the R-state 
enzyme in the absence and presence of ATP•Mg2+ is due exclusively  to the extra 
scattering caused by the bound ligands.  
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Figure 5-10 | Calculated SAXS scattering curves of ATCase. SAXS profiles of the biological 
unit  of ATCase were calculated using the FOXS Server30 in  the T-state (black  thin, PDB ID 
1ZA1  with  CTP removed) and R-state with  PALA (gray  thick,  PDB ID 1D09).  Also shown  are 
the calculated SAXS profiles for the RPALA•ATP•Mg2+•ATP structure with  ligands (black 
dotted) and the same structure with  the ATP and Mg2+ atoms removed (black dashed).  Inset, 
enlarged region to show detail. Protocols are provided in Chapter 7.
5.4.4 The role of the N-terminus of the regulatory chain of ATCase in 
allosteric regulation
 In most structures of wild-type and mutant versions of ATCase the N-
terminus of the regulatory  chain is disordered to a  significant extent making the 
determination of the atomic positions of the residues impossible. Depending upon 
139
the structure, between 1  and 10 residues have been excluded. In the 
RPALA•ATP•Mg2+•ATP and RPALA•CTP•Mg2+•UTP structures reported here, only  3 
and 6  residues needed to be excluded from  the N-termini due to weak electron 
density.  These two structures represent the most highly  inhibited and activated 
forms of the enzyme, and exhibit completely  different orientations of the N-terminal 
region of the regulatory  chains.  In the RPALA•ATP•Mg2+•ATP structure the N-
terminus of the r1  chain forms part  of the r6 chain B subsite and vise versa (see Fig. 
5-8). The cross over of the N-terminal region to the opposite regulatory  chain  of the 
dimer is particularly  intriguing as this would enhance the strength of the interface 
between the regulatory  chains within the regulatory  dimer, providing a  mechanism 
for ATP stabilization of the R state of ATCase.  The alternate position of the N-
termini in the RPALA•CTP•Mg2+•UTP structure would provide no added stabilization 
to this interface thus neutralizing the effect of ATP and by  inference, destabilizing 
the R-state.
5.4.5 Functional evidence for two subsites in each regulatory chain of 
ATCase
 Previous kinetic studies of single amino acid substitutions have been 
performed on residues identified here as involved in nucleotide binding to the B 
subsite. In particular, enzymes with the mutations D19A,31 H20A32 or  K56A33 lose 
their ability  to be inhibited synergistically  by  UTP in the presence of CTP. The loss of 
synergistic inhibition could not be explained from a structural perspective, especially 
for the K56A mutation as the B subsite had not been discovered. As seen in Fig. 5-6B 
and Fig. 5-6C, Asp19, His20 and Lys56 all provide stabilizing interactions to the UTP 
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bound in the B subsite and have few  or  no interactions with CTP bound in the A 
subsite. Mutations at residues Asp4, Lys6, and Leu7  of the N-terminal region of the 
regulatory  chain all influence the regulatory  properties of the enzyme.28 As seen in 
Fig. 5-8, Leu7  is involved in a hydrophobic interaction with the purine ring of the 
ATP in the B subsite and Lys6  helps to neutralize the charge of the two 
triphosphates. Therefore, the X-ray  structures reported here provide a structural 
explanation of altered regulatory  responses induced by  all of these single site 
mutations.   
5.4.6 A model of allosteric regulation of ATCase involving a 
dinucleotide binding site
 Based upon the kinetics and the 5 X-ray  structures reported here,  along with 
the previously  reported RPALA•UTP,16 T•dCTP•Mg2+•UTP and T•CTP•Mg2+•UTP 
structures17 a new model of allosteric regulation of ATCase can be proposed.
1) Each regulatory  chain of ATCase can bind two nucleotides simultaneously,  but 
only in the presence of a metal ion such as Mg2+ (see Fig. 5-6).
2) Reports for the last 57  years stating that CTP is the allosteric feedback inhibitor 
of ATCase are inaccurate. Reports for the last  24 years that ATCase is 
synergistically  inhibited by  UTP in the presence of CTP are incorrect. In the 
absence of metals,  CTP alone or  in combination with  UTP does not significantly 
inhibit the enzyme (see Table 5-1). In  the presence of a Mg2+ concentration 
much less than an intracellular concentration, CTP does not appreciably  inhibit 
ATCase (see Table 5-1). The natural allosteric inhibitor of ATCase is the 
combination CTP•Mg2+•UTP with  CTP binding  to the A  subsite and UTP 
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binding to the B subsite. Both end products of the pyrimidine pathway, CTP 
and UTP, act together to feedback inhibit ATCase. 
3) Although ATCase can be activated by  the binding of ATP alone, the highest 
extent of activation is by  ATP•Mg2+. Although GTP was never thought to play  a 
significant role in allosteric regulation of ATCase it can function in  conjunction 
with  ATP•Mg2+. Thus, both end products of the purine pathway, ATP and GTP 
can act together to allosterically activate ATCase.
4) The conformation of the N-termini of the regulatory  chains is governed by  the 
nucleotides in the A and B subsites. The inhibited form of the enzyme with 
CTP•Mg2+•UTP bound exhibits an intrachain orientation of the N-termini, 
while the activated form  of the enzyme with ATP•Mg2+•ATP(GTP) bound 
exhibits an interchain orientation of the N-termini. Thus, the activated form  of 
the enzyme has extra stabilization of the interface between the two chains of 
the regulatory  dimer, suggesting that the interface between the two chains of 
the regulatory  dimer  are functionally  critical for the stabilization of the T and R 
states of ATCase. This selective stabilization of the T and R states provides an 
explanation for how the nucleotides function in the activation and inhibition of 
ATCase that is consistent with the model of allostery  proposed by  Monod, 
Wyman and Changeux.34 
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Chapter 6: ViewMotions Rainbow: A New 
Method to Illustrate Molecular Motions in 
Proteins
This work was published in the Journal of Molecular Graphics and Modelling.
Cockrell, G. M. and Kantrowitz, E. R. ViewMotions Rainbow: A New Method to Illustrate 
Molecular Motions in Proteins. Journal of Molecular Graphics and Modelling. 2013, 40, 
48-53.
Contribution to work: Design of the ViewMotions Rainbow diagrams, involved in website 
design and layout, involved in preparation of the manuscript. Programming was done by Dr. 
Evan Kantrowitz.
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6.1 Summary
 The biological functions of many  enzymes are often coupled with significant 
conformational changes.  The end states of these conformational changes can often 
be determined by  X-ray  crystallography.  These X-ray  structures are snapshots of the 
two extreme conformations in which the macromolecule exists, but the dynamic 
movements between the states are not easily  visualized in  a two-dimensional 
illustration. Here we have developed a new method to visualize macromolecular 
motions called a ViewMotions Rainbow diagram. These diagrams show the initial 
and final states overlaid along with  approximately  30 intermediate structures 
calculated by  linear interpolation of the backbone coordinates of the initial and final 
states.  This group of structures is then spectrally  colored from the initial structure in 
blue to the final structure in red. ViewMotions Rainbow  diagrams provide the reader 
with  a much easier way  to understand the macromolecular  motions using a single 
two-dimensional illustration. Since producing these diagrams requires a  number  of 
different software packages,  we have setup the ViewMotions Web Server (http://
viewmotions.bc.edu) to automatically  generate these diagrams from two Protein 
Data Bank files or from  the Database of Macromolecular Movements (http://
molmovdb.org).
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6.2 Introduction
 Many  enzymes undergo significant  conformational changes during the course 
of their  biological function. These conformational changes may  be induced in a 
variety  of ways including the binding of substrates, allosteric effectors, or by 
phosphorylation. The end states of these conformational changes can often be 
determined by  X-ray  crystallography  or structural NMR. While these structures are 
snapshots of the two extreme conformations in which  the macromolecule exists, the 
dynamic movements between the states are not easily visualized. 
 Krebs and Gerstein have developed the Internet accessible Database of 
Macromolecular Movements,1 which  includes the Morph Server2 that can  be used to 
generate movies depicting the movement of the macromolecule from  its initial to its 
final state.  These movies are an excellent resource to visualize macromolecular 
motions; however, these molecular  motions are much more difficult to visualize 
using a  single diagram. A variety  of methods to illustrate conformational changes 
have been employed. However,  each of these two-dimensional representations lacks 
one important advantage of a movie depiction of the conformational change, which 
is to allow the reader to visualize the actual molecular motion. In order to solve this 
problem we have developed a new method to visualize the conformational changes of 
proteins in a two dimensional illustration. This new  method uses a number of 
existing software packages to generate a series of intermediate structures, typically 
thirty,  on the path between the initial and final conformations.  All of the structures 
are shown in a single image using a spectral color gradient to indicate the molecular 
motion. We have published a  number of these ViewMotions Rainbow  diagrams (see 
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Figs. 2-1  and 3-2) as an all-inclusive way  to convey  molecular motions.3-5 However, 
the steps required to generate these diagrams are cumbersome, therefore we have 
developed a Web Server to allow  the user  to easily  create ViewMotions Rainbow 
diagrams.  
6.3 Computational Methods
 In order  to generate a ViewMotions Rainbow diagram the coordinates of the 
initial and final positions of the macromolecule are required. These coordinates can 
be supplied either with two PDB files or a  MorphID corresponding to a particular 
macromolecular  movement from the Database of Macromolecular Movements.1 A 
flow chart of the steps necessary  to create a ViewMotions Rainbow diagram is 
illustrated in Fig. 6-1.
 After data input, the two structures are then aligned and superimposed by  one 
of four  alignment algorithms: a  standard least-squares procedure as described by 
Kabash6 (sRMSD),  the globally  optimized alignment method of Needleman and 
Wunsch7 as implemented in  SEQUOIA program,8 the sieve-fit algorithm,9, 10 and a 
Gaussian-weighted algorithm11 (wRMSD). The sieve-fit algorithm9, 10 has yielded the 
best alignments, particularly for domain motions.
 CNS12 is next  used to calculate the backbone and side chain RMSD values 
between the beginning and ending structures using the rmsd.inp procedure. A 
limitation with CNS is that  it  requires the same number of amino acids in the two 
structures.  The rmsd.inp procedure generates a list of RMSD values for the backbone 
and sidechains of each residue.  The backbone RMSD values are used for the coloring 
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of the ViewMotions Rainbow diagram in PyMol.  In order to accomplish this a 
custom written C language program  was written to replace the b-factor and 
occupancy  values in the initial and final PDB files with  the corresponding backbone 
and sidechain RMSD values, respectively, output from  the rmsd.inp procedure of 
CNS. LSQMAN from  the Uppsala  Software Factory  (http://xray.bmc.uu.se/usf/) is 
then used to generate the intermediate structures using its morph option. Usually  30 
intermediate structures are generated between the initial and final structures by 
LSQMAN.  However, if the maximal RSMD for the macromolecular movement is 
greater  than 1.8 Å or  3.0 Å, 45 or  60 structures are generated, respectively. Finally,  a 
custom shell script is used to generate a  command file for  PyMol (http://
www.pymol.org) or  Chimera (http://www.cgl.ucsf.edu/chimera) to generate the 
ViewMotions Rainbow diagram. 
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Figure 6-1 | Flow  chart  for  producing a ViewMotions Rainbow  diagram. The input data  is 
either  two PDB files corresponding to the initial  and final coordinates of the motion  or  a 
MorphID corresponding to a  macromolecular  motion  described by  the Database of 
Macromolecular  Movements.1 Each  of the computational steps is indicated by  a  box and the 
software used to perform the calculation is indicated.
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6.4 Results and Discussion
6.4.1 Commonly used methods to view macromolecular motions
 The catalytic cycle of most transferases involves a domain closure, which 
brings two substrates in close proximity  for  reaction and may  also change the active 
site environment to one more favorable for  reaction. The binding of glucose to 
hexokinase and glucokinase are two such examples. Shown in Fig. 6-2A,B are the 
open and closed forms of hexokinase as well as the two forms overlaid (Fig. 6-2C). 
From  this static representation of the conformational change in hexokinase, it  is 
difficult  to envision the actual motion. A modification that is often used to help 
direct  the viewer to the important portion of the molecule is to use a neutral color in 
regions where the conformational changes are the smallest (see Fig. 6-2D).
 To provide the reader with alternative methods to view molecular  motions, a 
variety  of different graphical representations have been employed. Shown in  Fig.  6-3 
are some examples. A tube representation  can be used in which the width of the tube 
is linearly  proportional to the displacement of the protein backbone atoms (Fig. 
6-3A,B).  A significant drawback to this representation is that  the variable tube width 
must be applied to a single structure, in this case either  the open or closed form. 
Neither of these individual representations clearly  conveys the conformational 
change that  the protein is undergoing. A CPK representation of each of the two states 
can also be used as illustrated with hexokinase in Fig.  6-3C (open form) and 6-3D 
(closed form). Although the domain motion is apparent,  this representation has its 
drawbacks as small conformational changes, or conformational changes in several 
parts of the protein are not well represented.
155
Figure 6-2 | A  comparison  of the open  and closed forms of hexokinase.  (A) The open  form 
of Sulfolobus tokodaii hexokinase in the absence of ligands (PDB ID 2E2N),13 (B)  the closed 
form  of S. tokodaii hexokinase in  the presence of glucose and Mg2+•ADP (PDB ID 2E2Q),13 
(C) the open and closed forms overlaid, and (D) the closed and open  forms overlaid with  the 
region of the protein undergoing significant conformational change in color.
Figure 6-3 | Representations of the hexokinase conformational change upon  binding 
glucose. (A) Tube diagram  of the open form  of hexokinase.   (B) Tube diagram  of the closed 
form  of hexokinase. In (A) and (B) the diameter of the tube is linearly  proportional to the 
RMSD between  the backbone atoms in  the open  and closed forms.  (C) CPK representation of 
hexokinase in the unliganded form  and (D) in  the presence of glucose and Mg2+•ADP.  The 
parts of the protein  are colored if the RMSD between  the open and closed forms is larger 
than 1.3 Å.
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 Krebs and Gerstein recognized the complexities of trying to view molecular 
motions in proteins and therefore developed a Morph Server2 and a database,1 as a 
means to create movies of molecular motions and the database to track the various 
types of molecular  motions.  Viewing a movie of a  conformational change provides a 
much easier  way  to understand a molecular motion  than any  of the two-dimensional 
representations mentioned above.
 In order to overcome the problem  of viewing protein  conformational changes 
in  textbook and journal diagrams we have devised a new representation, which we 
call the ViewMotions Rainbow diagram. This new representation starts with the 
initial and final coordinates of the protein (see Fig. 6-4A,B) and thirty  or  more 
intermediate structures generated by  linear interpolation of the protein backbone 
coordinates. All of these structures are shown simultaneously  and spectrally  colored 
from the initial structure in  blue to the final structure in red. In order to focus the 
viewer on the parts of the protein undergoing the conformational change, only  those 
portions of the protein that show a  RMSD of 1.3  Å  or greater  are colored (see Fig. 
6-4D).
 The Database of Macromolecular  Movements1 classifies macromolecular 
motions into three main categories: (I) motions of fragments smaller  than domains, 
(II) domain motions, and (III) larger movements than domain movements involving 
the motion of subunits. Furthermore, each of these categories is subdivided by  the 
type of motion (see Table 6-1). The first  two categories involve motions of a  single 
polypeptide chain and are those best visualized using a ViewMotions Rainbow 
diagram.
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Figure 6-4 | ViewMotions Rainbow  Diagram  of hexokinase.  (A) The open  form  of 
Sulfolobus  tokodaii hexokinase in the absence of ligands (PDB ID 2E2N),  (B)  the closed 
form  of S.  tokodaii hexokinase in  the presence of glucose and Mg2+•ADP (PDB ID 2E2Q), (C) 
the open  and closed forms of hexokinase overlaid, and (D)  the ViewMotions Rainbow 
diagram  of hexokinase showing the open  form  at  the blue end of the rainbow  and the closed 
form  at  the red end of the rainbow.   In  addition to the open and closed structures, this 
diagram  has thirty  intermediate structures calculated between  the two extreme forms. Those 
parts of the structure with a RSMD of greater than 1.3 Å are shown in color.
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Table 6-1. Krebs and Gerstein2 classification of the types of macromolecular motions. 
Motion Type Description
I Motions of Fragments Smaller than Domains
A Motion is predominantly shear
B Motion is predominantly hinge
C Motion can not be fully classified at present
D Motion is not hinge or shear
II Domain Motions
A Motion is predominantly shear
B Motion is predominantly hinge
C Motion can not be fully classified at present
D Motion is not hinge or shear
III Larger Movements than Domain Movements involving the Motion of Subunits
A Motion involves an allosteric transition
B
Motion does not involve an allosteric transition
C
Complex Protein Motions
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 The utility  of using ViewMotions Rainbow  diagrams can be seen in Fig. 6-5 
where the four types of macromolecular motions, defined by  Gerstein and Krebs,1 are 
depicted for motions of fragments smaller than domains (Type I) and domain 
motions (Type II).  For the Type I motions, the rainbow of color is associated with 
specific segments of the protein, smaller than domains. The motion is sometimes 
restricted to one location on the protein as in  Fig. 6-5.I.A or  in multiple parts as 
indicated in the other examples of Type I motions. Type II motions, within a single 
domain,  are shown in Fig. 6-5, however, the termini of the chains may  also show 
motions larger than the cut-off used for the diagram.
Figure 6-5 | Examples of protein conformational  changes shown as ViewMotions Rainbow 
diagrams. The Database of Molecular  Movements1 defines three classes of molecular 
motions two of which are depicted here.  Type I corresponds to motions of fragments smaller 
than  domains and Type II corresponds to domain  motions. Each  of these motion  types is 
subdivided into four  subtypes as specified in Table 6-1. See Table 6-2  for  details of each of 
the molecules shown in this figure.
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Table 6-2. Summary of example motion types used to produce Fig. 6-5.
Motion Type Example Morph ID PDB IDInitial      Final
I A Adenosylcobinamide Kinase va1cbuB-1c9kB 1CBU → 1C9K
I B Ras 989758-27939 4Q21 → 6Q21
I C Ribosomal Protein S15 401923-2485 1AB3 → 1A32
I D Lac Repressor 35866-16653 1lCC → 1lQC
II A Citrate Synthase cs 4CTS → 1CTS
II B HCV Helicase 109065-518 8OHM → 1CU1
II C Myosin 437354-14115 1B7T → 1DFK
II D Immunoglobulin 403713-16146 1MCP → 1NCA
6.4.2 Comparison of alignment algorithms 
 The ViewMotions Rainbow diagram is dependent upon the alignment 
algorithm  used to superimpose the two structures. We have tested four  alignment 
algorithms: the standard RMSD (sRMSD),6 the sieve-fit  algorithm,9, 10 the gaussian-
weighted RMSD (wRMSD),11 and the globally  optimized alignment method of 
Needleman and Wunsch7 as implemented in SEQUOIA.8 The simplest  of the 
alignments is the sRMSD, which is essentially  a least-squares minimization of the 
corresponding interatomic distances as described by  Kabsch.6 The sieve-fit method 
is an iterative process in which a sRMSD fit  is initially  performed. The program then 
eliminates the Cα atoms that  are the furthest apart  after  the initial alignment.  This 
step is repeated until approximately  50% of the atoms are excluded from  the 
alignment. The Gaussian-Weighted RMSD (wRMSD)11 is similar to the sieve-fit 
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algorithm, but includes a Gaussian-weighting term, where the atoms with  very  little 
movement are weighted more in the least  squares fit than atoms that  are further 
apart. Like the sieve-fit  method this alignment relies on several iterations until 
convergence. Each iteration changes the distance of the atoms and thus changing 
weights and in turn the wRMSD fit.  The final type of alignment method utilizes the 
SEQUOIA program,8 which uses a dynamic programming algorithm7 to find the 
globally optimal alignment.
 Shown in Fig. 6-6 are ViewMotions Rainbow diagrams for hexokinase and lac 
repressor using the four  alignment algorithms. In the case of the domain motion of 
hexokinase, the sieve-fit and gaussian-weighted algorithms produced the best 
representation of the molecular motion. In the case of the lac repressor, which 
undergoes a motion that is not  a hinge or shear,  the four alignment algorithms give 
similar results.
Figure 6-6 | Comparison  of different  alignment algorithms using hexokinase (top) and lac 
repressor  (bottom). (A)  standard RMSD fit,6 (B)  globally  optimized alignment7 as 
implemented in SEQUOIA,8 (C) Gaussian-Weighted,11 and (D) sieve-fit.9, 10
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6.4.3 The ViewMotions Server
 Because of the complexity  of the steps outlined in Fig. 6-1, we decided to 
create a  Web Server  to create ViewMotions Rainbow diagrams, the ViewMotions 
Server (http://viewmotions.bc.edu). The ViewMotions Server  (see Fig. 6-7) can be 
used in one of three modes to generate ViewMotions Rainbow diagrams. The first 
involves uploading two PDB files and identifying which chains are to be used in each 
file,  while the second involves the input of two PDB IDs from  the Protein Data Bank. 
The third involves simply  submitting a MorphID from the Database of 
Macromolecular Movements.1 All of the examples provided in  Fig.  6-5 were 
produced by directly using the MorphIDs as indicated in Table 6-2.
 The user  selects one of the four structural alignment options previously  
discussed. After the alignment and superposition  step, the RMSD deviations of the 
corresponding backbone and side chain atoms in the two structures are determined. 
The RMSD values for  the backbone atoms are used for the color  coding of the 
morphed structures in the final image generated by  PyMol. When the ViewMotions 
Server has completed its calculations it  sends an email to the user with the output 
information and a ray-traced ViewMotions Rainbow diagram. Since the orientation 
of this figure is often not optimal, the PyMol or  Chimera session file used to generate 
the image can be downloaded by  the user so that he/she can reorient the molecule 
and generate a ViewMotions Rainbow diagram from an alternate viewpoint. 
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Figure 6-7 | The ViewMotions Server home page (http://viewmotions.bc.edu).
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6.5 Conclusions
 Viewing motions of macromolecules, based on experimental structural data, 
in  movie format provides one of the best methods to understand molecular motions. 
However,  in journals and textbooks it is often not possible to access molecular 
motion videos. Therefore,  we have developed a new paradigm for  showing molecular 
motions in a single image, the ViewMotions Rainbow. This diagram  consists of the 
initial and final conformations of the macromolecule along with a number  of 
intermediate structures linearly  interpolated between the initial and final states 
colored from  blue to red. These ViewMotions Rainbow diagrams provide a new 
graphical representation to help understand molecular  motions.  In order to produce 
these images as easily  as possible,  we have setup a Web Server  (http://
viewmotions.bc.edu) for  the specific purpose of creating these images either from 
available Protein Data  Bank files or using a MorphID from the Database of 
Molecular Movements.1
 Currently  the ViewMotions web server is on Version 2.0. This version has 
implemented several features such  as the ability  to input two starting  structures that 
have N- or C- terminal deletions as well as sequences with a  small number  of 
mutations. In future versions of the ViewMotions server a minimization of the side 
chains for the calculated intermediate structures will be included.
165
6.6 References
1. Gerstein, M.; Krebs, W., A database of macromolecular  motions. Nucleic acids 
research 1998, 26, 4280-90.
2. Krebs, W. G.; Gerstein,  M., The morph server: a standardized system  for 
analyzing and visualizing macromolecular  motions in a database framework. 
Nucleic acids research 2000, 28, 1665-75.
3. Harris, K. M.; Cockrell,  G. M.; Puleo, D. E.; Kantrowitz, E. R., Crystallographic 
snapshots of the complete catalytic cycle of the unregulated aspartate 
transcarbamoylase from Bacillus subtilis. J. Mol. Biol. 2011, 411, 190-200.
4. Kantrowitz, E.  R., Allostery  and cooperativity  in Eschericha coli aspartate 
transcarbamoylase. Arch. Biochem. Biophys. 2012, 519, 81-90.
5. Peterson, A. W.; Cockrell, G. M.; Kantrowitz, E. R., A second allosteric site in E. 
coli aspartate transcarbamoylase. Biochemistry 2012, 51, 4776-4778.
6. Kabsch, W., A solution for the best rotation to relate two sets of vectors. Acta 
Cryst. 1976, A32, 922-923.
7. Needleman, S. B.; Wunsch, C.  D., A general method applicable to the search  for 
similarities in the amino acid sequence of two proteins. J. Mol. Biol. 1970, 48, 
443-453.
8. Bruns, C. M.; Hubatsch, I.; Ridderstrom, M.; Mannervik, B.; Tainer, J. A., 
Human glutathione transferase A4-4 crystal structures and mutagenesis reveal 
the basis of high catalytic efficiency  with toxic lipid peroxidation products. J. 
Mol. Biol. 1999, 288 (3), 427-439.
166
9. Lesk, A. M., Protein Architecture: A Practical Approach. IRL Press: Oxford, 
1991.
10. Gerstein, M.; Chothia, C. H.,  Analysis of protein loop closure: Two types of 
hinges produce one motion in lactate dehydrogenase. J. Mol. Biol. 1991, 220, 
133-149.
11. Damm, K. L.; Carkson, H. A., Gaussian-weighted RMSD superposition of 
proteins: a structural comparison for flexible proteins and predicted protein 
structures. Biophys. J. 2006, 90, 4558-4573.
12. Brünger,  A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros,  P.; Grosse-
Kunstleve,  R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, N.; Pannu, N.  S.; Read, R. 
J.; Rice, L. M.; Simonson, T.; Warren, G. L., Crystallography  and NMR system 
(CNS): A new software system  for macromolecular structure determination. 
Acta Cryst. 1998, D54, 905-921.
13. Nishimasu, H.; Fushinobu, S.; Shoun, H.; Wakagi, T., Crystal structures of an 
ATP-dependent hexokinase with broad substrate specificity  from  the 
hyperthermophilic archaeon Sulfolobus tokodaii. J Biol Chem 2007, 282, 
9923-31.
167
Chapter 7: Methods and Materials
7.1 Materials, Ampicillin, magnesium chloride hexahydrate, UTP, glycine, glucose, EDTA, 
agar, L-aspartate, N-carbamoyl-L-aspartate,  2-mercaptoethanol, uracil, and bis-Tris 
were obtained from  Sigma-Aldrich  (St.  Louis, MO). CTP was from Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA). Tris, 3-(cyclohexylamino)-1-propanesulfonic 
acid (CAPS),  electrophoresis-grade acrylamide and enzyme-grade ammonium sulfate 
and GTP were from MP Biomedicals (Santa  Ana, CA).  Antipyrine, 
diacetylmonoxime, sodium  molybdate dihydrate, tryptone and yeast extract were 
obtained from Fisher  (Pittsburgh, PA). Casamino acid was from Becton, Dickinson 
and Company  (Franklin Lakes, NJ). Agarose, ammonium persulfate (APS), sodium 
dodecyl sulfate, coomassie brilliant blue and Chelex 100 resin were purchased from 
Bio-Rad (Hercules, CA). Carbamoyl phosphate dilithium salt  obtained from  Sigma-
Aldrich was purified before use by  precipitation from 50% (v/v) ethanol and was 
stored desiccated at -20°C.1 The synthesis of N-(2-hydroxy-acetyl)-L-aspartic acid-
phosphate (LC1413)2,  H-phosphinate-acetyl-L-aspartate (HPALA)3, and β-
hydroxymethyl (PALA-OH)4 have been previously  reported. PALA was obtained 
from the National Cancer Institute.
7.2 Methods
7.2.1 Enzyme expression and purification
 B. subtilis ATCase (Chapter  2) was over-expressed in  M9 minimal media  using 
the E. coli strain EK1104 [F- ara,  thi,  ∆(pro-lac), ∆pyrB, pyrF±, rpsL] transformed 
with  plasmid pEK1715 containing the B. subtilis pyrB gene under the control of the 
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E. coli pyrBI  promoter6 The purification procedure is a  variation on that performed 
previously.5 First,  ion-exchange chromatography  was employed using a  Q-Sepharose 
Fast Flow  (QFF; GE Healthcare) column (11  cm  x 2.5 cm). The fractions containing 
ATCase were pooled and dialyzed against 0.05 M Tris-acetate, 2 mM 2-
mercaptoethanol pH 8.3  (Low Q buffer). The protein solution was then brought to 
20% ammonium sulfate saturation and purified by  hydrophobic-interaction 
chromatography  employing a Phenyl Sepharose (GE Healthcare) column (8.5 cm x 2 
cm).  The protein  was eluted using a linear gradient from  Low Q buffer  + 20% 
ammonium sulfate to Low Q buffer. The fractions containing pure ATCase, as 
confirmed by  SDS-PAGE,7 were pooled and dialyzed against storage buffer (40 mM 
KH2PO4, 2  mM 2-mercaptoethanol, and 2 mM EDTA, pH 7.0). Protein concentration 
was determined by  A280 measurement using the extinction coefficient of B. subtilis 
ATCase, 0.57 cm2•mg-1.8
 E. coli ATCase (Chapter 3  - Chapter 5) was overexpressed in M9 media 
supplemented with 5 g/L casamino acids using E. coli strain EK11046 [F- ara,  thi, 
∆(pro-lac), ∆pyrB, pyrF±, rpsL] transformed with plasmid pEK1529 containing the 
E. coli pyrBI gene. The isolation and purification procedures were modified versions 
of those previously  described.6 The first step was ion-exchange chromatography 
using a QFF column. The protein was eluted with a linear gradient  of Low  Q buffer  to 
Low Q buffer containing 0.5 M NaCl (0.4%/min, 250 mL total) at a flow rate of 1.0 
mL/min. The fractions containing ATCase were pooled and dialyzed against Low Q 
buffer. The protein  solution was then brought  to 20% ammonium sulfate saturation 
and purified by  hydrophobic interaction chromatography  using a  Phenyl Sepharose 
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column. The protein was eluted using a linear gradient from  Low Q buffer brought to 
20% ammonium sulfate saturation to Low Q buffer (0.5%/min, 200 mL total) at  a 
flow rate of 1.0 mL/min. The fractions containing pure ATCase, determined by  SDS-
PAGE,7 were pooled and dialyzed against 40 mM KH2PO4, 2 mM 2-mercaptoethanol, 
2  mM EDTA, pH 7.0.  Enzyme concentrations were determined by  absorbance 
measurements at 280 nm with an extinction coefficient of 0.59 cm2/mg.10
7.2.2 Crystallization 
Chapter 2. B. subtilis ATCase was crystallized by  the hanging drop vapor 
diffusion method as previously  reported.11 The enzyme, at a final concentration of 12 
mg/ml, was mixed with an equal volume of crystallization buffer (1.7  M (NH4)2SO4, 
0.1  M Tris-HCl, pH 8.5, 2.0% PEG 200) and equilibrated over a reservoir  of 0.5 ml of 
crystallization  buffer  at  20 ºC. Bar-shaped crystals grew  to average dimensions of 0.5 
x 0.3 x 0.1  mm  within one week. These crystals were used directly  to determine the 
structure of the unliganded enzyme. To determine the structure of the ATCase•CP 
complex,  these crystals were equilibrated in crystallization buffer containing 13.3 
mM CP for  one hour prior  to freezing. For the ATCase•PALA structure,  the enzyme 
was co-crystallized with PALA (2 mM) by  the hanging drop vapor  diffusion method, 
based upon conditions identified by  a crystal screen at the Hauptman-Woodward 
Institute (Buffalo, NY). The drop consisted of equal volumes of 10 mg/ml enzyme 
solution and crystallization buffer (0.1  M potassium bromide, 0.1  M CAPS buffer, pH 
10.0, 18% PEG 8000) over a reservoir of 0.5 ml of crystallization buffer. Hexagonal 
crystals grew to average dimensions of 0.2  x 0.2  x 0.05 mm within one week.  In  each 
case, crystals were transferred into cryoprotectant consisting  of 20% glycerol in 
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crystallization buffer before freezing in liquid nitrogen.
Chapter 3. E. coli ATCase (10 mg/mL) was placed in  50 µL dialysis buttons 
(Hampton Research, Aliso Viejo,  CA) and dialyzed against 20 mL 50 mM maleic 
acid, 3  mM sodium azide, and 1  mM PALA, pH 5.95.12 Hexagonal rods grew to 
average dimensions of 1.0 x 0.2 x  0.2  mm  within two weeks. The crystals were then 
dialyzed overnight  in crystallization buffer  plus 10 mM UTP. Before being flash 
frozen in liquid nitrogen, the crystals were dipped into UTP crystallization buffer 
with 20% (v/v) 2-methyl-2,4-pentandiol.
Chapter 4. E. coli ATCase (20 mg/mL) was placed in four  50 µL dialysis buttons 
and dialyzed against 20 mL of crystallization buffer (40 mM sodium  citrate, 1  mM 2-
mercaptoethanol, 0.2 mM EDTA,1.0 mM CTP, pH 5.7) at 20°C.  Crystals formed in 
about 1  week. One dialysis button was transferred to 2 mL of crystallization buffer 
with  5 mM UTP and 5 mM MgCl2 and allowed to equilibrate for 12  hours.  E. coli 
ATCase was co-crystallized with dCTP following the same procedure as indicated 
above, but dCTP was substituted for  CTP in  the crystallization buffer. Crystals 
formed in about 1  week and one button was dialyzed in crystallization buffer 
containing 5 mM UTP and 5 mM MgCl2 for 12 hours.  After equilibration in 
crystallization  buffer  with  5 mM UTP and 5 mM Mg2+, the crystals were transferred 
into a cryoprotectant of 20% 2-methyl-2,4-pentadiol in UTP•Mg2+ crystallization 
buffer for about 1 min prior to freezing in liquid nitrogen.
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Chapter 5. E. coli ATCase (10 mg/mL) was placed in 50 µL dialysis buttons and 
dialyzed against 20 mL of crystallization buffer (50 mM maleic acid,  1  mM PALA, 
and 3  mM sodium azide, pH 5.90) at 20°C.12 Crystals formed in about 1  week with 
average dimensions of 0.6  x  0.2 x 0.2 mm. Dialysis buttons were transferred to 1  mL 
of crystallization buffer with either 5 mM CTP, 5 mM ATP, 5 mM each of ATP and 
MgCl2, 5 mM each of UTP and MgCl2, or  5 mM each of CTP, UTP and MgCl2,  and 
allowed to equilibrate for 12  hours. The crystals were dipped in crystallization buffer 
with  5 mM each of the matching nucleotide and MgCl2 with 20% (v/v) 2-methyl-2,4-
pentandiol as a cryoprotectant for approximately 1 minute prior to flash freezing.
Supplementary Chapter 1. RPALA OH. E. coli ATCase (12.5 mg/mL) was placed in 
50 µL dialysis buttons and dialyzed against  20 mL of crystallization  buffer 
containing 50 mM maleic acid, 3 mM sodium  azide, and 5 mM PALA OH at pH 5.7. 
Rod-shaped crystals with approximate dimensions 4.0 x 2.0 x  1.0 mm formed in 
about 1  week. Crystals were soaked in a solution of 30% 2-methyl-2,4-pentanediol 
(MPD) in crystallization buffer for ~ 1 min prior to freezing in liquid nitrogen.
RHPALA. E. coli ATCase (12.5 mg/mL) was placed in 50 µL dialysis buttons and 
dialyzed against 20 mL of crystallization buffer containing 50 mM maleic acid, 3  mM 
sodium  azide, and 5 mM HPALA at pH 5.7. Rod-shaped crystals with  approximate 
dimensions 0.4 x 0.2 x 0.1  mm formed in  about 1  week. Crystals were soaked in  a 
solution of 25% MPD in crystallization buffer for  ~1  min prior  to freezing in liquid 
nitrogen.
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RLC1413. E. coli ATCase (16.3  mg/mL) was placed in 50 µL dialysis buttons and 
dialyzed against 20 mL of crystallization buffer containing 50 mM maleic acid, 3  mM 
sodium  azide, and 6 mM LC1413 at pH 5.7. Rod-shaped crystals with approximate 
dimensions 0.4 x 0.2  x 0.1  formed in about 3  weeks. A suitable cryoprotectant was 
not  found for the crystals under the conditions described. Therefore, prior to 
cryoprotection  the crystals were equilibrated in a new  buffer  containing 10 mM MES, 
15% PEG 8000, and 6 mM LC1413  at pH 7.0. The crystals were allowed to equilibrate 
overnight. Crystals were stable in the new  buffer and showed no signs of cracking. 
The crystals were soaked in a cryoprotectant of 25% MPD in soaking buffer for ~1 
min prior to freezing in liquid nitrogen.
7.2.3 X-ray data collection and processing
 Data were either collected on beamline X29  at  the National Synchrotron Light 
Source at Brookhaven National Laboratory  (Upton, NY) or collected on a Rigaku 
MicroMax-07  HF high intensity  microfocus rotating Cu anode X-ray  generator 
coupled with Osmic VariMax Optics and a  R-Axis IV++ image plate area detector at 
Boston College. The X29 diffraction data were integrated, scaled, and averaged using 
HKL2000.13 The BC diffraction data were integrated,  scaled, and averaged using 
d*TREK (Rigaku/MSC).14 A data collection summary  for each crystal is outlined in 
Table 7-1. Data collection and refinement statistics are shown in Table 1  of each 
corresponding chapter.
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Table 7-1. Summary of crystal data collection 
Structure State Accession Code
Data 
Collection
Initial 
Model Chapter
B subtilis ATCase - 3R7D X29 - 2
B subtilis ATCase•CP - 3R7F X29 - 2
B subtilis ATCase•PALA - 3R7L X29 - 2
RPALA•UTP R 4F04 X29 1D09 3
T•dCTP T 4FYV X29 1ZA1 4
T•CTP T 4FYW BC 1ZA1 4
T•dCTP•UTP•Mg2+ T 4FYX X29 1ZA1 4
T•CTP•UTP•Mg2 T 4FYY X29 1ZA1 4
RPALA•ATP R 4KGV X29 1D09 5
RPALA•CTP R 4KGX BC 1D09 5
RPALA•UTP•Mg2+•UTP R 4KGZ X29 1D09 5
RPALA•ATP•Mg2+•ATP R 4KH0 X29 1D09 5
RPALA•CTP•Mg2+•UTP R 4KH1 BC 1D09 5
RHPALA R - X29 1D09 S1
RPALA OH R - BC 1D09 S1
RLC1413 R - X29 1D09 S1
7.2.4 Structure solution and data refinement
 The structure of unliganded B.subtilis  ATCase (Chapter 2) was solved by  
molecular replacement using an E. coli c3 ATCase extracted from  a holoenzyme 
structure in the T-state (PDB entry  1ZA1)15 as the initial model after  removal of water 
and ligand molecules. Molecular replacement was performed using the AutoMR 
module of PHENIX.16 The structure of the ATCase•CP complex was refined directly 
175
using the unliganded structure as the initial model. Poor  fitting loops in the 
ATCase•CP complex were rebuilt using the AutoBuild module of PHENIX. The 
structure of the ATCase•PALA complex was solved by  molecular replacement using 
BALBES17 using an E. coli c3 ATCase extracted from a  holoenzyme structure in the R-
state (PDB entry  1D09)18 as the initial model.  The final ATCase•PALA structure 
contained two c3 units in the asymmetric unit as suggested by  the Matthews 
coefficient. The AutoBuild module of PHENIX was used for initial model building, 
then waters were removed from the active site and the LigandFit module of PHENIX 
was used to place the six PALA molecules into the asymmetric unit. Manual 
rebuilding, addition of waters and CP and Pi modeling were performed using COOT.
19 Waters were accepted if they  were within hydrogen bonding distance of either 
main chain or  side chain atoms. Automated refinement using non-crystallographic 
symmetry  restraints were initially  used but were turned off during final refinements 
performed by  PHENIX. The final structures were validated using MolProbity20, 21 
and PROCHECK.22 Residues 292-304 (C-terminus) were omitted in all chains of 
each structure due to weak electron density.
 Each structure of E. coli ATCase (Chapters 3-5; Supplementary  Chapter 1) was 
directly  solved using phases from E. coli ATCase in the T state (PDB ID 1ZA1)15 or  E. 
coli ATCase•PALA complex in  the R state (PDB ID: 1D09)18 as the initial model, after 
removal of water  and ligand molecules (see Table 7-1).  Automated refinements using 
translation libration screw-motion (TLS) parameters were performed in PHENIX 
after  an initial rigid body  refinement.16 Manual rebuilding, addition of waters, and 
ligand/nucleotide modeling  were performed using COOT.19, 23 Waters were accepted 
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if they  were within hydrogen-bonding distance of main-chain  or  side-chain atoms. 
The final structures were validated using MolProbity20 and PROCHECK.22
7.2.5 In silico calculations
Chapter 2 - Docking with GLIDE. Docking of substrates to the B. subtilis 
structure in  the absence and presence of ligands was performed using GLIDE 
(Schrödinger, Inc.) in  extra-precision mode (XP). The Protein Preparation Wizard of 
MAESTRO (Schrödinger, Inc.) was used to assign bond orders,  add hydrogen atoms, 
optimize the hydrogen-bonding network and to refine the hydrogen atom positions, 
using the OPLS2005 force field, while restraining the protein to a maximum 
displacement of 0.3 Å. Ligands were prepared for docking using the LigPrep module 
and all possible ionization states were generated. The Glide XP docking score was 
used to evaluate the results. In order to validate the GLIDE results CP was docked 
into the ATCase•CP structure with CP removed, and PALA was docked in the 
ATCase•PALA structure with PALA removed. The average difference in atomic 
positions between the docked CP and the CP position determined in the structure 
was 0.63Å, while the root  mean square deviation of the two conformations was 
0.22Å. The average difference in atomic position between the docked PALA and the 
PALA position determined in the structure was 0.31Å, while the root mean square 
deviation of the two conformations was 0.27Å.
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Chapter 5 - Calculation of small angle X-ray scattering profiles. X-ray 
scattering patterns were calculated from  the experimental X-ray  crystal data  using 
the fast  SAXS profile computation with Debye formula (FOXS) server(http://
modbase.compbio.ucsf.edu/foxs). The FoXS server explicitly  computes all inter-
atomic distances as well as models the first  solvation layer based upon the atomic 
solvent  accessible areas.24 Hydrogen atoms were considered implicitly. For 
consistency, the first 9 residues of each regulatory  chain were not included in the 
calculations. 
Supplementary Chapter 1 - GLIDE calculations. GLIDE (Schrödinger, Inc.) in 
extra-precision mode (XP) was used to assign scores for  each ligand in the solved 
structures.  The Protein Preparation  Wizard of MAESTRO (Schrödinger,  Inc.) was 
used to assign bond orders, add hydrogen atoms, optimize the hydrogen-bonding 
network and to refine the hydrogen atom  positions, using the OPLS2005 force field, 
while restraining the protein to a  maximum displacement  of 0.3  Å. Hydrogens and 
ionization states were incorporated into each ligand and then scores were calculated 
based on the coordinates observed in the crystal structure.
7.2.6 Determination of ATCase activity
Nucleotide Pretreatment. Prior to use,  nucleotide solutions were treated with 
chelating ion-exchange resin  (Chelex 100,  Bio-Rad) to remove metal contamination 
in  the commercial supply. The resin was directly  added to the solutions (0.5 g per 10 
mL of nucleotide solution) and stirred on ice for  one hour. Following centrifugation, 
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the solution was decanted from  the resin. The concentration of the nucleotide 
triphosphates was determined spectrophotometrically  at pH 7.0 using previously 
reported values of molar  absorptivity  (Table 7-2).25 When required, MgCl2 was added 
to adjust the Mg2+ concentration. 
Table 7-2. Spectrophotometric properties of NTPs used to determine solution 
concentrations
NTP λ (nm) εNTP (M-1cm-1)
CTP (dCTP) 271 9,000
UTP 262 10,000
ATP 259 15,400
GTP 253 13,700
ATCase Activity. Activity  measurement with  the nucleotide effectors ATP, CTP, 
GTP and UTP were performed in the absence and presence of Mg at 28°C (Chapter 4 
kinetics were performed at 25°C). The activity  of the ATCase reaction was 
determined colorimetrically26 in  a tri-part buffer at either pH 7.0 or pH 8.3, 
containing 20 mM Bis-Tris, 20 mM Tris, and 20 mM CAPS, in the presence of a 
saturating concentration of carbamoyl phosphate (2.0 mM). Kinetic measurements 
were determined in duplicate (Chapter  4) or  quadruplicate (Chapter  5), and the data 
points in the graphs are the average. Nucleotide inhibition curves were determined 
at the [Asp]0.5 (5 mM). Specific activity  is in  units of mM N-carbamoyl-L-
aspartate•min-1•mg-1. Fitting of the experimental data to theoretical equations was 
accomplished by nonlinear regression.
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Supplementary Chapters
Supplementary Chapter 1: Dissecting the Role of 
N-Phosphonoacetyl-L-Aspartate Functional 
Groups in the Inhibition of Aspartate 
Transcarbamoylase
A manuscript in preparation for publication.
Contribution to work: Solved the X-ray  crystal structures of the RHPALA, RPALA OH, and 
RLC1413 complexes. Synthesis of inhibitors and kinetic data was previously published.
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S1.1 Summary
 The compound N-phosphonacetyl-L-aspartate (PALA) is the most potent 
inhibitor of ATCase to date. It has been an invaluable molecule in studying the states 
and kinetics of ATCase, however PALA has proven to be a poor drug despite its 
potency. PALA consists of three negatively  charged groups: two carboxylic acids and 
a phosphonate. In this study  we analyze three crystal structures of ATCase, each  with 
a different derivative of PALA bound at the active site. Each of these derivatives 
replace one charged functional group with a neutral group.  Along with  existing 
structural and kinetic data,  we were able to systematically  compare the interactions 
of each functional group to provide a molecular basis for why  the α-carboxylate of 
PALA is the least important for potent inhibition.
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S1.2 Introduction
 ATCase and the enzymes of pyrimidine nucleotide biosynthesis are an 
attractive target for  anti-proliferation drugs in cancer treatment, since pyrimidine 
nucleotides are necessary  for rapid cell division. The most potent inhibitor  of ATCase 
is N-phosphonacetyl-L-aspartate (PALA).  PALA is a  bisubstrate analog1 (see Fig. 1-1) 
that has interactions with every  residue involved in the binding of both CP and L-Asp 
resulting in nanomolar affinity  to ATCase (see Fig. 1-11).1 PALA has been shown to 
bind and competitively  inhibit ATCases from mammals,2, 3 yeasts,4 and bacteria,5 
despite differences in the quaternary  structures between species. This is due to the 
common trimeric arrangement of the core catalytic subunit  and high level of 
homology  among active site residues for ATCases across a  variety  of organisms. Each 
catalytic trimer contains three active sites, where one active site lies between 
adjacent chains. Each active site is highly  conserved and makes the same contacts 
with  the PALA molecule. This has been shown in PALA-bound ATCase X-ray 
structures for  Escherichia coli (PDB 1D09, PDB 1Q95),6, 7 Bacillus subtilis (PDB 
3R7L),8 and Pyrococcus abyssi (PDB 1ML4).9
 As stated in Chapter 1,  the most  studied form  of ATCase is from E. coli, the 
catalytic chain of which  is shown in Fig. S1-1  outlining the loops and movements that 
occur during substrate binding. Upon CP binding there are significant 
conformational changes to the 50s loop and the 80s loop,  both containing critical 
residues for catalysis. This is followed by  the binding of aspartate which causes a 
closure of the active site, via 240s loop movements. The binding of PALA induces all 
of these conformational changes upon binding to ATCase. Two crystal structures of 
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E. coli ATCase with PALA bound have been previously  reported (PDB 1D09, PDB 
1Q95).6, 7
Figure S1-1 | Loop movements that occur  in  one catlytic  chain  and the adjacent 80s loop 
(*) of ATCase from  the unliganded enzyme (blue)  to the PALA bound complex  (red).  Areas 
with  an  RMSD greater  than  1.3  Å  are spectrally  colored. This figure was made on  the 
ViewMotions web server (see Chapter 6).
 PALA makes 20 hydrogen bonding contacts and has strong electrostatic 
interactions with the electropositive active site of ATCase. Active site residues 
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include Ser52, Thr53, Arg54, Thr55, Arg105,  His134, Arg167, Arg229,  Gln231, 
Leu267, as well as Ser80 and Lys84  that are donated from the adjacent chain (see 
Fig. 1-11).  Mutagenesis studies have shown that  Gln137, located in the active site 
pocket, is also involved in catalysis though it does not make contact with PALA10.  In 
molecular modeling studies with the catalytic subunit of B. subtilis  ATCase, the 
homologous residue to Gln137  has been suggested to form  an additional interaction 
with  the amine on the tetrahedral carbon present in the tetrahedral intermediate but 
not  in PALA.8 Structural evidence of this interaction is available in ATCase 
structures containing CP bound in the active site.11
 PALA has been tested in clinical trials as an anti-cancer  drug after it  was found 
to stop the growth of cancer cells in vitro.12-14 However, it was found that the 
effectiveness of PALA dropped significantly.14 This was due to the high amount of 
charge on the molecule, which makes it difficult  to diffuse through the cell 
membrane.15 Many  analogs of PALA have been reported with  functional group 
modifications that decrease the overall charge on the molecule. However,  they  have 
proven to be less potent than PALA.16, 17 New crystal structures of E. coli ATCase with 
a variety  of these PALA derivatives bound (Fig. S1-2) were analyzed in this study  to 
map the specific enzyme-ligand interactions and provide insights into the 
interactions most critical for potent inhibition.
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S1.3 Results and Discussion
 The poor  bioavailabilty  of PALA has lead to the synthesis of functional group 
analogs in an attempt  to decrease the amount of charge on the molecule. However, 
replacing these charged functional groups with neutral groups (Fig. S1-2) disrupts 
the many  electrostatic interactions and as a result,  weakens the inhibitory  effect. 
These analogs have been co-crystallized with E. coli ATCase in order to link 
structural and kinetic data of each  (Table S1-1).  Using new and existing structural 
data, the loss of specific interactions with  the active site have been mapped and 
compared to the experimental kinetic data.
Figure S1-2 | The structures of PALA  and the derivatives of PALA  that  have less overall 
charge. The differences in each derivative from the PALA molecule is outlined in red.
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Table S1-1. Data collection and refinement statistics.
RHPALA RPALA OH RLC1413
Data collection statistics
Space group P321 P321 P212121
Wavelength 1.075 1.542 1.075
Cell Dimensions
a, b, c (Å) 120.9, 120.9, 154.9 120.4, 120.4, 154.4 125.1, 151.7, 185.6
α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 90
Resolution (Å) 30 - 2.35 (2.43 -2.35) 28.4 - 2.2 (2.3 - 2.2) 50 - 2.6 (2.7 - 2.6)
Rsym 0.105 (0.571) 0.063 (0.450) 0.102 (0.535)
Average (I/σ) 22.7 (6.1) 8.6 (3.0) 18.3 (5.2)
Completeness (%) 99.4 (93.9) 98.1 (99.6) 99.3 (94.0)
Redundancy 22.6 (19.3) 5.4 (5.3) 13.9 (13.2)
Refinement statistics
Resolution (Å) 49.1 - 2.1 28.4 - 2.2 49.2 - 2.6
Reflections 54,255 64,860 106,802
Rwork/Rfree 0.180/0.223 0.200 / 0.254 0.154 / 0.218
Number of atoms
Protein 7,066 7,114 21,312
Waters 441 510 732
R.m.s. deviations
Bond lengths (Å) 0.008 0.008 0.007
Angles (°) 1.16 1.19 1.09
Mean B value (Å2) 57.8 60.4 50.7
Values in parentheses are for the highest resolution shell.
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S1.3.1 The structure of the RHPALA complex
 The phosphonate group of PALA mimics interactions with the enzyme that 
are involved in the binding of CP.  This comprises half of the interactions that  PALA 
makes with the ATCase active site. HPALA differs from  PALA by  a phosphinate 
functional group in place of the phosphonate. This change in  functional groups 
results in one less hydrogen bond acceptor and increases the formal charge from -4 
to -3. HPALA was designed as a potential prodrug that would be oxidized in vivo to 
PALA,18 however  the inhibitory  effect of the ligand was decreased by  a factor  of 9 
compared to PALA (Table S1-2).
Table S1-2. Reported inhibition constants and calculated Glide scores for PALA derivatives.
H- bonds Glide Score Ki (nM) Ki/Ki PALA
PALA 21 -11.84 36 -
LC1413 22 -12.26 215 6
PALA OH 20 -11.54 2600 72
PALI 22 -11.81 58 1.6
PASN 21 -10.32 8800 244.4
HPALA 17 -10.45, -10.71, -11.14 325 9
 The molecule HPALA was co-crystallized with ATCase to study  the resulting 
interactions from  reducing the overall charge on the phosphonate group. The 
complex  crystallized in the P321  space group with almost  identical unit cell 
dimensions as the RPALA complex (PDB ID 1D09) (Table S1-1). After  modeling  and 
refinement of HPALA into the active site density, excess Fo-Fc electron density  was 
observed at the 5σ level around the phosphinate portion of the ligand (Fig. S1-3). 
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Figure S1-3 | Electron density  profile of HPALA bound in  the active site of ATCase.(A) 
Shown  are the 2Fo – Fc (blue,  1.5  σ) and Fo – Fc  (green,  5.0 σ) electron  density  maps when  1 
phosphinate orientation  is modeled. (B) Shown  are the 2Fo – Fc (blue,  1.5  σ) and Fo – Fc 
(green, 3.0 σ) electron density maps when 3 phosphinate orientations are modeled.
 The electron density  profile in the ligand site looked very  similar  to that of 
PALA. This suggested that the phosphinate had oxidized to a phosphonate over the 
time for crystallization to occur. HPALA was placed in  the crystallization buffer and 
was checked by  31P-NMR in one-week intervals for  three weeks, the same amount of 
time for crystallization of the complex. The spectra showed no oxidation of the 
inhibitor. Therefore, the excess density  was likely  due to alternate orientations of the 
phosphinate  because of the rotatable bond between the carbon and the phosphorous 
atom. 
 Since the electron density  profile was similar  to the density  observed for  PALA 
three alternate conformations of the phosphinate were modeled and the occupancy 
of each was manually  set at  33%. No positive or negative Fo-Fc density  was observed 
after  an occupancy  refinement in PHENIX. One conformation of the phosphinate 
oxygens was observed at 23% occupancy  (Fig. S1-4A) and two conformations had 
relatively the same occupancy, 37% (Fig. S1-4B) and 40% (Fig. S1-4C).
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Figure S1-4 | Three observed orientations of the phosphinate group of HPALA  in  the active 
site of ATCase at  (A) low  occupancy,  23%,  (B) mid occupancy, 37%,  and (C) high  occupancy, 
40%, following an occupancy refinement in PHENIX.
 Both the α and β carboxylate groups of HPALA make the same interactions 
with  the active site as the α and β carboxylate groups of PALA. The phosphonate 
group of PALA makes 10 hydrogen bonding interactions with 50s loop residues 
Ser52, Thr53, Arg54,  and Thr55, Ser80 and Lys84 of the adjacent chain, and Arg105. 
There are also three electrostatic interactions with the residues Arg54, Lys84, and 
Arg105. In each of the three phosphinate orientations of the HPALA  structure, at 
least one electrostatic interaction is lost with the enzyme. The loss of one of these 
interactions means that there is positive charge that is unneutralized in the active 
site.  This could possibly  be a means of CP being able to displace the ligand HPALA, 
thus weakening its inhibitory effect compared to PALA.
 The decrease in the amount of hydrogen bonds between HPALA and PALA 
bound structures is most  likely  also a  reason for the observed decrease in inhibition. 
In the two highest occupancy  orientations,  the amount of hydrogen bonds observed 
with  the phophinate and the 50s loop residues is greatly  reduced compared to PALA. 
In the highest occupancy  orientation, there are no hydrogen bonds observed with 
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Thr53  or Arg54 and in  the middle occupancy  orientation there are no hydrogen 
bonds observed with Ser52 or Thr55. In the low occupancy  structure the hydrogen 
bonds that are missing are the ones with 80s loop residues Ser80 and Lys84. The 
entire hydrogen bonding network observed in  PALA binding is responsible for  a 
complete closure of the active site. The phosphonate group of PALA binds both the 
80s loop and 50s loop.  By  disrupting these hydrogen bonds, as seen in the RHPALA 
complex,  it  is likely  the active site is more accessible to the solvent and therefore the 
inhibitor is more susceptible to competition with  the natural substrate, CP, 
decreasing the effect of inhibition.
S1.3.2 The α-carboxylate functional group of PALA (RPALI complex)
 One complex that has been previously  crystallized is the RPALI complex (PDB 
2H3E).16 The ligand PALI has an α-amide in place of the α-carboxylate group of 
PALA. Again,  this ligand is structurally  very  similar  to PALA with a lower overall 
charge. The only  difference in  active site binding between PALA and PALI is with 
residue Arg167  (Fig. S1-5A). PALI has one less hydrogen bond to Arg167  and does 
not  have the electrostatic interaction that PALA does. The electrostatic interaction 
with  Lys84 is also a difference, although Lys84  still has a hydrogen bond interaction 
with  the amide. PALI is the best inhibitor out of the functional group analogs (see 
Table S1-2).  It has a  lower  inhibitory  effect as compared to PALA by  a factor  of only 
1.6. This shows that  the electrostatic interactions made by  the α-carboxylate of PALA 
are the least important for a good inhibitor. This is likely  because (1) the extent of the 
conformational change in the 160s region is small compared to the overall changes of 
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the 80s and 240s loops (see Fig. S1-1), meaning Arg167  does not significantly  change 
positions upon substrate binding and (2) the electrostatic interaction lost with  Lys84 
is not as important because of the strong interactions with the β-carboxylate and 
phosphonate groups.
Figure S1-5 | PALA derivatives bound in  the active site.Polar  interactions are shown  in  teal 
dashed lines. (A) PALI (B) PASN (C) PALA-OH (D) LC1413.
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S1.3.3 The structure of the RPALA-OH complex
 The β-carboxylate of PALA mimics the interactions made by  the β-carboxylate 
of L-Asp. This functional group makes four  hydrogen-bonding interactions with 
residues Lys84, Arg229  and Gln231  (see Fig 1-11).  Two electrostatic interactions are 
also present between the β-carboxylate and Lys84 and Arg229. There are 
significantly  fewer interactions between the enzyme and the β-carboxylate as 
compared to the phosphonate group, however these interactions are the only  ones 
made with the 240s loop. The 240s loop significantly  changes conformation upon 
the binding  of L-Asp (see Fig. S1-1). Two structures were analyzed to determine the 
importance of the β-carboxylate functional group interactions, PASN (Fig.  S1-5B) 
and PALA-OH (Fig. S1-5C). The RPASN crystal structure had been previously 
deposited (PDB entry 2IPO).
 PALA-OH has a neutral γ-hydroxyl functional group on the amino acid moiety  
of the molecule instead of a negatively  charged β-carboxylic acid. The two main 
differences between the RPALA and RPALA-OH complexes are hydrogen bonding 
interactions between the ligand and Arg229 and Lys84. In the RPALA-OH complex 
there is no hydrogen bonding interaction with Lys84.(see Fig  S1-5C). There is also 
only  one of the two hydrogen bonding interactions with  Arg229  observed in  the 
ATCase•PALA complex. In both ATCase complexes Gln231  interacts with the 
functional group. With no charged group at  this position, both of the electrostatic 
interactions are lost  comparing  the RPALA-OH complex to the RPALA complex. The 
difference in these interactions results in  a decrease in the inhibitory  effect  by  a 
factor of 72 (Table S1-2). 
198
 Structurally, the distance between the 240s loop and the ligand is slightly  
larger for the RPALA-OH complex than the RPALA complex. The distance between the 
hydroxyl group of PALA-OH and Arg229 is 3.1  Å compared to 2.7  Å of the β-
carboxylate of PALA and Arg229. The distances between the same ligand atoms and 
the Gln231  sidechain are 3.5 Å in the RPALA-OH complex and 3.1  Å in the RPALA 
complex.  The same concept of a more accessible active site for  natural substrates, as 
suggested for the RHPALA complex, may  be the reason for  decreased inhibition. 
However,  the extent of the inhibition is greatly  diminished as compared to HPALA. 
This is most likely  due to the smaller  amount of interactions the β-carboxylate group 
has with  the enzyme compared to the phosphonate. The smaller number of 
interactions with the 240s loop increases the importance each one. 
 To emphasize the importance of the interactions with the 240s loop in  PALA 
binding/enzyme inhibition, the structure of the RPASN complex was analyzed and 
compared to the RPALA-OH complex.  The ligand PASN has a β-amide functional group 
instead of the β-carboxylate group of PALA. This ligand more closely  resembles the 
geometry  of the PALA molecule while reducing the overall charge. Comparison of the 
distances between the PASN and PALA ligands with residues Arg229  and Gln231 
showed that  there was little difference. This suggested that with the same number of 
hydrogen bonds PASN brings the 240s loop into the active site as close as PALA. 
However,  the uncharged β-amide group has no electrostatic interactions with 
Arg229 or  Lys84, suggesting that both the 240s and 80s loops are not as stabilized 
by  the ligand PASN. This is reflected in  the kinetic data  where inhibition is decreased 
by  a factor of over  200 as compared to PALA. In fact, PASN was the worst inhibitor 
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with  PALA-OH as the second worst (see Table S1-2). This shows the importance of 
the charge on the β-functional group for inhibitor design. We hypothesize that 
PALA-OH was a much better inhibitor than PASN because the γ-hydroxyl group is 
much more flexible than the β-amide, and able to make more partial interactions as 
observed with the phosphinate in the RHPALA complex.
S1.3.4 The structure of the RLC1413 complex
 N-(2-hydroxy-acetyl)-L-aspartic acid-phosphate (LC1413) is the most  similar 
in  structure to PALA as all of the charged functional groups are present. The only 
difference between the two molecules is an oxygen atom between the phosphorus 
carbon bond making the phosphonate group on PALA a phosphate on LC1413. Since 
the carbon atom is still present, the overall size of the LC1413 molecule is bigger  than 
PALA. The extra oxygen atom results in two more hydrogen bonding interactions as 
compared to PALA. These interactions are with  residues Arg54 and Ser80 (Fig. 
S1-5D). Experimentally, even with the same electrostatic interactions intact and two 
more hydrogen bonds, LC1413 was a weaker inhibitor than PALA by a factor of 6. 
 The largest deviation observed in the protein between the RPALA and RLC1413 
structures is in the 240s loop. The RPALA complex has a  240s loop that  is pulled 
slightly  closer to the ligand. Another  active site residue that shows deviation between 
the two structures is His134. This residue shows the same effect  as the 220s loop in 
that it  is drawn in closer  in the PALA structure than it is in the LC1413 structure 
Once again this could result in a more accessible active site, weakening inhibition as 
seen in the β-carboxylate derivatives. The reason the active site is likely  more solvent 
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accessible may  be to deviations in the binding of PALA and LC1413. Comparing the 
two ligands in the binding sites of their respective structures, the LC1413  ligand 
appears more compacted. This adds a steric strain factor  on the ability  of the active 
site to fully  close, and may  be the reason for the weakened ability  of this molecule to 
inhibit ATCase. This hypothesis is consistent with kinetic data that shows the larger 
in size the inhibitor is compared with PALA, the weaker the inhibitor becomes.19, 20
S1.3.5 Glide scores for each inhibitor
 The molecular  docking program Glide was used to assign energy  values to the 
ligands observed in  each  of the crystal structures (Table S1-2). This was achieved by 
calculating  the Glide Score of each  ligand as it  was observed in the crystal structure 
meaning the ligands were not docked into the binding site. These scores were 
compared to the experimentally  determined Ki values to try  and correlate the 
observed ligand binding in the static crystal structure to the inhibition observed in 
solution.
 Using PDB 1D09, the calculated energy  of the PALA molecule,  the best 
inhibitor experimentally, was -11.8 kcal/mol. The values for PALA and PALI,  the 
next best inhibitor, were identical at -11.8 kcal/mol even though  PALI was a  slightly 
weaker inhibitor. Both of the β-carboxylate analogs, PALA-OH and PASN, had Glide 
scores of -11.5 kcal/mol and -10.3 kcal/mol respectively. Both of these ligands had 
calculated energies higher than PALA or PALI, which was consistent with 
experimental data.  Comparing  the two β-carboxylate analogs,  PASN had a  much 
lower Glide score than PALA-OH, which was also consistent with the kinetic data. 
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 While the values discussed above correlate to the experimentally  determined 
kinetics, the ligands LC1413 and HPALA were both outliers. The Glide score for 
LC1413 was -12.3 kcal/mol, a lower energy  than PALA but experimentally  a weaker 
inhibitor. Each of the phosphinate orientations was separately  calculated for  the 
ligand HPALA. Interestingly, the highest occupancy  orientation scored the highest 
energy  (-10.45 kcal/mol), while the lowest occupancy  orientation scored the lowest 
energy  (-11.14 kcal/mol). However, these values are more comparable to the values 
calculated for PASN, an inhibitor that is weaker than HPALA by a factor of 8.
 In the case of both  LC1413  and HPALA the reason these values did not 
correlate is most likely  because the binding of the inhibitor in the static structure 
does not accurately  mimic the dynamic motions of the enzyme. LC1413  is predicted 
to bind tighter  than PALA because it has more hydrogen bonds with the enzyme 
while having the same amount of electrostatic interactions. However, the energy 
values are linked to only  the binding of the ligand to the enzyme and does not 
account for the steric consequences of a larger inhibitor to the active site structure.
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S1.4 Conclusions
 PALA contains three charged functional groups: two carboxylic acids (α and 
β) and a  phosphonate. Reducing the overall charge of the molecule by  changing any 
one of the charged groups to a neutral functional group has proven to decrease the 
inhibition of ATCase. With high-resolution x-ray  crystallography  specific active site 
interactions have been mapped to explain the kinetic data that has been previously 
reported. These results show that the β-carboxylate functional group electrostatic 
interactions are extremely  important for  potent  inhibition. Disrupting this 
interaction with  the 240s loop of ATCase is detrimental to PALA inhibition. On the 
other hand,  the α-carboxylate electrostatic interactions seem  to be the least 
important. Each  of the structures presented here give new insights into the design of 
potent inhibitors for ATCase.
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Supplementary Chapter 2: Synthesis of 7-
[Bis(carboxymethyl)amino]-4-yl-methyl 
aspartate for Monitoring Fast Biological 
Processes
A manuscript in preparation for publication.
Contribution to work: Synthesis of 7-[Bis(carboxymethyl)amino]-4-
hydroxymethylcoumarin and initial kinetic experiments with ATCase.
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S2.1 Summary
 The enzyme aspartate transcarbamoylase from  E. coli undergoes significant 
quaternary  changes through the catalytic cycle.  One method to monitor this 
transition is time resolved small angle X-ray  scattering. However, this method has 
limitation due to the kinetics of the structural transition being faster than the 
instrument dead time. In this study, a caged aspartate was synthesized to overcome 
the dead time limitation. The compound 7-[Bis(carboxymethyl)amino]-4-yl-methyl 
aspartate was synthesized in 5 steps with a 11.6% yield.  Initial kinetic experiments 
with ATCase were also performed.
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S2.2 Introduction
 The conformational differences between the T and R states of ATCase were 
outlined in Chapter  1.4. The extreme elongation of 11  Å along the molecular  three-
fold axis of symmetry  allows for  the observation of each state by  differences in the 
solution X-ray  scattering curves. More recently,  time resolved SAXS curves have 
been measured for ATCase.1 These curves show the transition from the T state to the 
R state, in  the presence of substrates,  and the transition  of the R state back to the T 
state, once substrates are exhausted,  over  a  function of time (Fig. S2-1). These time 
resolved experiments are achieved by  a stopped-flow instrument coupled with  SAXS. 
The limitation to these experiments is the time it  takes for the enzyme and substrate 
solutions to mix and form a homogeneous solution, or instrument dead time.
Figure S2-1 | TR-SAXS curves presented by  West  et al.1 Data  shown  is for  CP + D-Asp (T 
state standard), CP + PALA (R-state standard), and CP +Asp (natural substrates).
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 The instrument dead time is apparent in  the curves shown in Fig.  S2-1.  No 
information, or the rate of the T to R transition, can be analyzed before about 2  ms. 
At this point  the enzyme is almost completely  in the R state as seen in the curve 
involving the natural substrates in Fig. S2-1. Another important piece of information 
that can not be determined because of the dead time limitation is whether  the T to R 
transition occurs in a  single or biphasic manner. As shown for the CP +  PALA curve 
in  Fig. S2-1, the transition to the R state seems to be biphasic, with a very  fast initial 
burst then a steady  increase in  intensity  to the R state.  Information about the rate 
and mode of transition is vital in  understanding the mechanism of the enzyme. For 
example,  a biphasic TR-SAXS curve would suggest intermediate states between the T 
and R states, while a  single phase would suggest only  a shift in  the equilibrium 
between the T and R states. This information could be useful in  clarifying the 
allosteric model that ATCase follows (see Chapter 1.2).
 The synthesis of caged compounds has become a useful tool in studying  fast 
biological processes.2, 3 Caged compounds are biologically  relevant molecules that 
are protected with a  photo-removable group. The introduction of this photo-labile 
protecting group renders the molecule biologically  inert. Cleaving off this group by 
photolysis will then result in a concentration jump of the biologically  active 
molecule. 
 Caged compounds are very  useful in  defining cellular regulation either 
temporally  or spatially  as well as intracellularly  or extracellularly. Light is able to 
pass through the cell membrane and therefore uncaging can rapidly  release the 
biomolecule inside the cell. In terms of studying kinetics, like the case for ATCase, 
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the rate of the photolysis reaction must be faster  than the process being studied (T to 
R transition). 
 There are many  examples of caged molecules. One of the most widely  used by  
biologists is a caged glutamate,  which is a  caged neurotransmitter.4 Several caging 
protecting groups have been used including an α-carboxy-ortho-nitrobenzyl (CNB) 
group and a 4-methoxy-7-nitroindolinyl group (MNI) (see Fig. S2-2). Caged 
nucleotides and nucleosides have also been synthesized and been uncaged in living 
cells.5, 6 ATP was protected with  a  1-(ortho-nitrophenyl)-ethyl (NPE) group.7 Caged 
Ca2+ has also been achieved by  synthesizing photolabile derivatives of high affinity 
calcium  chelators, since the calcium  cation can not form  covalent bonds.8-10 The 
calcium  ion is an important  second messenger in biology. There have also been 
examples of caged macromolecules such as DNA,11 mRNA,12, 13 and proteins.14
Figure S2-2 | Examples of caged compounds.  (A)  MNI-caged glutamate,  (B) NPE-caged 
ATP,  and (C)  caged calcium.  The photolabile protecting  group of each  is highlighted in 
purple.
 Here we outline the five step synthesis of a caged aspartate molecule for 
future studies into the rate and mode of the conformational changes in ATCase. The 
photolabile protecting group used was 7-[Bis(carboxymethyl)amino]-4-
hydroxymethylcoumarin. We also discuss initial data concerning photolysis 
efficiency and kinetic responses with ATCase.
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S2.3 Results and Discussion
S2.3.1 Synthesis of 7-[Bis(carboxymethyl)amino]-4-yl-methyl aspartate
 The synthesis of 7-[Bis(carboxymethyl)amino]-4-yl-methyl aspartate, 
Compound 4, was achieved in 5 steps and is outlined in Scheme S2-1. Compounds 1 
and 2 were prepared by  literature procedures.15, 16 The first step was addition of the 
carboxymethyl groups to 7-amino-4-methylcoumarin via  an SN2 reaction. The 
addition of sodium  iodine to the reaction mixture facilitated the reaction by  halogen 
exchange on BrCH2COOtBu, since iodine is the better  leaving group. Compound 1 
was the main  product while the singly  acylated compound was the major byproduct 
along with unreacted starting material. Compound 1 was recovered as a  yellow solid 
with a 49% yield.
Scheme S2-1 | Synthesis of caged aspartic  acid.  Reagents and conditions: (a) 
BrCH2COOtBu,  iPr2EtN,  NaI, Acetonitrile,  reflux; (b) SeO2, p-xylene, reflux; (c) NaBH4, 
EtOH, rt; (d) Boc-Asp-OtBu, DCC, DMAP, rt., dark; (e) TFA/DCM/H2O (75/24/1), rt., dark.
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 The next two steps involved oxidation of Compound 1 by  SeO2 followed by  
reduction with NaBH4. No purification was necessary  between these two steps as the 
byproduct of the reaction  with SeO2 is an aldehyde from over-oxidation,  which is 
then reduced to the desired hydroxymethyl product (Compound 2). Compound 2 
was recovered as a yellow solid with a 28% yield.
 Compound 3 was prepared by  the Steglich esterification using DCC and a 
catalytic amount of DMAP. This reaction was performed in  the dark because of the 
photosensitive product. The final step in the synthesis was deprotection of the three 
t-butyl ester  protecting groups and the –BOC protecting group with TFA. These steps 
had yields of 93% and 91% respectively  and the overall yield of this synthesis was 
11.6%. The low yield was attributed to the first two inefficient steps. However, more 
than enough material was produced for enzymatic studies in the mM range.
S 2 . 3 . 2 S y n t h e s i s o f 7 - [ B i s ( c a r b o x y m e t h y l ) a m i n o ] - 4 -
hydroxymethylcoumarin 
 Compound 5 was produced by  TFA deprotection of compound 3 and is 
outlined in Scheme S2-2.  This compound was studied because it is a  byproduct of the 
photolysis reaction to get the desired free aspartate and must be inert with respect to 
enzyme activity. Compound 5 was recovered as a yellow solid with a 72% yield.
Scheme S2-2 | Deprotection of compound 3 to yield photolysis byproduct 5.
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S2.3.3  Photochemical Properties of Caged Aspartate
 The photochemical properties of both compounds 4 and 5  were studied and 
summarized in Table S2-1. Caged aspartate 4 had a λmax that  was red-shifted by  5 nm 
relative to that of compound 5. Serial dilutions of 1  mM stock solutions of 
compounds 4 and 5  were made. Standard curves of absorbance versus concentration 
were made for each compound and the molar  absorbtivity  (ε) corresponding to the 
λmax was calculated utilizing Beer’s Law. 
Table S2-1. Photochemical properties of compounds 4 and 5. 
λmax (nm) ελmax (mM-1cm-1) λem (nm) ΦF
4 379 17.10 + 0.09 494 0.1
5 374 16.18 + 0.02 487 0.2
 Relative quantum  yield of fluorescence (ΦF) was calculated according to 
literature procedures.17 This procedure related the fluorescence efficiency  of 
compounds 4 and 5 to a standard flourophore according to the following equation.
 The subscripts X and S correspond to the unknown and the standard, 
respectively, where A is the absorbance at the excitation wavelength, F is the area 
under  the corrected emissions spectrum, and η is the refractive index of the solvents 
used. The standard fluorophore used to determine quantum yield of fluorescence 
was 7-diethylamino-4-methylcoumarin (ΦF(S) =  0.73)18 because of its similar 
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absorption and emissions bands to compounds 4 and 5. Compound 5  had a 
fluorescence efficiency  (ΦF) of 0.2, which was double of that of compound 4, 
meaning the caged aspartate emits half the number  of photons as the protecting 
group for every photon absorbed.
S2.3.4  Photolysis and Qualitative Analysis
 Laser flash photolysis was performed on compound 4 at 388 nm. The 
photolysis reaction is shown in Scheme S2-3. The sample of compound 4 that 
underwent photolysis was in D2O and the reaction was performed directly  in a glass 
NMR tube. Directly  after exposure to the laser, the sample was wrapped to protect 
from further photolysis from ambient light.
Scheme S2-3 | Photolysis of compound 4 to yield compound 5 and bioactive aspartate.
 Shown in Fig. S2-3  are the spectra  of compound 5, the photolysis byproduct, 
and compound 4,  prior  to the photolysis reaction.  The important  peaks are labeled 
1-6  on the spectra.  The peaks for compound 4 are slightly  shifted downfield as 
compared to compound 5, but the biggest shift is associated with peak 5.
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Figure S2-3 | 1H-NMR spectra  of (Top) compound 5 from  0-8  ppm  and (Bottom) 
compound 4 from  4-8 ppm  (emphasis on  aromatic  region).  Peaks are labeled according  to 
the numbering on the inset structures of compounds 4 and 5.
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 For  compound 4,  the caged aspartate, peak 5 is a singlet at 5.36  ppm. For 
compound 5,  the photolysis byproduct, peak 5 is a  singlet at 4.68 ppm. This shift is 
due to the methyl group in the 4  position on the coumarin. This peak is shifted in 
compound 5 because of long-range coupling with the protons of the aspartic acid.
 After exposure to the laser, the 1H-NMR spectrum  of the sample was taken. 
Shown in Fig. S2-4 is the spectrum  of the sample after  photolysis. The spectrum  is 
expanded between 4.5 and 8 ppm to show only peaks 1-5.
Figure S2-4 | 1H-NMR spectrum  of compound 4 from  4.5-8  ppm  immediately  after  flash 
photolysis.  Peaks corresponding to compound 4 are labeled 4  and peaks corresponding  to 
compound 5 are labeled 5.
 In Fig.  S2-4, peaks corresponding to both  compounds 4 and 5 are present and 
shows that the photolysis reaction had occurred. The most apparent difference being 
peak 5 (see Fig.  S2-3).  Integration  of the peaks showed that about 14% of the caged 
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aspartate (compound 4) had been deprotected after a  30 s exposure. There are 
several reasons as to why  the photolysis reaction was not very  efficient. Firstly, the 
available laser set up was calibrated at 388 nm  as opposed to the λmax of 379  nm. A 
higher absorbance of light would produce a more efficient reaction. Another  factor in 
photolysis efficiency  may  be the glass NMR tube. The λmax of 379 nm  is close to the 
lower limit of glass cuvetts (380 nm) and it may be more efficient to use quartz.
S2.3.5  Initial ATCase Kinetic Experiments
 As previously  mentioned, the caged aspartate must not elicit any  kinetic 
response from  the enzyme, catalytic or inhibitory. Initial assays were conducted to 
determine any  activity  by  the caged aspartate (compound 4) as well as any  inhibitory 
effect by  the photolysis byproduct (compound 5). ATCase activity  is measured by  a 
colormetric assay  at  25 C and at pH 8.3. The product of the ATCase reaction, CA, 
forms a  yellow complex with  the compound 2,3-butanedione monoxime and the 
absorbance of each sample is read at 470 nm. The absorbance spectra  of compound 
5 and the CA complex were overlaid and shown in Fig. S2-5. The spectra  show that 
compound 4 does not absorb light  at the wavelength  required for  measuring the 
assay, and therefore will not contribute to high absorbance readings.
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Figure S2-5 | Overlay  of the absorbance spectra of compound 5  and the CA complex  that is 
measured at 470 nm during ATCase colormetric assays. 
 To test  the activity  of the caged aspartate and any  inhibition of the photolysis 
byproduct a series of samples was prepared at pH 8.3. First, a standard curve of 
absorbance versus CA concentration was constructed (Fig. S2-6A).  This standard 
curve was used to calculate the theoretical amount of CA produced at known Asp 
concentrations used in the assay.  For a quality  check, Asp samples were prepared at 
various known concentrations and the CA produced in the reaction was compared to 
the theoretical concentrations calculated from the CA standard curve. Here, the 
enzyme concentration, the CP concentration, and the assay  time were all  in  excess so 
that the amount of CA made was solely  due to the amount  of Asp in the sample. 
These were linearly  plotted to give a slope of 1  (see Fig. S2-6B). Therefore, the 
amount of CA produced experimentally  should equal the amount of Asp in the assay 
sample. 
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 After the photolysis reaction of compound 4, the amount of compound 5  
would equal the amount of free aspartate in the sample. Therefore, an assay  was 
performed where the concentration of compound 5 and Asp were equal under  the 
same conditions as the Asp control assay. The slope of the line comparing the 
calculated and experimental values of CA was 0.93 (Fig. S2-6C), meaning that 
compound 5 was causing slight inhibition. This is not  surprising as compound 5 has 
negatively  charged acetyl groups that  could potentially  bind to the electropositive 
active site. However, the amount of inhibition is minor and likely  would not be a 
factor in TR-SAX studies. 
Figure S2-6 | Colometric  assay  results. (A) CA  standard curve.  (B) Asp standard curve.  (C) 
[Asp] = [Cage], and (D) Caged Asp.
 The final assay  performed was with  no free aspartate. The samples were 
prepared with compound 4 in  the same concentrations as used for  Asp in the 
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previously  described assays.  The slope of calculated CA concentration versus the 
caged aspartate concentration was 0.13 (Fig. S2-6D).  While this is low, the expected 
slope was 0, since no free Asp was added to the sample. This likely  means that Asp is 
being formed from hydrolysis of compound 4. 
 The hydrolysis of compound 4 at pH 8.3  and pH 7  was monitored by  UV-Vis-
spectroscopy  over the course of 24 hours. At   pH 8.3, conditions used for the assay,  a 
blue shift in λmax was observed. This suggested that  hydrolysis was occurring to give 
the compound 5 and free aspartate. The spectra  taken at pH 7  showed no shift, 
suggesting that basic conditions were facilitating  the hydrolysis reaction. This was 
also confirmed by  running a pure sample (verified by  NMR) of compound 4 on an 
anion exchange column at pH 11. At this pH compound 4 and 5 would have different 
net charges and would be easily  separable. The spectra show that a peak 
corresponding to compound 5 appears in the pure compound 4.  The standard assay 
conditions for  ATCase at pH 8.3 must be changed to pH 7  to avoid hydrolysis of the 
caged Asp. At pH 7, the enzyme is not as active as it is at pH 8.3.
S2.4 Conclusions
 This work shows the five step synthesis of a caged aspartic acid that can be 
used to monitor fast biological processes in  which aspartate is a substrate. With the 
complete synthesis, preliminary  work has been done concerning the photolysis 
reaction as well as the use of this caged aspartate in the enzymatic process of 
ATCase. Much  more work needs to be completed to achieve the goal of using this 
caged aspartate in TR-SAXS studies of ATCase.
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S2.5 Experimental Procedures
S2.5.1  General Methods
 Compounds 1,  2 and 5 were prepared according to literature procedures.15, 16 
Chemicals were obtained from commercial sources and used as received.  The 1H 
NMR spectra were measured on a Varian Gemini/2000 400 MHz NMR 
spectrometer. Mass spectra  were recorded with  a JEOL AccuTOF mass 
spectrometer, configured with a  Direct Analysis in Real Time (DART) ion source. 
UV-Vis spectra  were recorded on a Jasco V-630 double beam  spectrophotometer and 
f luorescence measurements were obtained from a Jasco FP-6300 
spectrofluorometer.
S2.5.2   7-[Bis(t-butoxycarbonylmethyl)amino]-4-methylcoumarin (1)
 A solution of 7-amino-4-methylcoumarin (4.5 g, 26 mmol) was prepared in 30 
mL of acetonitrile. Sodium  iodide (3.8 g, 1  eq.), diisopropylethylamine (22.0 g, 5 eq.) 
and t-butyl bromoacetate (37.1  mL, 10 eq.) were added to the reaction mixture and 
refluxed under nitrogen gas for 4 days.  After 4  days the reaction mixture was cooled 
to room  temperature and filtered. The solvent was evaporated under reduced 
pressure and the residue was dissolved in  ethyl acetate. The solution was washed 
with  water and brine then dried over sodium sulfate. The crude product was 
concentrated and purified by  column chromatography  with EtOAc/hexane (1:3). 
Compound 1 was recovered as a  yellow solid (5.1  g, 49% yield),  1H NMR (CDCl3) δ 
7.43  (1H, d, J =  8.8 Hz), 6.58 (1H, dd, J =  8.8-2.4 Hz), 6.45 (1H, d,  2.4  Hz), 6.03  (1H, 
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s),  4.06 (4H, s),  2.35 (3H, s), 1.48 (18H, s); MS (ESI+) m/z calcd for (C22H29NO6 + 
H)+ 404.47, found 404.30.
S 2 . 5 . 3  7 - [ B i s ( t - b u t o x y c a r b o n y l m e t h y l ) a m i n o ] - 4 -
hydroxymethylcoumarin (2)
 Compound 1 (1.03 g, 2.5 mmol) was dissolved in p-xylene and selenium 
dioxide (0.43  g, 1.5 eq.) was added. The reaction mixture was stirred vigorously  and 
refluxed for  24 hours under a nitrogen atmosphere.  The reaction mixture was then 
filtered and the p-xylene was removed under reduced pressure. The residue was 
dissolved in ethanol, sodium  borohydride (25 mg, 0.7  mmol) was added, and the 
reaction was allowed to stir  at  room  temperature for 1  hour.  The reaction was 
hydrolyzed using 1  M HCl and water  was added. The crude product was extracted 
using ethyl acetate. The organic layer  was washed with water  and brine, then dried 
over sodium  sulfate.  The crude product was concentrated under reduced pressure 
and was purified by  column chromatography  with EtOAc/hexane (1:3). Compound 2 
was recovered as a yellow solid (300 mg, 28 % yield), 1H NMR (CDCl3) δ 7.19 (1H, d, 
J =  8.8 Hz), 6.42 (2H, m), 6.29 (1H, s), 4.67  (2H, s),  4.06  (4H, s), 1.48 (18H, s); MS 
(ESI+) m/z calcd for (C22H29NO7 + H)+ 420.49, found 420.28.
S2.5.4  7-[Bis(t-butoxycarbonylmethyl)amino]-4-yl-N-t-BOC-L-aspartic 
acid -γ-butyl ester coumarin (3)
 N-t-BOC-L-aspartic acid -γ-butyl ester  (150 mg, 0.518mmol) was dissolved in 
DCM. DMAP (8 mg, 0.065 mmol) and DCC (100 mg, 0.485 mmol) were added and 
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the mixture was stirred at room  temperature for  10 mins. Compound 2 (150 mg, 
0.358 mmol) was then dissolved into 30 mL of DCM and was added to the stirring 
mixture. The reaction was stirred in the dark for 1  hour  under  nitrogen. The reaction 
was then poured into water  and the separated organic layer was washed with sat. 
sodium  bicarbonate, dried over sodium  sulfate, and concentrated under  reduced 
pressure.  The crude product was purified by  column chromatography  with  EtOAc/
hexane (1:3). Compound 3 was recovered as a yellow  solid (229 mg, 93 % yield), 1H 
NMR (CDCl3) δ 7.29  (1H, d, J =  8.8 Hz), 6.45 (2H, m),  6.18 (1H, s),  5.41  (1H, d), 5.22 
(2H, d), 4.46  (1H, m), 4.03 (4H, s), 2.98 (2H, dd), 1.42 (36H, d); MS (ESI+) m/z 
calcd for (C35H48N2O12 + Na)+ 711.77, found 713.2.
S2.5.5  7-[Bis(carboxymethyl)amino]-4-yl-methyl aspartate (4)
 Compound 3 (63 mg, mmol) was dissolved in 4.5 mL of DCM and cooled to 0 
°C. TFA (1.5 mL) and water (75 µL) were added to the solution. The reaction was 
stirred in the dark for  40 minutes. The solvent was removed under  reduced pressure. 
The remaining residue was dissolved in acetonitrile (10 mL) and chloroform  (10 mL) 
was added to precipitate Compound 4 as a yellow solid (35 mg,  91  % yield). 1H NMR 
(DMSO) δ 7.19  (1H, d, J =  8.8 Hz), 6.42  (2H, m), 6.29 (1H, s),  4.33 (4H, s), 1.48 
(18H, s); MS (ESI+) m/z calcd for (C18H18N2O10 + H)+ 423.3, found 422.9. 
S2.5.6   7-[Bis(carboxymethyl)amino]-4-hydroxymethylcoumarin (5)
 Compound 2 (156 mg,  0.372  mmol) was stirred in  7  mL TFA/DCM/H2O 
(74:25:1) for 20 mins. The solvents were then removed under reduced pressure. The 
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residue was coevaporated twice with  diethyl ether,  dissolved in H2O, filtered, and 
lyophilized. Compound 5 was recovered without further purification (82 mg, 72% 
yield), 1H NMR (D2O) δ 7.58 (1H, d, J = 8.8 Hz), 6.61  (2H, m), 6.29 (1H, s), 4.33 (4H, 
s), 1.23 (2H, t); MS (ESI-) m/z calcd for (C14H13NO7) 306.06, found 306.10
S2.5.7   Fluorescence
 Relative quantum  yield of fluorescence (ΦF) was calculated according to 
literature procedures.17 Stock solutions (0.1  M) of compounds 4 and 5 were prepared 
in  10 mM HEPES buffer at pH=7.3.  A stock solution (0.1  M) of the 7-diethylamino-4-
methyl coumarin standard was prepared in ethanol.  Serial dilutions (0.035 M, 0.025 
M, 0.18 M, 0.01  M, and 0.0075 M) of each  compound were prepared from  the stock 
solutions to give absorbance values between 0.1  and 1. Absorbance measurements 
were collected for each solution at 374 nm and absorbance vs. concentration 
standard curves were constructed. The concentration needed for each solution to 
give an absorbance measurement of 0.040 was back calculated from  the standard 
curves. Dilutions were made to each necessary  concentration and the emissions 
spectra were collected at an excitation wavelength of 374  nm. The area under  each 
emission spectrum  was measured and the ΦF for compounds 4 and 5 was calculated 
using Equation 1. 
S2.5.8  Photolysis
 A NMR sample of Compound 4 was prepared in D2O. An 1H-NMR spectrum 
was taken prior to exposure. The laser source produced 388 nm light  with a 
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frequency  of 1  kHz. The average power was 60 mW, 200 fs pulses with a pulse energy 
of 0.06 mJ. The sample was placed in the laser beam for approximately  30 s followed 
immediately  by  covering the sample to protect from ambient light.  An 1H-NMR 
spectrum was immediately taken after exposure.
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Here, we report high-resolution X-ray structures of Bacillus subtilis aspartate
transcarbamoylase (ATCase), an enzyme that catalyzes one of the first
reactions in pyrimidine nucleotide biosynthesis. Structures of the enzyme
have been determined in the absence of ligands, in the presence of the
substrate carbamoyl phosphate, and in the presence of the bisubstrate/
transition state analog N-phosphonacetyl-L-aspartate. Combining the
structural data with in silico docking and electrostatic calculations, we
have been able to visualize each step in the catalytic cycle of ATCase, from
the ordered binding of the substrates, to the formation and decomposition
of the tetrahedral intermediate, to the ordered release of the products from
the active site. Analysis of the conformational changes associated with these
steps provides a rationale for the lack of cooperativity in trimeric ATCases
that do not possess regulatory subunits.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Aspartate transcarbamoylase (ATCase; aspartate
carbamoyltransferase; E.C. 2.1.3.2) plays a critical
role in metabolism. It catalyzes one of the first
reactions in the biosynthesis of pyrimidine nucleo-
tides by the transfer of the carbamoyl group from
carbamoyl phosphate (CP) to L-aspartate (Asp),
forming N-carbamoyl-L-aspartate (CA) and inor-
ganic phosphate (Pi)1 (Fig. 1). The reaction mech-
anism is ordered, with CP binding before Asp and
with CA departing before Pi.2 The quaternary
structure of ATCases varies. However, there is
one repeating theme: the core catalytic unit is
composed of three chains (catalytic chains) grouped
together as a trimer (c3), exhibiting 3-fold rotational
symmetry. The trimeric arrangement is required for
catalysis, since the three active sites each occur at
the interface between two adjacent chains, with
catalytic residues donated from both chains.3,4 As is
the case for many other transferases, each chain of
ATCase is composed of two domains, specifically
CP and Asp domains, each binding their respective
substrate. A closure of the domains provides
assistance in lowering activation energy via catal-
ysis by approximation.5
The structurally simplest ATCases are composed
of one homotrimer of catalytic chains and exhibit no
cooperativity, as observed in Bacillus subtilis. Other
organisms have more complex ATCases, as is the
case in Escherichia coli, where two catalytic trimers
and three regulatory dimers combine to form a
dodecameric enzyme. The E. coli enzyme demon-
strates both homotropic cooperativity and allosteric
regulation—mechanisms that modulate the rate of
*Corresponding author. E-mail address:
evan.kantrowitz@bc.edu.
Abbreviations used: ATCase, aspartate
transcarbamoylase; CP, carbamoyl phosphate; CA,
N-carbamoyl-L-aspartate; Pi, inorganic phosphate; PALA,
N-phosphonacetyl-L-aspartate; XP, extra precision; TET,
tetrahedral intermediate; PDB, Protein Data Bank.
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pyrimidine nucleotide biosynthesis.1 Unregulated
ATCases often exist as multienzyme complexes with
other pyrimidine biosynthetic enzymes. For exam-
ple, several genera of the fungi kingdom, such as
Saccharomyces and Neurospora, display ATCase as a
complex with CP synthetase.6 However, in some
eukaryotes, the first three enzymes in pyrimidine
nucleotide biosynthesis—CP synthetase, ATCase,
and dihydroorotase—are fused together on a single
polypeptide chain, CAD.7 These enzymes oligomer-
ize to create a complex with at least one ATCase
catalytic trimer.
The primary sequence of the catalytic chain of
ATCase is highly conserved. Based on an analysis of
250 species, 20% of the residues, including all of the
residues thought to be involved in catalysis, are
conserved. Structural data from a variety of species
have been determined, but no unregulated trimeric
ATCase has had its structure determined in more
that one functional form.
Numerous X-ray structures of ATCase from a
variety of organisms, in the presence and in the
absence of substrates and substrate analogs, have
been reported,8 although most of the structures are
of theE. coli enzyme either as the dodecamer or as the
isolated catalytic trimer. The E. coli catalytic trimer
has the same quaternary structure as the B. subtilis
ATCase, for which structures are available in the
absence of ligands9 and in the presence of N-
phosphonacetyl-L-aspartate (PALA).10 These struc-
tures have been used to assess the allosteric
mechanism based on a comparison of the structures
of the isolated catalytic trimer with the correspond-
ing component of the holoenzyme. The details of the
catalytic cycle could not be deduced from these
studies, since the only information available is for the
enzyme in the absence of ligands or that with a
bisubstrate analog bound. Although a structure of
the holoenzyme in the presence and in the absence of
CP is available,11 the conformational changes asso-
ciated with ligand binding and those involved in
allostery are not easy to deconvolute. With the use of
the unregulated B. subtilis ATCase as our model
system, the conformational changes involved in
allostery are disconnected from those involved in
substrate binding and catalysis.
Here, we report a description of the entire catalytic
cycle of the unregulated ATCase from B. subtilis.
Using X-ray structures in the absence and in the
presence of CP or a substrate analog, in silico
docking, and electrostatic calculations, we provide
a molecular-level glimpse into catalysis by the
unregulated ATCase, which helps to explain the
manifestation of homotropic cooperativity in those
ATCases that exhibit this property.
Results and Discussion
Overall structure of B. subtilis ATCase
The overall topology of the B. subtilis ATCase
structure is similar to that observed for c3 units of
other ATCases, such as that from E. coli,9,12 and is
congruous with a previously published 3-Å α-
carbon trace.13 All active-site residues shown to be
important in other ATCases14 are conserved in the B.
subtilis enzyme, including Ser74 and Lys77, which
are donated to the active site from an adjacent chain.
The binding of the first substrate, CP,
in the ordered-binding mechanism
In the ordered-binding mechanism,2 CP must
bind before Asp. A comparison of the structures of
the unliganded (open form) and ATCase·CP com-
plexes reveals extensive conformational changes
induced by CP binding. Figure 2a illustrates these
movements, with the unliganded structure
highlighted in blue andwith the CP-bound structure
Fig. 1. The reaction of CP and Asp to form CA and Pi. The reaction proceeds via TET. The structure of the bisubstrate
analog PALA is also shown.
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highlighted in red. These conformational changes
are localized around the active site, with the 40’s
(residues 44–49), 70’s (residues 69–78), 100’s (resi-
dues 101–105), 120’s (residues 122–126), 160’s
(residues 160–165), 180’s (residues 184–191), and
220’s (residues 212–225) loops all moving substan-
tially toward the CP binding site in the ATCase·CP
structure (CP-bound form).
The movement of the 40’s loop, specifically Arg49,
dramatically reconfigures the active-site pocket in
the CP-bound form of the enzyme. Using CASTp,16
we calculated the volume of the active-site cavity,
which is visualized in Fig. 3a–d. The binding of CP
reduces the volume of the active-site cavity by one-
half, from 1848 Å3 (Fig. 3a) to 918 Å3 (Fig. 3b). In
order to help understand how the substrates bind to
the enzyme and induce conformational changes (Fig.
2a and b), we used DELPHI17 to calculate the
electrostatic potentials of each of the structures and
mapped the potentials onto the corresponding
surface (Fig. 4a–d). In addition, Glide,18,19 in extra
precision (XP) mode,20 was used to dock substrates
to the unliganded and ATCase·CP structures as a
tool to identify potential binding sites. Shown in
Fig. 4a is a sliced image of the surface of the
unliganded enzyme. An area of significant positive
electrostatic potential is observed where CP docks.
The position of CP in Fig. 4a corresponds to the
CP pose with the highest affinity for the unli-
ganded enzyme. The docked position of CP is not
the site observed in the ATCase·CP structure
(compare the positions of CP in Fig. 4a and c).
Fig. 2. Structural changes in the α-carbon backbone associated with the binding of CP and PALA. (a and b) Structure of
one catalytic chain of B. subtilis ATCase along with the 70’s loop from the adjacent chain (70’s loop*), and (c and d)
structure of one catalytic chain of E. coliATCase along with the 80’s loop from the adjacent chain (80’s loop*) (a and c). The
structure of the unliganded enzyme is shown with blue highlights, while the structure of the ATCase·CP complex is
shown with red highlights, with CP represented as spheres and with active-site residues represented as sticks. (b and d)
The structure of the ATCase·CP complex is shown with blue highlights, while the structure of the ATCase·PALA complex
is shown with red highlights; PALA is represented as spheres, and active-site residues are represented as sticks. The color
spectral change from blue to red corresponds to 30 structures calculated linearly between the two determined X-ray
structures. PDB IDs 1ZA1,11 1ZA2,11 and 1D0915 were used for (c) and (d).
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Analysis of the structural data, electrostatics, and
docking results suggests that the initial binding of
CP, particularly the phosphate portion, induces
conformational changes in the 40’s, 70’s, 100’s, and
120’s loops. The conformational changes in the 40’s
loop, particularly Arg49, reorient CP into a higher-
affinity CP binding site in the ATCase·CP structure
(Fig. 3b). The Glide XP docking scores for CP
binding to the unliganded structure and to the
ATCase·CP structure with CP removed are −6.8 and
−9.6 kcal/mol, respectively. These in silico docking
calculations reveal that CP interacts mainly with
residues Arg49, Thr50, Gln130, and Arg281 of the
unliganded enzyme. All of these interactions are
maintained after the conformational changes in-
duced by CP binding, except for Arg281. In
addition, new interactions are observed between
CP and Ser47, Thr48, Arg99, His127, and Ser74 from
the adjacent chain. All of the interactions with CP in
the ATCase·CP structure (Fig. 5a) explain the
enhanced CP affinity for the active-site conforma-
tion of the ATCase·CP structure compared to the
unliganded active site, as predicted by the Glide XP
calculations.
The binding of the second substrate, Asp,
in the ordered-binding mechanism
A feature of the kinetics of many ATCases,
including the B. subtilis enzyme, is a very strong
Fig. 4. X-ray structures of B.
subtilis ATCase showing the ac-
tive-site electrostatic potential
mapped onto the surface, as calcu-
lated by DELPHI.17 (a–d). Also
shown, represented as sticks, are
(a) CP, (b) Asp, (c) Asp, and (d)
CA docked into the structures. (a
and b) Solvent-accessible surface
representation of the structure of
B. subtilis ATCase in the absence of
ligands, (c) in the presence of CP,
and (d) in the presence of PALA.
The surface was sliced to reveal
details of the active site. The
electrostatic potential of the struc-
ture was mapped onto the surface
[−10 kT/e (red) to +10 kT/e
(blue)]. The CP in (c) is that determined in the ATCase·CP complex. In (d), Pi corresponds to the position of the
phosphonate of PALA.
Fig. 3. X-ray structures of B.
subtilis ATCase showing the ac-
tive-site cavity, as calculated by
CASTp16 (a–d). (a) The active site
of the enzyme in the absence of
ligands. (b) The active site of the
ATCase·CP complex, with CP
shown as sticks. (c) The active site
of the ATCase·PALA complex. (d)
A cutaway view into the active-site
cavity of the ATCase·PALA com-
plex showing the interactions (dot-
ted lines) between active-site
residues and PALA (sticks).
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substrate inhibition by Asp.21 A possible explana-
tion for the observed substrate inhibition is that
aspartate binds in a nonproductive mode with its
two carboxylates reversed. However, Glide XP
docking calculations on the unliganded structure
provide another explanation. When Asp is docked
to the unliganded enzyme, it docks to approximate-
ly the same positively charged pocket as does CP,
with a Glide XP score of −6.5 kcal/mol (compare
Fig. 4a and b). The ability of Asp to bind to the same
Fig. 5. Substrates, products, and analogs bound to ATCase. The active-site orientation is the same as in Fig. 3. An
asterisk indicates that the residue was donated to the active site from the adjacent chain. The label on Thr48 has been
omitted for clarity. (a) Structure of the ATCase·CP complex with Asp bound, as determined by docking. A red arrow, with
the head at the carbonyl carbon of CP from the α-amino nitrogen of Asp, demonstrates the first chemical event in the
reaction to form TET. (b) Structure of the ATCase·PALA complex with TET docked in place of PALA. (c) Structure of the
ATCase·PALA complex with CA docked into the active site in place of PALA. In addition, Pi was substituted for the
phosphonate of PALA. (d) Electron density maps of the ATCase·PALA structure overlaid on the final refined coordinates.
An Fo−Fc electron density map with PALA omitted from the calculation is shown in green contoured at 5 σ, and a 2Fo−Fc
electron density map is shown in blue contoured at 2 σ. (e) The active site of the ATCase·PALA complex with Pi at the
position occupied by the phosphonate of PALA (Pi1). Pi2 corresponds to one of three binding sites for Pi determined in the
Glide docking calculations. (f) A possible path of Pi release from the active site. In addition to the Pi1 and Pi2 positions
shown in (e), two additional possible Pi binding sites are shown: Pi3 and Pi4. Pi4 is closest to an exit from the active site. For
clarity, docked substrates are shown with pink carbon atoms, while substrates or analogs determined by crystallography
are shown with cyan carbons.
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site as CP in the unliganded enzyme explains the
strong substrate inhibition exhibited by Asp.
The conformational changes induced by the
binding of CP dramatically alter the active-site
pocket (compare Fig. 3a and b) and electrostatics
of the active site (compare Fig. 4a and c). In the
unliganded structure, the portion of the active site
where Asp would be expected to bind in order to
react with CP is essentially neutral in charge.
However, in the ATCase·CP structure, there exists
a positively charged pocket adjacent to CP. In order
to visualize how Asp might bind to the ATCase·CP
structure, we docked Asp to the ATCase·CP
structure using the XP mode of Glide. Shown in
Fig. 5a is the highest-affinity Asp docking pose with
a Glide XP score of −8.4 kcal/mol. PROPKA22,23
was used to calculate the pKa of the amino group of
Asp in the active site of the ATCase·CP complex: the
calculation gave a pKa value of less than 2 such that,
at physiological pH, Asp would bind to the
ATCase·CP complex with a neutral amino group,
poised for nucleophilic attack.
The reaction between CP and Asp to form the
tetrahedral intermediate
Stopped-flow small-angle X-ray scattering has
been used to establish that, when Asp is mixed
with the E. coli ATCase·CP complex, there is an
alteration in the structure of the enzyme on the
millisecond timescale.24 Although these experi-
ments were performed on a type of ATCase with
both catalytic and regulatory chains, the structure of
the E. coli ATCase·PALA complex after the Asp-
induced conformational change has the same overall
structure as the B. subtilis ATCase·PALA complex.
Therefore, it would be expected that the structure of
the B. subtilis ATCase·PALA complex corresponds
to the overall structure of the enzyme immediately
upon the addition of Asp to the ATCase·CP
complex. For the B. subtilis enzyme, these confor-
mational changes are shown in Fig. 2b, with blue
highlighting the ATCase·CP structure and with red
highlighting the ATCase·PALA structure (closed
form). The conformational changes associated with
Asp binding involve substantial motions of the 180’s
and 220’s loops, which undergo smaller motions
upon CP binding to the unliganded enzyme.
However, the portions of the structure involved in
the creation of the CP binding site are less altered
upon the conversion to the closed form of the active
site (compare Fig. 2a and b).
As indicated above, the conformational changes
associated with the binding of CP not only create a
physical binding pocket for Asp but also substan-
tially change the electrostatic environment of the
active site (Fig. 4c). Shown in Fig. 5a is the highest-
affinity pose of Asp docked into the ATCase·CP
structure. The Asp amino group nitrogen is 3.4 Å
from the carbonyl of CP and perpendicular to its
plane, at an optimal distance and orientation for the
nucleophilic attack. Furthermore, the interactions
with the carbamoyl group of CP observed in the
ATCase·CP structure would further promote nucle-
ophilic attack by stabilizing the negative charge on
the carbonyl oxygen of the transition state.
Asp docks to the ATCase·CP complex (Fig. 5a)
such that its α-carboxylate interacts with Lys77 of
the adjacent chain. The conformational changes that
occur as Asp binds to the ATCase·CP complex
include the closure of the 220’s loop toward the
active site, allowing interactions to form between
the β-carboxylate of Asp and Arg211 and Gln213.
The structural data suggest that Lys77 first posi-
tions Asp for nucleophilic attack and then acts as a
bridge between the two substrate molecules, hold-
ing them together as the transition state forms
(compare Fig. 5a and b). The binding of Asp causes
the closing of the two domains of the catalytic
chain, creating the environment necessary for the
formation of the tetrahedral intermediate (TET). As
shown in Fig. 1, the structural similarity between
PALA and TET suggests that PALA can be used to
model the structure of the ATCase·TET complex.
Shown in Fig. 5d is a close-up of the PALA
binding site in the ATCase·PALA complex. A total
of 26 interactions position PALA in the active site, of
which 3 are hydrophobic in nature and are not
shown in Fig. 5d. The plethora of interactions with
PALA explains the nanomolar affinity of this
bisubstrate analog.25
In order to validate the in silico dockings, we
docked PALA into the ATCase·PALA complex with
PALA removed. PALA docked within the cavity
shown in Fig. 3c. All of the highest-affinity poses
determined from the docking calculations have the
phosphonate in exactly the same position as
observed in the X-ray structure. However, there
were variations in the position of the β-carboxylate
within this set of poses. The Glide XP docking score
of the highest-affinity pose was −11.7 kcal/mol. For
comparison, the structure of the proposed TET was
also docked to the ATCase·PALA complex with
PALA removed, using exactly the same protocol. As
seen in Fig. 5b, TET interacts with ATCase in
essentially the same manner as does PALA. How-
ever, the number of interactions increases from 26 to
28, 2 of which are hydrophobic in nature. Arg49,
Lys77, and Gln130 form additional interactions with
TET that are not observed in the ATCase·PALA
complex. Three of these interactions are with atoms
that are not available in the PALA structure. Two
interactions with the amino group on the tetrahedral
carbon are formed: one from the side chain of
Gln130 and the other from the backbone carbonyl of
Pro249. The side chains of Arg49 and Lys77 also
interact with the bridging phosphate oxygen. The
Glide XP docking score of the highest-affinity pose
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of TET was −13.6 kcal/mol, almost 2 kcal/mol more
negative than that calculated for PALA.
The closure of the domains upon Asp binding
further reduces the volume of the active site by an
additional one-half, from 918 Å3 in the ATCase·CP
complex (Fig. 3b) to 411 Å3 in the ATCase·PALA
complex (Fig. 3c), essentially forcing Asp toward
CP. The closure of the domains also dramatically
alters the electrostatic environment of the active site
(Fig. 4d). CASTp calculations indicate that the
active-site cavity in the ATCase·PALA complex
has no exit. This closed, positively charged cavity
provides the perfect environment to promote the
formation of the transition state and to stabilize its
negative charge.
The ATCase·PALA complex and the TET docked
to the ATCase·PALA structure with PALA removed
each show an interaction between the backbone
carbonyl of Ala250 and the Asp amino group (Fig.
5b and d). Ala250 acts as a hydrogen-bond acceptor,
as Asp is brought in proximity to the CP-binding
domain, increasing the nucleophilicity of the Asp
amine. Ala250 is not conserved in all ATCases;
however, since the interaction with Asp involves the
backbone carbonyl of Ala250, the nature of the side
chain is unimportant. Interestingly, this particular
alanine is flanked by two proline residues, which are
conserved. Moreover, this primary-sequence feature
results in Ala250 having phi/psi angles in a
forbidden region of the Ramachandran plot. The
unusual phi/psi angles at this position are observed
in other ATCase structures even when alternate
residues are present.11,15
The breakdown of TET to form CA and Pi
The breakdown of TET involves the collapse of
the oxyanion and the release of Pi, as shown in
Fig. 1. For the E. coli enzyme, Gouaux et al.
proposed that the conformation of the transition
state for the breakdown of TET involves an
intramolecular proton transfer where a phosphate
oxygen acts as a general base, accepting a proton
from the ionized secondary amine.26 The interac-
tion between the phosphate oxygen and the amine
proton completes a six-membered ring in a chair
conformation, supporting their modeling and
mechanism for the decomposition of the transition
state.
Analysis of the structure of TET docked into the B.
subtilis enzyme (Fig. 5b) indicates that the confor-
mation of the transition state wouldmost likely be in
a distorted chair conformation. The structural data
of the ATCase·PALA complex and the conformation
of TET docked into that structure with PALA
removed suggest an alternate mechanism that
utilizes an enzyme-mediated proton transfer, with
Arg99 acting as a general acid. Using PROPKA, we
calculated the pKa values of all ionizable amino acid
side chains in the structure. The pKa of Arg99 was
calculated to be 6.2, as compared to the average pKa
of 12.0 for all the other Arg residues in the structure.
This decrease in pKa can be explained by the highly
electropositive pocket where Arg99 lies (Fig. 4d).
This extremely low pKa value allows Arg99 to act as
an acid at physiological pH. The phosphate oxygen
acceptor was 2.1 Å from the labile Arg99 proton.
Protonation of the phosphate groupmakes it a better
leaving group and promotes product formation.
The conformational changes needed for the
release of the first product, CA
There is sufficient room in the closed form of the
active-site pocket (Fig. 3c and d) to accommodate
not only PALA or TET but also the products CA and
Pi. However, the combination of CA and Pi takes up
sufficiently more space than PALA or TET due to the
required separation between the two products, as
opposed to the unimolecular nature of PALA or
TET. We propose that the closed form of the
enzyme, as exemplified by the ATCase·PALA
complex (Fig. 3c), is transient in nature. As the
transition state decomposes, the products separate
and destabilize the closed form. Based on modeling,
the 220’s loop that closed in toward the active site
during Asp binding now opens at least partially. We
estimate that the conformation of the catalytic chain
must relax back between 30% and 40% toward the
CP-bound conformation before an exit route that is
large enough for CA to leave the active site and be
released into solution is formed.
The exit of the second product, Pi, from the
active site
Once CA leaves the active site, the remaining
product Pi can leave the active site via the same
opening. In silico docking calculations were per-
formed on the ATCase·PALA complex with PALA
removed and with Pi positioned in place of the
PALA phosphonate. Three different Pi locations,
with Glide XP docking scores of −7.2, −7.1, and
−6.3 kcal/mol, were identified (Fig. 5e and f). As the
XP docking scores become more positive, the
relative position of the Pi becomes farther from the
position occupied by the phosphonate portion of
PALA and closer to the exit from the active site.
These three positions suggest an exit route of Pi from
the active site (Fig. 5e and f).
Lack of cooperativity in the unregulated
B. subtilis ATCase
One of the properties of the B. subtilis ATCase that
distinguishes it from some other ATCases is its lack
of homotropic cooperativity. The structure of the B.
subtilis ATCase·CP complex reported here helps
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clarify the lack of cooperativity in c3 ATCases.
Although the wild-type B. subtilis ATCase is not
cooperative, amino acid substitutions can result in
the manifestation of cooperativity in the B. subtilis
ATCase. Specifically, the R99A mutation results in a
cooperative enzyme with a Hill coefficient of 1.5.27
As seen in Fig. 5a, Arg99 is critically involved in the
binding of CP. Although the R99A mutation allows
the B. subtilis ATCase to manifest cooperativity, it
has a detrimental influence on the binding of both
CP and Asp. In order for the R99A B. subtilisATCase
to exhibit cooperativity, the enzyme shifts between
two states that differ in activity and/or affinity for
substrate.28,29 The altered binding of the substrates
to the R99A enzyme essentially creates a two-state
system that did not previously exist, providing an
explanation for the observed cooperativity of this
mutant enzyme.27
How is it then that the E. coli ATCase
holoenzyme (c6r6) exhibits cooperativity while the
E. coli c3 ATCase and the wild-type B. subtilis
ATCase do not? A comparison of the structural
changes induced by the binding of CP to the B.
subtilis ATCase and the E. coli ATCase holoenzyme
provides an explanation. As seen in Fig. 2a, CP
binding induces dramatic alterations to the B.
subtilis enzyme structure, with major conforma-
tional changes involving the 40’s, 70’s, 100’s, 120’s,
160’s, 180’s, and 220’s loops. The binding of CP to
the E. coli holoenzyme induces much less dramatic
conformational changes, with only the equivalent
of the 40’s and 70’s loops undergoing major
structural alterations26 (Fig. 2c). The reduced
magnitude of the conformational changes is
partially due to stabilizing interactions between
the catalytic and regulatory chains that restrict
some of the loop motions observed in the B.
subtilis enzyme.
The conformational changes induced by the
saturation of the unliganded B. subtilis ATCase
with CP result in the creation of active sites that have
high activity and high affinity for Asp. Thus, Asp
binding does not induce cooperativity. In contrast,
the R99A B. subtilis ATCase does not bind CP in the
correct position to induce the necessary conforma-
tional changes. Asp binding to one of the active sites
in the R99A ATCase·CP complex can transmit
conformational changes to the other active sites,
enhancing their affinity for Asp. In the case of the E.
coli holoenzyme, the binding of CP alone does not
shift the active-site conformation sufficiently to
create the high-affinity binding site; rather, it is
only the binding of Asp to the E. coli ATCase·CP
complex that causes the necessary loop movements
that induce cooperativity. This explanation is
supported by stopped-flow small-angle X-ray scat-
tering measurements that showed CP to have little
or no influence on the quaternary structure of the E.
coli holoenzyme,30 while the binding of Asp to the E.
coli ATCase·CP complex induces the allosteric
structural transition that manifests itself in the
observed kinetic cooperativity.24 Furthermore, CP
binding induces much larger quaternary conforma-
tional changes in versions of E. coli ATCase that
have weakened interactions either between the
regulatory and catalytic chains31 or between the
two catalytic trimers in the holoenzyme.32
The unique set of the three X-ray crystallographic
structures of B. subtilis ATCase reported here, in the
absence and in the presence of a substrate and a
bisubstrate analog, in combination with electrostatic
calculations and ligand docking, has provided
sufficient data to visualize each step in the catalytic
cycle of ATCase: the ordered binding of the sub-
strates; the formation of TET, followed by its
decomposition into the products; the conformation-
al changes associated with these steps; and the
ordered release of the products from the active site.
In addition, this work has helped us understand the
manifestation of homotropic cooperativity in some
ATCases.
Materials and Methods
Materials
Chemicals were purchased from commercial sources
and used as received, with the exception of CP, which
was purified before use by precipitation from 50%
(vol/vol) ethanol and stored desiccated at −20 °C prior
to use.1 PALA was obtained from the National Cancer
Institute.
Protein expression and purification
B. subtilis ATCase was overexpressed in M9 minimal
media using the E. coli strain EK1104 [F− ara, thi, Δ(pro-
lac), ΔpyrB, pyrF±, rpsL] transformed with plasmid
pEK17121 containing the B. subtilis pyrB gene under
the control of the E. coli pyrBI promoter.33 The
purification procedure is a variation on that performed
previously.21 First, ion-exchange chromatography was
employed using a Q-Sepharose Fast Flow column
(11 cm×2.5 cm; GE Healthcare). The fractions contain-
ing ATCase were pooled and dialyzed against 0.05 M
Tris–acetate and 2 mM 2-mercaptoethanol (pH 8.3; Low
Q buffer). The protein solution was then brought to
20% ammonium sulfate saturation and purified by
hydrophobic interaction chromatography using a Phe-
nyl Sepharose column (8.5 cm×2 cm; GE Healthcare).
The protein was eluted using a linear gradient from
Low Q buffer+20% ammonium sulfate to Low Q
buffer. The fractions containing pure ATCase, as
confirmed by SDS-PAGE,34 were pooled and dialyzed
against storage buffer [40 mM KH2PO4, 2 mM 2-
mercaptoethanol, and 2 mM ethylenediaminetetraacetic
acid (pH 7.0)]. Protein concentration was determined by
A280 measurement using the extinction coefficient of B.
subtilis ATCase (0.57 cm2/mg).35
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Crystallization, X-ray data collection, and processing
B. subtilis ATCase was crystallized by the hanging-drop
vapor diffusion method, as previously reported.13 The
enzyme, at a final concentration of 12 mg/ml, was mixed
with an equal volume of crystallization buffer [1.7 M
(NH4)2SO4, 0.1M Tris–HCl (pH 8.5), and 2.0%polyethylene
glycol 200] and equilibrated over a reservoir of 0.5 ml of
crystallization buffer at 20 °C. Bar-shaped crystals grew to
average dimensions of 0.5 mm×0.3 mm×0.1 mm within
1 week. These crystals were used directly to determine the
structure of the unliganded enzyme. To determine the
structure of the ATCase·CP complex, we equilibrated these
crystals in crystallization buffer containing 13.3 mM CP for
1 h prior to freezing. For the ATCase·PALA structure, the
enzyme was cocrystallized with PALA (2 mM) by the
hanging-drop vapor diffusion method, based on conditions
identified by a crystal screen at the Hauptman–Woodward
Institute (Buffalo, NY). The drop consisted of equal
volumes of 10 mg/ml enzyme solution and crystallization
buffer [0.1 M potassium bromide, 0.1 M N-cyclohexyl-3-
aminopropanesulfonic acid (pH 10.0) and 18% polyethyl-
ene glycol 8000] over a 0. 5-ml reservoir of crystallization
buffer. Hexagonal crystals grew to average dimensions of
0.2 mm×0.2 mm×0.05 mm within 1 week.
In each case, crystals were transferred into a cryopro-
tectant consisting of 20% glycerol in crystallization buffer
before being frozen in liquid nitrogen and before data
collection on beamline X29 at the National Synchrotron
Light Source at Brookhaven National Laboratory (Upton,
NY). The diffraction data were integrated, scaled, and
averaged using HKL2000.36 Data collection and refine-
ment statistics are shown in Table 1.
Structure solution and data refinement
The structure of the unliganded enzyme was solved by
molecular replacement using, as the initial model, an E.
coli c3 ATCase extracted from a holoenzyme structure in
the T-state [Protein Data Bank (PDB) ID: 1ZA1]11 after
removal of water and ligand molecules. Molecular
replacement was performed using the AutoMR module
of PHENIX.37 The structure of the ATCase·CP complex
was refined directly using the unliganded structure as the
initial model. Poor-fitting loops in the ATCase·CP
complex were rebuilt using the AutoBuild module of
PHENIX. The structure of the ATCase·PALA complex was
solved bymolecular replacement with BALBES38 using, as
the initial model, an E. coli c3 ATCase extracted from a
holoenzyme structure in the R-state (PDB ID: 1D09).15 The
final ATCase·PALA structure contained two c3 units in the
asymmetric unit, as suggested by the Matthews coeffi-
cient. The AutoBuild module of PHENIX was used for
initial model building, then waters were removed from the
active site, and the LigandFit module of PHENIX was
used to place the six PALA molecules into the asymmetric
unit. Manual rebuilding, addition of waters, and CP and Pi
modeling were performed using Coot.39 Waters were
accepted if they were within hydrogen-bonding distance
of either main-chain or side-chain atoms. Automated
refinement using noncrystallographic symmetry restraints
was initially used but was turned off during final
refinements performed by PHENIX. The final structures
were validated using MolProbity40,41 and PROCHECK.42
Residues 292–304 (C-terminus) were omitted in all chains
of each structure due to weak electron density.
Docking with Glide
Docking of substrates to the B. subtilis structure in the
absence and in the presence of ligands was performed
using Glide (Schrödinger, Inc.) in XP mode. The Protein
Preparation Wizard of MAESTRO (Schrödinger, Inc.) was
used to assign bond orders, to add hydrogen atoms, to
optimize the hydrogen-bonding network, and to refine the
hydrogen atom positions, using the OPLS2005 force field,
while restraining the protein to a maximum displacement
of 0.3 Å. Ligands were prepared for docking using the
LigPrep module, and all possible ionization states were
generated. The Glide XP docking score was used to
evaluate the results. In order to validate the Glide results,
we docked CP into the ATCase·CP structure with CP
removed, and PALA was docked into the ATCase·PALA
structure with PALA removed. The average difference in
atomic positions between the docked CP and the CP
position determined in the structure was 0.63 Å, while the
root-mean-square deviation (RMSD) of the two confor-
mations was 0.22 Å. The average difference in atomic
position between the docked PALA and the PALA
position determined in the structure was 0.31 Å, while
the RMSD of the two conformations was 0.27 Å.
Accession codes
Coordinates and structure factors for the unliganded,
CP-bound, and PALA-bound B. subtilis ATCases have
been deposited in the PDB under accession codes 3R7D,
3R7F, and 3R7L, respectively.
Table 1. Data collection and refinement statistics
Unliganded CP bound PALA bound
Data collection
Space group C2 C2 C2
Cell dimensions
a, b, c (Å) 253.5, 153.0,
51.1
251.9, 153.0,
51.2
189.7, 141.4,
114.8
α, β, γ (°) 90.0, 96.9,
90.0
90.0, 96.1,
90.0
90.0, 110.0,
90.0
Resolution (Å)a 50–2.20
(2.28–2.20)
50.0–2.10
(2.18–2.10)
50–2.60
(2.69–2.60)
Rsym (%)a 0.088 (0.52) 0.085 (0.61) 0.126 (0.61)
Average (I/σ)a 20.02 (3.21) 22.55 (3.31) 17.38 (2.98)
Completeness (%)a 99.9 (99.8) 100.0 (100.0) 100.0 (100.0)
Redundancya 7.2 (6.8) 7.5 (7.5) 7.2 (6.8)
Refinement
Resolution (Å) 49.17–2.20 34.12–2.10 47.28–2.58
Reflections 98,205 111,454 88,161
Rwork/Rfree 0.17/0.20 0.17/0.20 0.18/0.22
Number of atoms
Protein 6974 6922 13,752
Waters 583 624 720
RMSD
Bond lengths (Å) 0.007 0.008 0.007
Bond angles (°) 1.01 1.06 0.74
Mean B-value (Å2) 45.4 47.8 36.6
a Values in parentheses are for the highest-resolution shell.
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ABSTRACT: Escherichia coli aspartate transcarbamoylase
is feedback inhibited by CTP and UTP in the presence of
CTP. Here, we show by X-ray crystallography that UTP
binds to a unique site on each regulatory chain of the
enzyme that is near but not overlapping with the known
CTP site. These results bring into question all of the
previously proposed mechanisms of allosteric regulation in
aspartate transcarbamoylase.
Escherichia coli aspartate transcarbamoylase (EC 2.1.3.2,
aspartate carbamoyltransferase, ATCase) is a model for
allosteric regulation.1 The enzyme catalyzes the committed
step in pyrimidine nucleotide biosynthesis, the formation of N-
carbamoyl-L-aspartate and phosphate from carbamoyl phos-
phate and L-aspartate.2 N-Carbamoyl-L-aspartate then continues
through the pathway to form UTP and CTP. ATCase is
regulated homotropically by L-aspartate and heterotropically by
nucleotide eﬀectors. ATP, the end product of the purine
biosynthetic pathway, is an activator of ATCase, while CTP, as
one of the end products of the pyrimidine pathway, is an
inhibitor. The pyrimidine nucleotide UTP does not inhibit the
enzyme alone, but it synergistically inhibits the enzyme in the
presence of CTP.3
E. coli ATCase is a dodecamer composed of six regulatory
chains (Mr = 17000) and six catalytic chains (Mr = 33000),
organized into two catalytic trimers and three regulatory
dimers. The substrate binding sites, responsible for enzyme
activity, are located in the catalytic chains, whereas the
nucleotide eﬀectors bind in the regulatory chains.4 There are
two states of the enzyme characterized by large changes in
quaternary structure: the low-activity, low aﬃnity for the
substrate T state and the high-activity, high aﬃnity for the
substrate R state. The substrates and allosteric eﬀectors
inﬂuence the equilibrium between the T state and the R state
structure.5
Structural and kinetic analyses have shown that ATP and
CTP, which exhibit opposing eﬀects on ATCase activity,
compete for and bind to the same sites on the regulatory
chains,6 with one binding site per chain. Similarly, other studies
have indicated that UTP and ATP bind competitively.7 Binding
experiments have shown that for both CTP and ATP there are
three high-aﬃnity sites and three low-aﬃnity sites per
holoenzyme,8 suggesting that each regulatory dimer contains
one high-aﬃnity site and one low-aﬃnity site. Binding
experiments using the isolated regulatory dimer conﬁrm the
two classes of sites with high and low aﬃnities.8 To explain the
synergistic inhibition by UTP in the presence of CTP, it has
been proposed that CTP binds to the high-aﬃnity sites while
UTP binds to the low-aﬃnity sites, because addition of UTP to
ATCase with CTP bound results in a decrease in the number of
CTP binding sites from six to three.9
The binding of nucleotides to the regulatory sites was further
investigated using an unnatural ﬂuorescent amino acid [L-(7-
hydroxycoumarin-4-yl)ethylglycine] in place of Glu52, located
near the nucleotide binding site.10 Fluorescence measurements
showed that CTP and UTP do not bind competitively,
consistent with the notion of a functional asymmetry between
the two allosteric sites of the regulatory dimer. This study also
indicated that ATP, CTP, GTP, and UTP bind with similar
aﬃnities and have two classes of binding sites, one with high
aﬃnity and one with low aﬃnity. However, other studies have
shown that UTP has a much lower binding aﬃnity than
CTP.11−13
While CTP and UTP are structurally very similar, they have
very diﬀerent eﬀects on ATCase activity. To further elucidate
the mechanism of UTP action, speciﬁcally the synergistic
inhibition in the presence of CTP and the lack of inhibition by
UTP alone, X-ray crystallography was used here to determine
the structure of ATCase in the presence of UTP. R state
crystals of ATCase were obtained by microdialysis in 50 μL
wells using previously reported conditions.14 The crystals were
then dialyzed overnight in crystallization buﬀer with 10 mM
UTP. Before being ﬂash-frozen in liquid nitrogen, the crystals
were dipped into UTP crystallization buﬀer with 20% (v/v) 2-
methyl-2,4-pentanediol. These crystals diﬀracted to a maximal
resolution of 2.3 Å in space group P321 (Table S1 of the
Supporting Information). The 2.1 Å R state structure of
ATCase [Protein Data Bank (PDB) entry 1D09]15 was used as
the initial model. After a number of rounds of reﬁnement,
model building, and water placement, the ﬁnal Rfactor and Rfree
values were 0.173 and 0.207, respectively. As an indication of
the quality of the reﬁnement, Figure S1 of the Supporting
Information shows a portion of the electron density map
corresponding to a portion of the regulatory chain. Residues 1−
10 of the regulatory chains were omitted from the ﬁnal model,
because of weak electron density. Complete experimental
details, including data collection and reﬁnement, are provided
in the Supporting Information. Coordinates and structure
factors for the structure have been deposited as PDB entry
4F04.
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The main-chain root-mean-square deviation (rmsd) between
the 1D09 and UTP-bound structures was 0.42 Å, indicating
that the binding of UTP had little overall inﬂuence on the
structure of the enzyme. For the regulatory chain and its
allosteric domain, the main-chain rmsds between the structure
with and without UTP were 0.43 and 0.47 Å, respectively,
suggesting that UTP binding may result in localized conforma-
tional changes near its binding site. Figure 1 shows a
representation of the conformational changes that occur in
the r6 regulatory chain due to the binding of UTP. Besides
motions near the N- and C-termini, the major conformational
change is restricted to the 50s loop (residues 48−58), with
smaller motions in the 70s helix (residues 68−77) and the 130s
loop (residues 129−134).
The binding site of UTP is located adjacent to, but not
overlapping with, the site canonically occupied by CTP and
ATP.6 In the P321 space group, the asymmetric unit is
composed of chains c1, r1, r6, c6, or one-third of the
holoenzyme. The electron density for UTP is not as strong as
the density for the protein overall. In addition, the electron
density for UTP is weaker in the r1 chain than in the r6 chain.
Still, the data clearly show that UTP binds in this unique
location on the regulatory chain.
The relatively weak electron density observed for UTP is
reﬂected in the high B factors of the UTP atoms, 173 and 140
Å2 for UTP in the r1 and r6 chains, respectively. These values
are considerably higher than the B factors for the atoms of the
r1 (76 Å2) and r6 (94 Å2) chains. The weaker electron density
of UTP in the r1 versus r6 regulatory chains suggests that these
two sites have diﬀerent aﬃnities for UTP. This supposition is
supported by the data, which show that the UTP in the r6 chain
forms more interactions with the protein than the UTP in the
r1 chain. Figure 2 shows the interactions between UTP and the
r6 chain, and stereoviews of UTP bound in the r1 and r6 chains
are shown in Figure S2 of the Supporting Information. Of
particular note is the stretch of residues Leu48, Pro49, Ser50,
Gly51, Glu52, Lys56, Leu58, and Lys60, which all interact with
UTP in the r6 chain. These residues comprise the 50s loop that
undergoes the largest structural alteration upon UTP binding
(see Figure 1). In addition to these residues, Glu10, His20, and
Arg41 also interact with UTP. The interaction between UTP
and Arg41 is between UTP bound to the r6 chain and Arg41 of
the r1 chain. A complete list of the interactions with UTP in the
r1 and r6 chains is provided in Table S2 of the Supporting
Information. The smaller number of interactions between
residues in the r1 chain and UTP reinforces the asymmetric
nature of the r1 and r6 chains and provides support for the
previously proposed hypothesis that there are two classes of
UTP binding sites having diﬀerent aﬃnities for the
nucleotide.10
To show the spatial relationship between the new nucleotide-
binding site and the canonical site, the surfaces of the regulatory
chain with CTP (PDB entry 8AT1)16 and UTP bound are
shown in panels a and b of Figure 3, respectively. To
distinguish between the two nucleotide binding sites in each
regulatory chain, the canonical site where ATP and CTP bind
will be called the A site while the newly discovered, UTP-
binding site will be termed the B site. Thus, each of the six
regulatory chains of ATCase has two, A and B, nucleotide sites.
Some of the residues that make direct interactions with UTP
have been previously studied by site-speciﬁc mutagenesis. The
H20A17 or K56A18 mutation resulted in the complete loss of
synergistic inhibition by UTP. These two residues make direct
contacts with UTP in the B site, as shown in Figure 2,
explaining the loss of synergistic inhibition. In the case of the
K56A mutant, previous studies could not explain the loss of
Figure 1. Structural changes upon the binding of UTP to a regulatory
chain of ATCase. The structures of ATCase in the absence and
presence of UTP (PDB entry 1D09) are shown with blue and red
highlights, respectively. Thirty structures are shown, calculated linearly
between the two determined X-ray structures. The portions of the
structures with a main-chain rmsd of >1.5 Å are spectrally colored.
Figure 2. UTP bound to the r6 regulatory chain of ATCase. Residues
making polar interactions (---) are shown with gray carbons, while
those making hydrophobic interactions are shown with white carbons.
The asterisk after Arg41 indicates that it is donated from the r1 chain.
Figure 3. Comparison of the A and B nucleotide-binding sites using
PDB entry 8AT1 to show the CTP binding location. The identical
orientation is shown for (a) CTP (green carbons) bound in the A site
and (b) UTP (teal carbons) bound in the B site.
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synergistic inhibition as Lys56 did not show any interactions
with CTP.
The X-ray structure reported here shows that UTP binds to
the B site, a site diﬀerent from that normally occupied by CTP
or ATP (A site). The lack of any evidence of binding of UTP in
the A site suggests that UTP has a signiﬁcantly higher aﬃnity
for the B site than the A site. The diﬀerence in UTP aﬃnity
between the A and B sites can be explained by electrostatic
interactions between the UTP and Lys60. The 4-keto group of
UTP has a more favorable electrostatic interaction with the ε-
amino group of Lys60 than with the main-chain oxygen atoms
of Ile12 and Tyr89 in the A site. The oxygen atoms of Ile12 and
Tyr89 as well as the 4-keto group of UTP bear partial negative
charges because of the resonance, leading to charge repulsion
between the protein and UTP in the A site. This also explains
why previous crystallographic studies have not observed CTP
in the B site because positive charge−charge repulsion would
occur between the ε-amino group of Lys60 and the 4-amino
group of CTP.
With the discovery that UTP binds to a unique site on the
regulatory chain, we propose a revised mechanism of UTP
action that is consistent with the structural data. The X-ray
structure of ATCase in the presence of UTP reported here
provides an explanation for the lack of inhibition of the enzyme
by UTP alone, and the ability of UTP to synergistically inhibit
ATCase in the presence of CTP. As seen in panels a and b of
Figure 3, the binding sites of CTP and UTP on one regulatory
chain of ATCase are in the proximity of each other but do not
overlap. When UTP alone is present, binding occurs exclusively
at the B site, because of the stabilizing interactions between
Lys60 and the 4-keto group of uracil mentioned above. This
same interaction prevents or weakens binding of CTP at the B
site. This is supported by the fact that even at relatively high
concentrations of CTP, no CTP is observed in the B site by X-
ray crystallography.16 However, when UTP binds to the B site
no allosteric inhibition is observed.
When CTP is present in the A site (see Figure 3a), there is
suﬃcient space for UTP to bind to the B site. Previous studies
have indicated that the aﬃnity of CTP is enhanced in the
presence of UTP, and the binding of UTP is enhanced upon
the binding of CTP.11 These data suggest that the two
nucleotides act together in the combined AB allosteric site to
synergistically enhance the binding of the other and induce
conformational changes that shift the T to R equilibrium
further toward the T state than CTP alone can induce. Thus,
the binding of UTP to the B site functions to amplify the eﬀect
of the nucleotide bound in the A site. The molecular basis of
the synergistic inhibition could be via interactions with the 50s
loop, the N-terminus, and/or the r1−r6 interface, all of which
are close to the B site.
The structure of ATCase in the presence of UTP reported
here shows that the previously hypothesized CTP−UTP
binding pattern is incorrect. It agrees with the notion that
there is a functional asymmetry between the nucleotide sites of
a regulatory dimer and indicates that there are four distinct
nucleotide binding sites per dimer. With the discovery of this
new allosteric site in E. coli ATCase, the previously proposed
mechanisms for allosteric regulation based on two asymmetric
nucleotide binding sites per regulatory dimer must be revised.
More crystallographic studies are needed to determine
conclusively the mechanism of the synergistic eﬀect, although
this study provides insights into the likely binding pattern.
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ABSTRACT: Escherichia coli aspartate transcarbamoylase
(ATCase) allosterically regulates pyrimidine nucleotide
biosynthesis. The enzyme is inhibited by CTP and can be
further inhibited by UTP, although UTP alone has little or no
inﬂuence on activity; however, the mechanism for the
synergistic inhibition is still unknown. To determine how
UTP is able to synergistically inhibit ATCase in the presence
of CTP, we determined a series of X-ray structures of
ATCase·nucleotide complexes. Analysis of the X-ray structures
revealed that (1) CTP and dCTP bind in a very similar
fashion, (2) UTP, in the presence of dCTP or CTP, binds at a site that does not overlap the CTP/dCTP site, and (3) the
triphosphates of the two nucleotides are parallel to each other with a metal ion, in this case Mg2+, coordinated between the β- and
γ-phosphates of the two nucleotides. Kinetic experiments showed that the presence of a metal ion such as Mg2+ is required for
synergistic inhibition. Together, these results explain how the binding of UTP can enhance the binding of CTP and why UTP
binds more tightly in the presence of CTP. A mechanism for the synergistic inhibition of ATCase is proposed in which the
presence of UTP stabilizes the T state even more than CTP alone. These results also call into question many of the past kinetic
and binding experiments with ATCase with nucleotides as the presence of metal contamination was not considered important.
The enzyme aspartate transcarbamoylase (aspartate carba-moyltransferase, ATCase, EC 2.1.3.2) from Escherichia coli
catalyzes the committed step in pyrimidine nucleotide
biosynthesis and allosterically regulates the pathway. Allosteric
regulation is critical in the overall control of many metabolic
pathways as the speciﬁc needs of the cell are fulﬁlled by
modulating the ﬂux through the pathway. E. coli ATCase has
been extensively studied and has become a classic model of
allosteric regulation.1 Kinetic studies have shown that the
enzyme is inhibited by CTP, activated by ATP,2 and
synergistically inhibited by UTP in the presence of CTP.3
The kinetic response of the enzyme to these eﬀectors helps to
maintain a balanced pool of pyrimidine and purine nucleotides
in the cell.
The E. coli ATCase holoenzyme is a dodecamer composed of
six regulatory chains and six catalytic chains arranged into three
regulatory dimers and two catalytic trimers. The catalytic chains
are responsible for enzyme activity, while the regulatory chains
bind the allosteric eﬀectors. Each regulatory chain is composed
of two separate folding domains, the allosteric domain,
responsible for binding the nucleotide eﬀectors, and the zinc
domain, responsible for the binding of a structural zinc ion.
Each catalytic chain is also composed of two separate folding
domains, the CP domain, responsible for binding of carbamoyl
phosphate, and the Asp domain, responsible for binding of Asp.
ATCase exists in two states: a low-activity, low-aﬃnity for the
substrates T state and a high-activity, high-aﬃnity for the
substrates R state. These two states diﬀer in both tertiary and
quaternary structures. Each of the substrates and the allosteric
eﬀectors have an eﬀect on the T to R equilibrium.4
Structural and kinetic data have shown that ATP and CTP
compete for and bind to the same site in the allosteric domain
but have opposite eﬀects on ATCase activity.5 Binding
experiments with the holoenzyme have shown that both ATP
and CTP exhibit three high-aﬃnity and three low-aﬃnity sites,6
and binding experiments with the isolated regulatory dimer
have shown one high-aﬃnity and one low-aﬃnity site per
dimer.6 UTP alone binds but does not inhibit the enzyme
unless CTP is present.7 Upon addition of UTP, the number of
CTP binding sites decreases from six to three, suggesting that
CTP is binding to the high-aﬃnity sites and UTP is binding to
the low-aﬃnity sites.8
The binding of nucleotides to the allosteric sites has also
been investigated by incorporating the non-natural ﬂuorescent
amino acid L-(7-hydroxycoumarin-4-yl)ethylglycine at position
52 into the regulatory chain and measuring the change in
ﬂuorescence intensity of the enzyme as a function of nucleotide
concentration.9 These experiments indicated that CTP binds to
the enzyme with the same aﬃnity regardless of the presence of
UTP and vice versa, suggesting that CTP and UTP do not
compete for the same binding site. They concluded by
speculating that the two identical allosteric sites on a regulatory
dimer were functionally asymmetric.
Understanding the allosteric mechanism of ATCase has
proven to be diﬃcult with many conﬂicting results, notably the
observed asymmetry, and the synergistic inhibition by UTP in
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the presence of CTP. A recent R-state structure of the
ATCase·UTP complex provided an important clue for
understanding the allosteric regulation of ATCase.10 UTP
was shown to bind to the regulatory chain of ATCase in a
position diﬀerent from that previously observed for either ATP
or CTP (Figure 1). Peterson et al.10 proposed that each
regulatory chain consists of two adjacent but not overlapping
binding sites, the A and B sites, with ATP and CTP binding in
the A site and UTP binding in the B site. To determine how
UTP is able to synergistically inhibit ATCase in the presence of
CTP, we determined a series of X-ray structures of
ATCase·nucleotide complexes, including the structures of
ATCase·dCTP, ATCase·CTP, ATCase·dCTP·UTP, ATCa-
se·dCTP·UTP·Mg2+, and ATCase·CTP·UTP·Mg2+. By show-
ing that dCTP and CTP bind in essentially the same manner to
ATCase and that UTP can synergistically inhibit ATCase in the
presence of dCTP in kinetic experiments, we were able to use
dCTP as a surrogate for CTP in the structural studies. The use
of dCTP as a functional and structural analogue of CTP
allowed us to distinguish the nucleotide bound in the A and B
sites of the enzyme. These structures provide the critical
information necessary for the formulation of a new mechanism
of allostery for ATCase.
■ MATERIALS AND METHODS
Enzyme Expression and Puriﬁcation. E. coli ATCase was
overexpressed in M9 medium supplemented with 5 g/L
casamino acids using E. coli strain EK110411 [F− ara, thi,
Δ(pro-lac), ΔpyrB, pyrF ±, rpsL] transformed with plasmid
pEK15212 containing the E. coli pyrBI gene. The isolation and
puriﬁcation procedures were modiﬁed versions of those
previously described.11 The ﬁrst step was ion-exchange
chromatography using a Q-Sepharose Fast Flow column (11
cm × 2.5 cm, GE Healthcare). The protein was eluted with a
linear gradient from 0.05 M Tris-acetate and 2 mM 2-
mercaptoethanol (pH 8.3) (Low-Q buﬀer) to Low-Q buﬀer
containing 0.5 M NaCl (0.4%/min, 250 mL total) at a ﬂow rate
of 1.0 mL/min. The fractions containing ATCase were pooled
and dialyzed against Low-Q buﬀer. The protein solution was
then brought to 20% ammonium sulfate saturation and puriﬁed
by hydrophobic interaction chromatography using a Phenyl
Sepharose column (8.5 cm × 2 cm, GE Healthcare). The
Figure 1. (A) CTP and (B) UTP binding sites in ATCase. The r6
regulatory chains of the ATCase·CTP structure (PDB entry 8AT1)
and the ATCase·UTP structure (PDB entry 4F04) are shown from the
same viewpoint. The allosteric sites are shown as a surface
representation with the nucleotide shown as CPK.
Table 1. Data Collection and Reﬁnement Statisticsa
ATCase·dCTP ATCase·CTP ATCase·dCTP·UTP·Mg2+ ATCase·CTP·UTP·Mg2+
Data Collection
PDB entry 4FYV 4FYW 4FYX 4FYY
space group P321 P321 P321 P321
wavelength 1.075 1.542 1.075 1.075
cell dimensions
a, b, c (Å) 120.7, 120.7, 142.5 121.3, 121.3, 142.3 121.2, 121.2, 141.8 121.1, 121.1, 141.4
α, β, γ (deg) 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120
resolution (Å) 50−2.1 (2.2−2.1) 43.2−2.1 (2.2−2.1) 50−2.1 (2.2−2.1) 50−1.9 (2.0−1.9)
Rsym 0.107 (0.562) 0.063 (0.450) 0.145 (0.684) 0.137 (0.608)
average I/σ 15.0 (4.3) 11.8 (2.9) 13.2 (4.1) 11.9 (4.0)
completeness (%) 99.8 (98.4) 99.7 (100.0) 100.0 (99.6) 100.0 (99.9)
redundancy 23.1 (21.1) 5.4 (5.3) 22.3 (20.3) 22.0 (19.5)
Reﬁnement
resolution (Å) 49.1−2.1 43.2−2.1 49.2−2.1 49.2−1.9
no. of reﬂections 70567 70733 71745 89120
Rwork/Rfree 0.176/0.216 0.184/0.229 0.165/0.213 0.193/0.237
no. of atoms
protein 7082 7083 7149 7140
water 496 571 634 574
rmsd
bond lengths (Å) 0.009 0.008 0.009 0.007
bond angles (deg) 1.18 1.13 1.07 1.14
mean B value (Å2) 54.8 30.0 39.3 41.2
ligand B value (Å2)b
CTP (r1/r6) 103.5/84.0 44.8/55.5 46.2/40.7 46.3/45.7
UTP (r1/r6) − − 46.6/42.0 43.9/47.2
Mg2+ (r1/r6) − − 47.1/43.4 45.5/44.4
aValues in parentheses are for the highest-resolution shell. bOccupancies of all ligands were 1.0.
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protein was eluted using a linear gradient from Low-Q buﬀer
brought to 20% ammonium sulfate saturation to Low-Q buﬀer
(0.5%/min, 200 mL total) at a ﬂow rate of 1.0 mL/min. The
fractions containing pure ATCase, determined by sodium
dodecyl sulfate−polyacrylamide gel electrophoresis,13 were
pooled and dialyzed against 40 mM KH2PO4, 2 mM 2-
mercaptoethanol, and 2 mM EDTA (pH 7.0). Enzyme
concentrations were determined by absorbance measurements
at 280 nm with an extinction coeﬃcient of 0.59 cm2/mg.14
Determination of ATCase Activity. ATCase activity
measurements were determined colorimetrically in 20 mM
bis-Tris, 20 mM Tris, and 20 mM CAPS buﬀer (pH 7.0) at 25
°C in the presence of 5.0 mM L-aspartate and a saturating
concentration of carbamoyl phosphate (2.4 mM).15 Kinetic
measurements were taken in duplicate, and the data points in
the graphs are the average. Nucleotide inhibition curves were
determined at an [Asp]0.5 of 5 mM. Prior to use, nucleotide
solutions were treated with chelating ion-exchange resin
(Chelex 100, Bio-Rad) to remove trace divalent metals. The
resin was directly added to the solutions (0.5 g/10 mL of
nucleotide solution), and the solutions were stirred on ice for 1
h. Following centrifugation, the solution was decanted from the
resin. Nucleotide concentrations were determined by absorb-
ance measurements at 271 nm (ε = 9000 M−1 cm−1; pH 7.0)
for CTP and dCTP and at 262 nm (ε = 10000 M−1 cm−1; pH
7.0) for UTP.16 For inhibition curves with CTP or dCTP and
UTP, MgCl2 was added to an aliquot of the demetaled UTP
solution in a 1:1 molar ratio. Fitting of the experimental data to
theoretical equations was accomplished by nonlinear regres-
sion.
Crystallization, X-ray Data Collection, and Processing.
E. coli ATCase (20 mg/mL) was placed in four 50 μL dialysis
buttons (Hampton Research, Aliso Viejo, CA) and dialyzed
against 20 mL of crystallization buﬀer [40 mM sodium citrate, 1
mM 2-mercaptoethanol, 0.2 mM EDTA, and 1.0 mM CTP
(pH 5.7)] at 20 °C. Crystals formed in ∼1 week. One dialysis
button was transferred to 2 mL of crystallization buﬀer with 5
mM UTP and 5 mM MgCl2 and allowed to equilibrate for 12 h.
E. coli ATCase was cocrystallized with dCTP following the
same procedure as indicated above, but dCTP was substituted
for CTP in crystallization buﬀer. Crystals formed in ∼1 week,
and one button was dialyzed in crystallization buﬀer containing
5 mM UTP and 5 mM MgCl2 for 12 h.
After equilibration in crystallization buﬀer with 5 mM UTP
and 5 mM Mg2+, the crystals were transferred into a
cryoprotectant of 20% 2-methyl-2,4-pentanediol in UTP·Mg2+
crystallization buﬀer for ∼1 min prior to being frozen in liquid
nitrogen. Data were collected on beamline X29 at the National
Synchrotron Light Source at Brookhaven National Laboratory
(Upton, NY) with the exception of the ATCase·CTP data,
which were collected on a Rigaku MicroMax-07 HF high-
intensity microfocus rotating Cu anode X-ray generator
coupled with Osmic VariMax Optics and a R-Axis IV++
image plate area detector. The diﬀraction data were integrated,
scaled, and averaged using HKL2000.17 Data collection and
reﬁnement statistics are listed in Table 1.
Structure Solution and Data Reﬁnement. Each
structure was directly determined using the coordinates for E.
coli ATCase in the T state with CTP bound (PDB entry
1ZA1)18 as the initial model, after removal of water and ligand
molecules. Automated reﬁnements using translation libration
screw-motion (TLS) parameters were performed in PHE-
NIX.19 Manual rebuilding, addition of waters, and nucleotide
modeling were performed using COOT.20,21 Waters were
accepted if they were within hydrogen bonding distance of
main chain or side chain atoms. The ﬁnal structures were
validated using MolProbity19 and PROCHECK.22 Coordinates
and structure factors for the ATCase·dCTP, ATCase·CTP,
ATCase·dCTP·UTP·Mg2+, and ATCase·CTP·UTP·Mg2+ com-
plexes have been deposited in the PDB as entries 4FYV, 4FYW,
4FYX, and 4FYY, respectively.
■ RESULTS AND DISCUSSION
Structural data of ATCase with only CTP bound18 or only
UTP bound10 do not clarify how the two nucleotides
synergistically inhibit ATCase. A single structure of the enzyme
with both nucleotides bound is needed to deﬁnitively
determine the mode of binding of UTP to the enzyme in the
presence of CTP and would help to elucidate the mechanism of
synergistic inhibition. However, at a resolution of ∼2 Å, the
electron density proﬁles for CTP and UTP are virtually
indistinguishable. Therefore, we sought a functional analogue of
CTP with an altered electron density proﬁle that still retained
UTP synergic inhibition. Previous studies have shown that
dCTP inhibits ATCase to approximately the same extent as
CTP,23 suggesting that the 2′-hydroxyl group is not important
for allosteric inhibition of ATCase. UTP does function as a
synergistic inhibitor in the presence of dCTP. As seen in Figure
2, at 2 mM dCTP inhibits the enzyme 67% as compared to 43%
for CTP. The combination of 2 mM dCTP and 2 mM UTP
inhibits the enzyme 93% as compared to 86% for 2 mM CTP
and 2 mM UTP. The ability of UTP to synergistically inhibit
Figure 2. Inﬂuence of nucleotides on the activity of ATCase. Relative
activity was measured at increasing concentrations of nucleotide
(NTP). When UTP and CTP or dCTP were present simultaneously,
the abscissa corresponds to the total nucleotide concentration. (A)
Inﬂuence on activity of dCTP alone (○) and dCTP with UTP·Mg2+
(●). When the concentration of dCTP reached 2 mM, UTP·Mg2+ was
added. The UTP·Mg2+ concentration was increased from 0 to 2 mM
while the concentration of dCTP remained constant (2 mM). (B)
Same experiment as that depicted in panel A using CTP in place of
dCTP.
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ATCase in combination with either dCTP or CTP allowed us
to use dCTP as a surrogate of CTP in the structure
determination.
Comparison of the ATCase·dCTP and ATCase·CTP
Structures. To further validate the use of dCTP as a substitute
for CTP, the structures of the ATCase·dCTP and ATCa-
se·CTP complexes were determined. Identical conditions were
used to cocrystallize the enzyme with either dCTP or CTP.
Both complexes crystallized in the P321 space group with
almost identical unit cell dimensions (Table 1), and in both
cases, data were collected to a resolution limit of 2.1 Å. The
structure of the ATCase·CTP complex determined here is at a
higher resolution than previously reported.5,18,24
Overall, the ATCase·CTP and ATCase·dCTP structures are
very similar with a main chain rmsd of 0.187 Å. For
comparison, the main chain rmsd between the ATCase·CTP
complex previously determined (PDB entry 1ZA1) and the
structure of the same complex reported here is 0.221 Å. Both
CTP and dCTP bind in the A site of the regulatory chain
(Figure 1), as deﬁned by Peterson et al.,10 and bind with
identical interactions with the exception of the one involving
the 2′-hydroxyl of CTP (Figure 3). The binding site includes
two Lys residues; Lys94 interacts with the phosphates of the
nucleotide, and Lys60 interacts with the 2-keto group on the
cytosine ring. Backbone atoms of Tyr89 and Ile12 also make
polar interactions with the cytosine ring, and His20 and Asp19
interact with the γ-phosphate and the 3′-hydroxyl group,
respectively. There are also several residues that contribute to
the binding via hydrophobic interactions, including Ile12,
Val17, Leu58, Ile86, and Val91.
The binding of dCTP in the r1 and r6 chains is asymmetric.
The all-atom rmsd between dCTP in the two chains is 2.28 Å.
The positions of the cytosine rings in the r1 and r6 chains are
nearly identical; however, the ribose triphosphate portion is
displaced in the r1 chain as compared to the r6 chain. This
displacement may be due to the loss of an interaction between
Lys94 and a γ-phosphate oxygen that is observed in the r6 chain
but not in the r1 chain. In fact, there are no interactions
between the triphosphate portion of dCTP with the protein in
the r1 chain. In the ATCase·CTP complex, the CTPs bound in
the r1 and r6 chains exhibit very similar interactions, and the
all-atom rmsd between CTP in the r1 and r6 chains is 0.269 Å.
The all-atom rmsds between dCTP and CTP in the two
structures bound in the r1 and r6 chains are 2.39 and 0.88 Å,
respectively. The higher rmsd in the r1 chain reﬂects the
asymmetry observed between the r1 and r6 chains in the
ATCase·dCTP structure mentioned above.
Structure of the ATCase·dCTP·UTP Complex. Crystals
of the ATCase·dCTP complex were dialyzed against a 5 mM
solution of UTP in crystallization buﬀer for 12 h before the
crystals were dipped in cryoprotectant and frozen for data
collection. The previously determined structure of the
ATCase·CTP complex (PDB entry 1ZA1)18 was used as the
initial model for structure reﬁnement. This preliminary
structure of the ATCase·dCTP·UTP complex suggested that
dCTP bound in the A site and UTP bound in the B site on
each regulatory chain simultaneously, with their β- and γ-
phosphates essentially parallel to each other. The data also
showed excess electron density between the β- and γ-
phosphates up to the 11.0σ level. This density and its position
could be explained by the presence of a metal ion serving to
neutralize the repulsion of the negatively charged phosphate
oxygens of the dCTP and UTP. The metal ion would thereby
assist and/or stabilize the binding of the two nucleotides to the
A and B sites by diminishing the repulsion of the phosphate
oxygens and create an additional interaction site for each
nucleotide. The buﬀers used for the growth of these crystals
contained no added metals, so presumably, the electron density
Figure 3. Stereoview of the r6 regulatory site of ATCase shown with (A) dCTP and (B) CTP bound. Polar interactions are represented with dashed
lines. Simple Fo − Fc omit electron density maps are shown at 3.0σ. For these maps, the nucleotides were omitted from the calculations.
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observed was the result of metal ion contamination in the
buﬀer components or the nucleotide solutions.
The Synergistic Inhibition of ATCase by CTP and UTP
Is Metal-Dependent. The preliminary structure of the
ATCase·dCTP·UTP complex, discussed above, suggested that
a metal ion was coordinated between the β- and γ-phosphates
of the two nucleotides. Previous studies reported the allosteric
eﬀectors ATP and CTP are inﬂuenced by the presence of Mg2+,
presumably because of the formation of the ATP·Mg2+ and
CTP·Mg2+ complexes.25−27 Honzatko et al.27 tested a variety of
metal ions, including Al3+, Mg2+, Mn2+, and Ca2+, and found
that Mg2+ and Mn2+ altered the response of the nucleotides the
most. However, the inﬂuence of metal ions on the synergistic
inhibition of ATCase by UTP in the presence of CTP has not
been reported. Because the concentration of Mg2+ in E. coli cells
is approximately 2.5 mM,28,29 and the formation of
Mg2+·nucleotide complexes is well established, the inﬂuence
of Mg2+ on the ability of UTP to synergistically inhibit ATCase
in the presence of CTP was measured. For these experiments,
all nucleotide solutions were demetaled before being used.
As seen in Figure 4, demetaled UTP did not synergistically
inhibit ATCase in the presence of dCTP or CTP, although
demetaled CTP or dCTP was able to inhibit the enzyme (see
Figure 2). The inhibition proﬁle was diﬀerent with UTP·Mg2+
(1:1 ratio). UTP·Mg2+ was able to inhibit the enzyme in the
presence of CTP or dCTP (Figure 4A,B). Therefore, the metal
not only assists in the binding of UTP to the B site when CTP
is present, as suggested by the structural data, but also is critical
in the synergistic inhibition of the enzyme. Furthermore, the
reported enhanced aﬃnity of UTP in the presence of CTP and
vice versa7 can also be explained by the Mg2+, as it would add
additional binding loci for each nucleotide when present.
As a control, the inﬂuence of Mg2+ on the activity of ATCase
was determined in the presence of 2 mM dCTP or CTP
(Figure 4). In each case, the addition of Mg2+ increased the
activity; however, the extent of the increase was not as large as
the extent of the decrease induced by 2 mM dCTP or CTP.
One explanation for this increase in activity is the ability of
Mg2+ to form a complex with CTP (CTP·Mg2+). Depending
upon the relative aﬃnities of Mg2+ and ATCase for CTP, the
addition of Mg2+ may result in some dissociation of CTP from
the enzyme, thereby increasing enzyme activity. This
explanation is supported by the results of the experiments in
which UTP·Mg2+ was added. As seen in Figure 4, at low
UTP·Mg2+ concentrations, there is also a small increase in
relative activity before the synergistic UTP inhibition is
observed. Any free Mg2+ may be forming a complex with
enzyme-bound CTP.
Structure of the ATCase·dCTP·UTP·Mg2+ Complex.
Because the preliminary structure of the ATCase·dCTP·UTP
complex suggested the presence of a metal ion helping to
neutralize the charges on the phosphate oxygens, and the
synergistic inhibition is not readily observed in the absence of a
divalent metal (e.g., Mg2+), the structure of the ATCase·dCT-
P·UTP·Mg2+ complex was determined. In this study,
ATCase·dCTP crystals were dialyzed against crystallization
buﬀer supplemented with 5 mM UTP and 5 mM Mg2+. The
structure of the ATCase·dCTP·UTP·Mg2+ complex was
essentially identical to the preliminary ATCase·dCTP·UTP
structure, with the Mg2+ clearly visible between the dCTP and
UTP.
Figure 5A shows the 2Fo − Fc electron density map of the
nucleotides bound to the allosteric site. To verify the
assignment of dCTP to the A site and UTP to the B site,
electron density maps were generated with UTP modeled in
the A site and dCTP modeled in the B site. In the case of UTP,
the resulting Fo − Fc electron density map showed signiﬁcant
negative density around the oxygen at the 2′-hydroxyl in the A
site (Figure 5B), indicating that the molecule in the A site was
dCTP and not UTP. Furthermore, the Fo − Fc electron density
map for dCTP bound in the B site (Figure 5B) exhibited
positive density at the 2′-ribose position, indicating that the
molecule in the B site was UTP and not dCTP.
The interactions observed between the protein and dCTP in
the A site (Figure 6A) of this structure are consistent with
previously published crystal structures of the ATCase·CTP
complex,18 as well as the structures of the ATCase·dCTP and
ATCase·CTP complexes reported here. As shown in Figure 6A,
Figure 4. Inﬂuence of Mg2+, UTP, and UTP·Mg2+ on ATCase activity.
Each data point was determined in duplicate, and the data points
shown are the average. Relative activity was measured in the presence
of 2 mM (A) dCTP or (B) CTP with increasing concentrations of
Mg2+ (□), UTP (○), and UTP·Mg2+ (●).
Figure 5. Allosteric site of ATCase showing the A and B subsites. (A)
Mg2+ (green sphere) is coordinated to β- and γ-phosphates of both
dCTP (green carbons) and UTP (yellow carbons) and two water
molecules. (B) Modeling of UTP in the A site and dCTP in the B site.
Shown in both panels A and B are the 2Fo − Fc (blue, 1.5σ) and Fo −
Fc (green, 5.0σ, and red, −3.5σ) electron density maps.
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UTP binds in the B site and exhibits interactions with N-
terminal residues Gln8 and Val9, 50s loop residues Ser50,
Gly51, Glu52, and Lys56, and residues His20 and Lys60. The
backbone atoms of the N-terminal residues Gln8 and Val9
make hydrogen bonding interactions with uracil and the ribose
ring, while the 50s loop residues hydrogen bond with the
triphosphate portion of UTP. Residues His20 and Lys60 are
positioned at the interface of the A and B sites, and each makes
contact with both nucleotides. His20 interacts with the γ-
phosphate on each molecule, while Lys60 interacts with the 2-
keto group of dCTP and the 4-keto group of UTP (Figure 6A).
In addition to the polar contacts described, there are several
hydrophobic interactions that contribute to the binding of UTP
in the B site involving Leu7, Leu48, Pro49, and Leu58.
The previously reported structure of the ATCase·UTP
complex was crystallized in the presence of N-phosphonoacetyl-
L-aspartate (PALA), which stabilizes the enzyme in the R
state.10 The structures reported here were determined in the
absence of PALA and in the T state, based upon the vertical
separation between the catalytic subunits. The interactions
between the enzyme and UTP in the ATCase·UTP·PALA
complex in the r6 chain are identical to those observed in the
ATCase·dCTP·UTP·Mg2+ complex, with the exception of
Arg41 from the adjacent regulatory chain. In the structure
reported here, Arg41 makes a water-mediated interaction with
the 3′-ribose oxygen of UTP (Figure 6A). The most likely
reason this interaction is not a direct interaction, as seen in the
ATCase·UTP·PALA complex, is the conformational diﬀerence
in the regulatory dimer between the T- and R-state structures.
Structure of the ATCase·CTP·UTP·Mg2+ Complex. On
the basis of the fact that in the ATCase·CTP complex no CTP
was observed in the B site, crystals of the ATCase·CTP
complex were dialyzed into crystallization buﬀer containing 5
mM UTP and 5 mM Mg2+ for 12 h in a fashion identical to that
indicated above for the crystallization of the ATCase·dCT-
P·UTP·Mg2+ complex. Crystals were then cryoprotected and
ﬂash-frozen before data collection. Although the densities of the
nucleotides in the A and B sites are nearly identical, CTP was
modeled into the A site and UTP was modeled into the B site
(Figure 6B), because of the selective binding observed for
dCTP and CTP in the A site and UTP in the B site. All the
interactions mentioned above between the enzyme and dCTP
and UTP are present in the ATCase·CTP·UTP·Mg2+ structure.
However, there is an additional polar interaction between the
2′-hydroxyl of CTP and the 4-keto group of UTP. Interestingly,
the interaction between Lys60 and the 2′-hydroxyl group
observed in the ATCase·CTP complex (Figure 3) was not
present in the ATCase·CTP·UTP·Mg2+ complex. As seen in
Figure 7, the Mg2+ in the ATCase·CTP·UTP·Mg2+ complex
exhibits square bipyramidal geometry with all oxygen ligands.
The oxygens in the four equatorial positions are donated by β-
and γ-phosphate oxygens of both CTP and UTP, while the axial
positions are both donated from oxygens of water molecules.
Hydrogen bonding interactions that the Mg2+ creates, between
the side chains of Asp19 and His20 and the phosphate oxygens,
add to the interactions between the two nucleotides.
These structural and kinetic results call into question many
of the previously reported binding and kinetic studies involving
the function of the allosteric eﬀectors on ATCase, as these
Figure 6. Stereoview of the nucleotide binding sites in the (A) ATCase·dCTP·UTP·Mg2+ and (B) ATCase·CTP·UTP·Mg2+ complexes. Polar
interactions are shown as magenta dashed lines; the Mg2+ is shown as a green sphere, and ordered waters are shown as red spheres. The asterisk after
Arg41 indicates that this residue is donated from the adjacent regulatory chain in the dimer.
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studies did not take into account metal ion contamination.
Steps to control metal ion contamination prior to binding and
kinetic experiments with ATCase should be taken to ensure
that the allosteric response of the enzyme corresponds to what
are most likely the conditions in the cell.
Nucleotide Binding Site Speciﬁcity. X-ray structures of
the ATCase·CTP and ATCase·UTP10 complexes showed that
CTP and UTP bind at close but not overlapping sites in the
allosteric domain (see Figure 1). Figure 8 shows the
electrostatic potential of the protein, calculated using Delphi,30
mapped onto the surface. The entire nucleotide binding site
exhibits an overall positive electrostatic potential, which would
enhance the binding of the triphosphate portion of the
nucleotides in the A and B sites.
The speciﬁcity of CTP for the A site is related to the
electrostatic and hydrogen bonding interactions with the
cytosine ring. The most positive portion of the binding site,
corresponding to Lys60, interacts with the 4-keto group of
UTP, and the 2-keto group of CTP, which have negative partial
atomic charges. In the A site, the 4-amino group of CTP with a
partial atomic charge of +0.4, as calculated using Jaguar
(Schrödinger, Inc.), interacts with the backbone oxygen atoms
of Tyr89 and Ile12, which have partial atomic charges of −0.6
and −0.5, respectively. If UTP were to bind in the A site, there
would be no hydrogen bonding donors to form interactions
with Ile12 and Tyr89, suggesting that UTP would have
diminished aﬃnity for the A site as compared to the B site.
The speciﬁcity of UTP for the B site is related to the
electrostatic and hydrogen bonding interactions with the uracil
ring. In the B site, the 2-keto group and the hydrogen on the 3-
nitrogen of UTP interact with the backbone nitrogen and
oxygen atoms of Val9. In addition, the 4-keto group interacts
with the ε-amino group of Lys60 and the 2′-hydroxyl of CTP. If
CTP were to bind in the B site, the interactions with Val9
would still be possible; however, the +0.4 partial atomic charge
on the 4-amino group would result in a repulsive interaction
with Lys60, thus signiﬁcantly reducing the aﬃnity of CTP for
the B site.
Conformational Changes Due to Nucleotide Binding.
A comparison of the ATCase·CTP·UTP·Mg2+ structure to a T-
state structure in the absence of nucleotides (PDB entry
1NBE)31 indicates that the largest conformational changes are
observed at the N-terminus and the 50s loop in the allosteric
domain and the 120s and 130s loops in the zinc domain. The
conformational diﬀerences in the N-termini are most likely due
to the mobility of these regions, which is reﬂected in weak
electron density. For this reason, between ﬁve and nine residues
were not included in the deposited coordinates. As Peterson et
al.10 previously observed for the ATCase·UTP structure, the
50s loop is perturbed upon UTP binding as this loop has a
number of interactions with the nucleotide. The 120s loop, a
loop remote from the nucleotide binding site but in the
proximity of the regulatory−catalytic chain interface, undergoes
structural alterations upon nucleotide binding. This displace-
ment of the 120s loop may propagate to the CP domain of the
catalytic chain via the regulatory−catalytic chain interface.
The Structures of the ATCase·dCTP·UTP·Mg2+ and
ATCase·dCTP·UTP·Mg2+ Complexes Explain Results of
Previous Mutagenesis Studies. The discovery that UTP
binds to the B site of each regulatory chain explains previous
kinetic results observed for many single-amino acid substitution
mutants of ATCase that result in the loss of the ability of UTP
to inhibit catalysis in the presence of CTP. Until now, the
reasons why regulatory mutants K56A,32 K60A,33 H20A,34
D19A,35 K6A,36 and L7A36 did not exhibit UTP synergistic
inhibition were not known. From this work, the side chains of
Asp19, His20, and Lys60 interact with both CTP and UTP.
The lack of synergistic inhibition previously reported but not
wholly understood at the time is most likely due to the reduced
aﬃnity of both CTP and UTP. In the case of the D19A
mutation, the binding of UTP in the presence of CTP could
not be detected.35 Both Lys6 and Leu7 were shown by
crystallography to be involved in the binding of UTP in the B
site, and the loss of these stabilizing interactions can explain
why the mutant enzymes do not exhibit synergistic inhibition.
The salt link between Lys56 and UTP explains the loss of
synergistic inhibition, when Lys56 is replaced with alanine.
While it is clear that these mutant enzymes would show
diminished synergistic eﬀects for the reasons mentioned above,
the kinetic studies of all of the mutant enzymes involved in
CTP and UTP binding can be questioned, because of the metal
ion site between the nucleotides. Kinetic experiments in this
study showed that removal of trace metals from the nucleotide
solutions resulted in no synergistic eﬀect. In previous studies
Figure 7. Metal binding site in the allosteric regulatory site of ATCase.
For the sake of clarity, only the triphosphate portions of the
nucleotides are shown.
Figure 8. X-ray structure of the ATCase·CTP·UTP·Mg2+ complex
showing the r6 regulatory chain electrostatic potential mapped onto
the solvent accessible surface in the absence of ligands, as calculated by
Delphi.30 Also shown are the regulatory site ligands, CTP, UTP, Mg2+,
and the two water molecules that complete the coordination sphere of
the Mg2+. The electrostatic potential of the structure was mapped onto
the surface [−10 kT/e (red) to 10 kT/e (blue)].
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showing synergistic inhibition of UTP in the presence of CTP,
it is most likely that there were suﬃcient amounts of metal ion
contamination to induce the eﬀect. Because the intracellular
concentrations of metals such as Mg2+ are signiﬁcant, metal ion
involvement in the allosteric regulation of ATCase is certain.
Mechanism of the Synergistic Inhibition of ATCase by
UTP in the Presence of CTP. On the basis of the results
reported here and previous studies, we know (1) CTP alone
binds to the enzyme and causes inhibition, (2) Mg2+ has only a
weak inﬂuence on the inhibition of the enzyme by CTP, (3)
UTP alone binds to the enzyme but does not cause
inhibition,3,10 (4) Mg2+ is required for the synergistic inhibition
of the enzyme by UTP in the presence of CTP, and (5) CTP
and UTP bind at distinct sites on the regulatory chain that are
not overlapping. The crystal structures of the ATCase·dCT-
P·UTP·Mg2+ and ATCase·CTP·UTP·Mg2+ complexes, along
with these experimental results, allow us to propose a
mechanism for the synergistic inhibition of ATCase by UTP
in the presence of CTP.
The binding of CTP to the allosteric “A site”10 induces
conformational changes within the enzyme resulting in a
stabilization of the T state. In the absence of CTP, the [T]/[R]
ratio is ∼250, which increases to ∼1250 in the presence of
CTP.4 This shift in the [T]/[R] ratio explains the observed
shift to the right in the aspartate saturating curve in the
presence of CTP, and the decrease in enzyme activity at a ﬁxed
concentration of aspartate. The fact that UTP can bind to the
allosteric “B site” in the absence of metals10 but does not
inﬂuence the activity of the enzyme3 indicates that the binding
of UTP alone does not stabilize the T or R state of the enzyme.
However, under physiological conditions, it is unlikely that
UTP would not be complexed with Mg2+. The structures of
ATCase·dCTP·UTP·Mg2+ and ATCase·CTP·UTP·Mg2+ both
support a model in which the two nucleotides act together in a
combined AB allosteric site. However, a combined allosteric
response is elicited only if CTP is bound to the A site and
UTP·Mg2+ is bound to the B site. The role of the Mg2+ is
essentially to allow both nucleotides to bind simultaneously, as
the repulsion of their negatively charged phosphates would
preclude their simultaneous binding. Because the binding of
UTP alone to the enzyme in the B site elicits no inhibitory
response, we propose that the AB allosteric site, where the two
nucleotides are linked by a metal ion, allows UTP to amplify
the kinetic response of the CTP bound in the A site. Thus, the
ATCase·CTP·UTP·Mg2+ complex stabilizes the T state more
than CTP alone and shifts the aspartate saturating curve to the
right more than CTP alone,3 and the activity of the enzyme is
even more reduced than that with CTP alone at a ﬁxed
concentration of aspartate.3
Previous studies suggested that the role of the B site in
amplifying or modifying the functional eﬀect of the nucleotide
in the A site is not restricted to just the synergistic inhibition of
UTP in the presence of CTP. For example, Kleppe and
Spaeren25 ﬁrst observed that Mg2+ altered the response of the
enzyme for ATP. Detailed kinetic and small-angle X-ray
scattering experiments37 showed that ATP·Mg2+ could
stimulate the activity of ATCase almost twice as much as
ATP in the absence of Mg2+. The enhanced stimulation of the
enzyme by ATP·Mg2+ may be explained by the simultaneous
binding of two ATP molecules to the AB allosteric site bridged
by a Mg2+. Again in this case, the B site nucleotide, here ATP,
would amplify the response of the ATP in the A site. ATP alone
shifts the [T]/[R] ratio from 250 to ∼70. The combined
binding of ATP·Mg2+·ATP in the allosteric site could stabilize
the R state even more than ATP alone and reduce the [T]/[R]
ratio even more. This change in the [T]/[R] ratio would shift
the aspartate saturating curve to the left such that at a ﬁxed
concentration of aspartate, the binding of ATP·Mg2+·ATP at
the allosteric site would stimulate the enzyme more than ATP
alone. In addition, Honzatko et al.27 reported that GTP·Mg2+
had a stronger inﬂuence on ATCase activity than GTP alone. It
is clear that the role of a metal cation in the allosteric regulation
of ATCase has been underestimated. Furthermore, the data
from many previous studies are now essentially impossible to
interpret correctly as the extent of metal ion contamination is
unknown. A reevaluation of the eﬀects of nucleotides on
ATCase is now required with emphasis on nucleotide
combinations in the presence of physiological levels of metal
cations.
Rationale for the Synergistic Inhibition of ATCase by
UTP in the Presence of CTP. As described by Wild et al.,3
high concentrations of CTP not only feedback inhibit ATCase
but also inhibit CTP synthetase by competitive inhibition of its
own synthesis.38 A possible result of the inhibition of CTP
synthetase would be to elevate levels of UTP. The synergistic
feedback inhibition of ATCase by UTP in the presence of CTP
would therefore act to modulate the biosynthesis of UTP as
well as CTP. However, if cellular levels of UTP were low, the
synergistic feedback inhibition of ATCase by UTP would not
occur, allowing for higher levels of pyrimidine nucleotide
biosynthesis resulting in elevated levels of UTP.
Conclusions. Although there have been many binding and
kinetic studies measuring the aﬃnity and functional con-
sequences of nucleotide binding at the allosteric sites of
ATCase, discrepancies between these studies have hindered the
development of a consistent mechanism for allosteric regulation
in ATCase. The ﬁndings in this work provide two new facts
that need to be reconciled with all of the previous experimental
data. First, the allosteric site on each regulatory chain of
ATCase can bind two nucleotide triphosphates simultaneously,
in adjacent but not overlapping sites. Second, a metal ion, Mg2+
in these studies, is required for the nucleotide in the B site to
function and perhaps for binding as well. In the case of the
synergistic inhibition of ATCase by UTP in the presence of
CTP, it is the UTP·Mg2+ bound in the B site that enhances the
inhibition of CTP. UTP alone does not inhibit the enzyme,
because the A site has a preference for cytosine rather than a
uracil base. Furthermore, UTP does not enhance the CTP
inhibition without Mg2+. Because Mg2+ is known to enhance
the allosteric activation of the enzyme by ATP, it is more than
likely that the AB allosteric site of ATCase can accommodate
ATP·Mg2+·ATP in a similar fashion as has been shown here for
CTP·Mg2+·UTP. New structural and functional studies of
ATCase are required to probe the allosteric response of the
enzyme in the presence of nucleotides and metal ions,
conditions that would be more physiologically relevant than
those used in previous studies.
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The  biological  functions  of  many  enzymes  are often  coupled  with  significant  conformational  changes.
The  end  states  of these  conformational  changes  can often  be determined  by X-ray  crystallography.  These
X-ray  structures  are snapshots  of  the  two  extreme  conformations  in which  the  macromolecule  exists,  but
the  dynamic  movements  between  the states  are not  easily  visualized  in  a two-dimensional  illustration.
Here  we  have developed  a new  method  to  visualize  macromolecular  motions  called  a  ViewMotions
Rainbow  diagram.  These  diagrams  show  the  initial  and  final  states  overlaid  along  with approximately
30  intermediate  structures  calculated  by  linear  interpolation  of  the  backbone  coordinates  of the  initial
and  final  states.  This  group  of structures  is  then spectrally  colored  from  the  initial  structure  in  blue  to
the final  structure  in  red.  ViewMotions  Rainbow  diagrams  provide  the reader  with a much  easier way
to understand  the  macromolecular  motions  using  a  single  two-dimensional  illustration.  Since  producing
these  diagrams  requires  a number  of  different  software  packages,  we have  setup  the  ViewMotions  Web
Server  (http://viewmotions.bc.edu) to automatically  generate  these  diagrams  from  two  Protein  Data  Bank
files or  from  the Database  of  Macromolecular  Movements  (http://molmovdb.org).
© 2013  Elsevier  Inc.  All rights  reserved.
1. Introduction
Many enzymes undergo significant conformational changes
during the course of their biological function. These conformational
changes may  be induced in a variety of ways including the binding
of substrates, allosteric effectors, or by phosphorylation. The end
states of these conformational changes can often be determined by
X-ray crystallography or structural NMR. While these structures are
snapshots of the two extreme conformations in which the macro-
molecule exists, the dynamic movements between the states are
not easily visualized.
Krebs and Gerstein have developed the Internet accessible
Database of Macromolecular Movements [1],  which includes the
Morph Server [2] that can be used to generate movies depicting
the movement of a macromolecule from its initial to its final state.
These movies are an excellent resource to visualize macromolec-
ular motions; however, these molecular motions are much more
difficult to visualize using a single diagram. A variety of methods
to illustrate conformational changes have been employed. How-
ever, each of these two-dimensional representations lacks one
important advantage of a movie depiction of the conformational
Abbreviations: RMSD, root mean square deviation; Database of Macro-
molecular Movements (Morph Server), http://molmovdb.org; ViewMotions Server,
http://viewmotions.bc.edu.
∗ Corresponding author. Tel.: +1 617 552 4558.
E-mail address: evan.kantrowitz@bc.edu (E.R. Kantrowitz).
change, which is to allow the reader to visualize the actual molec-
ular motion. In order to solve this problem we have developed a
new method to visualize the conformational changes of a protein
in a two dimensional illustration. This new method uses a number
of existing software packages to generate a series of intermedi-
ate structures, typically thirty, on the path between the initial and
final conformations of the same protein. All of the structures are
shown in a single image using a spectral color gradient to indi-
cate the molecular motion. We  have published a number of these
ViewMotions Rainbow diagrams as an all-inclusive way to convey
molecular motions [3–5]. However, the steps required to generate
these diagrams are cumbersome, therefore we have developed a
Web  Server to allow the user to easily create ViewMotions Rainbow
diagrams.
2. Computation methods
In order to generate a ViewMotions Rainbow diagram the coor-
dinates of the initial and final positions of the macromolecule are
required. These coordinates can be supplied either with two PDB
files or a MorphID corresponding to a particular macromolecular
movement from the Database of Macromolecular Movements [1].  A
flow chart of the steps necessary to create a ViewMotions Rainbow
diagram is illustrated in Fig. 1.
After data input, the two  structures are then aligned and
superimposed by one of four alignment algorithms: a standard
least-squares procedure as described by Kabash [6] (sRMSD), the
globally optimized alignment method of Needleman and Wunsch
1093-3263/$ – see front matter © 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.jmgm.2012.12.012
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Fig. 1. Flow chart for producing a ViewMotions Rainbow diagram. The input data is
either two PDB files corresponding to the initial and final coordinates of the motion
or a MorphID corresponding to a macromolecular motion described by the Database
of  Macromolecular Movements [1].  Each of the computational steps is indicated by
a  box and the software used to perform the calculation is indicated.
[7] as implemented in SEQUOIA program [8],  the sieve-fit algo-
rithm [9,10],  and a Gaussian-weighted algorithm [11] (wRMSD).
The sieve-fit algorithm [9,10] usually yields the best alignments,
particularly for domain motions.
CNS [12] is next used to calculate the backbone and side chain
RMSD values between the beginning and ending structures using
the rmsd.inp procedure. The rmsd.inp procedure generates a list
of RMSD values for the backbone and sidechains of each residue.
The backbone RMSD values are used for the coloring of the View-
Motions Rainbow diagram. In order to accomplish this a custom
written C language program was written to replace the b-factor
and occupancy values in the initial and final PDB files with the
corresponding backbone and sidechain RMSD values, respectively,
output from the rmsd.inp procedure of CNS. LSQMAN from the Upp-
sala Software Factory (http://xray.bmc.uu.se/usf/) is then used to
generate the intermediate structures using its morph option. Usu-
ally 30 intermediate structures are generated between the initial
and final structures by LSQMAN. However, if the maximal RSMD
for the macromolecular movement is greater than 1.8 A˚ or 3.0 A˚,
45 or 60 structures are generated, respectively. Finally, a cus-
tom shell script is used to generate a command file for PyMol
(http://www.pymol.org) to generate a ViewMotions Rainbow
diagram. PyMol and Chimera (http://www.cgl.ucsf.edu/chimera)
session files are also generated, which can be downloaded by the
user.
3. Results and discussion
3.1. Commonly used methods to view macromolecular motions
The catalytic cycle of most transferases involves a domain clo-
sure, which brings two substrates in close proximity for reaction
and may  also change the active site environment to one more
favorable for reaction. The binding of glucose to hexokinase and
glucokinase are two such examples. Shown in Fig. 2(A and B) are
the open and closed forms of hexokinase as well as the two forms
overlaid (Fig. 2(C)). From this static representation of the confor-
mational change in hexokinase, it is difficult to envision the actual
motion. A modification that is often used to help direct the viewer
to the important portion of the molecule is to use a neutral color
in regions where the conformational changes are the smallest (see
Fig. 2(D)).
To provide the reader with alternative methods to view molec-
ular motions, a variety of different graphical representations have
been employed. A tube representation can be used in which the
width of the tube is linearly proportional to the displacement of
the protein backbone atoms (Fig. 2(E and F)). A significant draw-
back to this representation is that the variable tube width must be
applied to a single structure, in this case either the open or closed
form. Neither of these individual representations clearly conveys
the conformational change that the protein is undergoing. A CPK
representation of each of the two  states can also be used as illus-
trated with hexokinase in Fig. 2G (open form) and 2H (closed form).
Although the domain motion is apparent, this representation has
its drawbacks as small conformational changes, or conformational
changes in several parts of the protein are not well represented.
Krebs and Gerstein recognized the complexities of trying to view
molecular motions in proteins and therefore developed a Morph
Server [2] and a database [1],  as a means to create movies of molecu-
lar motions and the database to track the various types of molecular
motions. Viewing a movie of a conformational change provides a
much easier way  to understand a molecular motion than any of the
two-dimensional representations mentioned above.
In order to overcome the problem of viewing protein con-
formational changes in textbook and journal diagrams we have
devised a new representation, which we call the ViewMotions Rain-
bow diagram. This new representation starts with the initial and
final coordinates of the protein (see Fig. 2(I and J)) and thirty or
more intermediate structures generated by linear interpolation of
the protein backbone coordinates. Although, a linear interpolation
of macromolecular motions does not truly represent the actual
motion of the protein, the resulting structures are useful for illus-
trating the molecular motion. All of these structures are shown
simultaneously and spectrally colored from the initial structure in
blue to the final structure in red. In order to focus the viewer on the
parts of the protein undergoing the conformational change, only
those portions of the protein that show a RMSD of 1.3 A˚ or greater
are colored (see Fig. 2(L)).
The Database of Macromolecular Movements [1] classifies
macromolecular motions into three main categories: (I) motions
of fragments smaller than domains, (II) domain motions, and (III)
larger movements than domain movements involving the motion
of subunits. Furthermore, each of these categories is subdivided by
the type of motion (see Table 1). The first two  categories involve
motions of a single polypeptide chain and are those best visualized
using a ViewMotions Rainbow diagram.
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Fig. 2. Representations of macromolecular motions. (A–D) A comparison of the open and closed forms of hexokinase. (A) The open form of Sulfolobus tokodaii hexokinase
in  the absence of ligands (PDB ID 2E2N) [13], (B) the closed form of S. tokodaii hexokinase in the presence of glucose and Mg2+•ADP (PDB ID 2E2Q) [13], (C) the open and
closed  forms overlaid, and (D) the closed and open forms overlaid with the region of the protein undergoing significant conformational change in color. (E–H) Alternate
representations of the hexokinase conformational change upon binding glucose. (E) Tube diagram of the open form of hexokinase. (F) Tube diagram of the closed form of
hexokinase. In (E) and (F) the diameter of the tube is linearly proportional to the RMSD between the backbone atoms in the open and closed forms. (G) CPK representation of
hexokinase in the unliganded form and (H) in the presence of glucose and Mg2+•ADP. The parts of the protein are colored if the RMSD between the open and closed forms is
larger  than 1.3 A˚. (I–L) Steps in the generation of the ViewMotions diagram of hexokinase. (I) The open form of Sulfolobus tokodaii hexokinase in the absence of ligands (PDB
ID  2E2N), (J) the closed form of S. tokodaii hexokinase in the presence of glucose and Mg2+•ADP (PDB ID 2E2Q), (K) the open and closed forms of hexokinase aligned, and (L)
the  ViewMotions Rainbow diagram of hexokinase showing the open form at the blue end of the rainbow and the closed form at the red end of the rainbow. In addition to the
open  and closed structures, this diagram has thirty intermediate structures calculated between the two  extreme forms. Those parts of the structure with a RSMD of greater
than  1.3 A˚ are shown in color.
The utility of using ViewMotions Rainbow diagrams can be seen
in Fig. 3.1 and 3.2 where the four types of macromolecular motions,
defined by Gerstein and Krebs [1],  are depicted for motions of frag-
ments smaller than domains (Type I) and domain motions (Type II).
For Type I motions, the rainbow of color is associated with specific
segments of the protein, smaller than domains. The motion is some-
times restricted to one location on the protein as in Fig. 3.1(A) or in
Table 1
Krebs and Gerstein [2] classification of the types of macromolecular motions.
Motion type Description
I Motions of fragments smaller than domains
A  Motion is predominantly shear
B  Motion is predominantly hinge
C  Motion can not be fully classified at present
D  Motion is not hinge or shear
II  Domain motions
A Motion is predominantly shear
B  Motion is predominantly hinge
C  Motion can not be fully classified at present
D  Motion is not hinge or shear
III  Larger movements than domain movements involving
the motion of subunits
A Motion involves an allosteric transition
B  Motion does not involve an allosteric transition
C Complex protein motions
multiple parts as indicated in the other examples of Type I motions.
Type II motions, within a single domain, are shown in Fig. 3.2(A–D),
however, the termini of the chains may  also show motions larger
than the cut-off used for the diagram.
3.2. Comparison of alignment algorithms
The ViewMotions Rainbow diagram is dependent upon the
alignment algorithm used to superimpose the two structures.
We have tested four alignment algorithms: the standard RMSD
(sRMSD) [6],  the sieve-fit algorithm [9,10],  the gaussian-weighted
RMSD (wRMSD) [11], and the globally optimized alignment method
of Needleman and Wunsch [7] as implemented in SEQUOIA [8].
The simplest of the alignments is the sRMSD, which is essentially
a least-squares minimization of the corresponding interatomic
distances as described by Kabsch [6].  The sieve-fit method is an
iterative process in which a sRMSD fit is initially performed. The
program then eliminates the C! atoms that are the furthest apart
after the initial alignment. This step is repeated until approximately
50% of the atoms are excluded from the alignment. The Gaussian-
Weighted RMSD (wRMSD) [11] is similar to the sieve-fit algorithm,
but includes a Gaussian-weighting term, where the atoms with
very little movement are weighted more in the least squares fit
than atoms that are further apart. Like the sieve-fit method this
260
G.M. Cockrell, E.R. Kantrowitz / Journal of Molecular Graphics and Modelling 40 (2013) 48–53 51
Fig. 3. (1–2) Examples of protein conformational changes shown as ViewMotions Rainbow diagrams. The Database of Molecular Movements [1] defines three classes of
molecular motions two  of which are depicted here. (1) Type I corresponds to motions of fragments smaller than domains, and (2) Type II corresponds to domain motions.
Each  of these motion types is subdivided into four subtypes as specified in Table 1. See Table 2 for details of each of the molecules shown in this figure. (3–4) Comparison of
different alignment algorithms using hexokinase (3) and lac repressor (4). (A) standard RMSD fit [6],  (B) globally optimized alignment [7] as implemented in SEQUOIA [8],
(C)  Gaussian-Weighted [11], and (D) sieve-fit [9,10].
alignment relies on several iterations until convergence. Each iter-
ation changes the distance of the atoms and thus changing weights
and in turn the wRMSD fit. The final type of alignment method util-
izes the SEQUOIA program [8],  which uses a dynamic programming
algorithm [7] to find the globally optimal alignment.
Shown in Fig. 3.3(A–D) and 3.4(A–D) are ViewMotions Rainbow
diagrams for hexokinase and lac repressor, respectively, using the
four alignment algorithms. In the case of the domain motion of hex-
okinase, the sieve-fit Fig. 3.3(C) and Gaussian-weighted Fig. 3.3(D)
algorithms produced the best representation of the molecular
motion. In the case of the lac repressor, which undergoes a motion
that is not a hinge or shear, the four alignment algorithms give
similar results.
3.3. The ViewMotions server
Because of the complexity of the steps outlined in Fig. 1, we
decided to create a Web  Server to create ViewMotions Rainbow
diagrams, the ViewMotions Server (http://viewmotions.bc.edu).
The ViewMotions Server (see Fig. 4) can be used in one of two modes
to generate ViewMotions Rainbow diagrams. The first involves
uploading two  PDB files and identifying which chains are to be
used in each file, while the second involves simply submitting a
MorphID from the Database of Macromolecular Movements [1].
Uploading two PDB files directly has a number of limitations due
to the software used. For example, CNS will generate an error if the
two PDB files differ in the number of residues or sequence. There-
fore, the ViewMotions Server will not generate an image comparing
a wild-type enzyme to the same enzyme with a mutation(s). The
Morph Server [2] uses a more robust approach for the alignment,
superposition, and generation of the morph. Therefore, the Morph
Server can handle cases in which the initial and final PDB files do not
have the same number of residues, there is a break in the protein
chain, or the initial and final PDB files are different by mutation(s).
If the structures being compared have already been deposited into
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Fig. 4. The ViewMotions Server home page (http://viewmotions.bc.edu).
the PDB it will typically be easier to first run the files through the
Morph Server then submit the MorphID to the ViewMotions Server,
although this is not a requirement. All of the examples provided in
Fig. 3.1 and 3.2 were produced by directly using the MorphIDs as
indicated in Table 2.
The user selects one of the four structural alignment options
previously discussed. After the alignment and superposition step,
the RMSD deviations of the corresponding backbone and side chain
atoms in the two structures are determined. The RMSD values for
the backbone atoms are used for the color coding of the mor-
phed structures in the final image generated by PyMol. When the
Table 2
Summary of example motion types used to produce Fig. 3.1 and 3.2.
Motion type Example Morph ID PDB ID
initial final
I A Adenosylcobinamide Kinase va1cbuB-1c9kB 1CBU → 1C9K
I  B Ras 989758-27939 4Q21 → 6Q21
I  C Ribosomal protein S15 401923-2485 1AB3 → 1A32
I  D Lac repressor 35866-16653 1lCC → 1lQC
II  A Citrate synthase cs 4CTS → 1CTS
II  B HCV helicase 109065-518 8OHM → 1CU1
II  C Myosin 437354-14115 1B7T → 1DFK
II  D Immunoglobulin 403713-16146 1MCP → 1NCA
ViewMotions Server has completed its calculations it sends an
email to the user with the output information and a ray-traced
ViewMotions Rainbow diagram. Since the orientation of this fig-
ure is often not optimal, the PyMol or Chimera session file used to
generate the image can be downloaded by the user so that he/she
can reorient the molecule and generate a ViewMotions Rainbow
diagram from an alternate viewpoint.
3.4. Limitations
While ViewMotions Rainbow diagrams are very useful to
illustrate macromolecular motions, there are limitations to this
procedure. As previously stated, the input structures must be
the same sequence and same number of residues to directly run
through the ViewMotions web server. Therefore, this Web  Server
is for illustrating conformational changes of the same protein and
not for comparing conformations of homologous proteins. These
limitations can often be countered by using the Morph Server and
then submitting the Morph ID to the ViewMotions Server.
Another limitation of these diagrams is that extremely large
motions are more difficult to illustrate. While the ViewMotion
Server will automatically generate more intermediate structures
based on the maximum RMSD, the resulting image may  not be
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able to convey other parts of the protein because the ribbon
becomes too large. The advantage of the ViewMotions Server how-
ever, is that the user is able to download the Pymol or Chimera
session file and can further manipulate the ViewMotions Rain-
bow Diagram with many built in tools such as transparency. The
user is also able to make images of multiple orientations of the
protein.
4. Conclusion
Viewing motions of macromolecules, based on experimental
structural data, in movie format provides one of the best meth-
ods to understand molecular motions. However, in journals and
textbooks it is often not possible to access molecular motion
videos. Therefore, we have developed a new paradigm for showing
molecular motions in a single image, the ViewMotions Rainbow.
This diagram consists of the initial and final conformations of a
macromolecule along with a number of intermediate structures
linearly interpolated between the initial and final states colored
from blue to red. These ViewMotions Rainbow diagrams provide
a new graphical representation to help understand molecular
motions. In order to produce these images easily, we  have setup
a Web  Server (http://viewmotions.bc.edu) for the specific pur-
pose of creating these images either from available Protein Data
Bank files or using a MorphID from the Database of Molecular
Movements [1].
Note added in proof
As of version 2.0 the restriction that the two structures must
have exactly the same number of amino acids has been elimi-
nated. Deletions at the N-terminal or C-terminal can be processed.
In addition, sequences with a small number of mutations can now
be handled. There is also a new input method to directly use PDB
IDs.
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